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Abstract
Nicotine Replacement Therapy (NRT) products, having been in the pharmaceutical mar-
ket for over three decades and sold without prescription for a long period of time in many 
countries, are the most commonly used smoking cessation (SC) pharmacotherapy. 
This study explores the deregulation of NRT products from pharmacy-only distribu-
tion to general sales in Finland, which took place in 2006. The overall aim of this study 
was	to	assess	the	reasons	for	the	NRT	deregulation	and	its	reflections	on	SC	practices	in	
Finland. NRT deregulation was explored from three perspectives: 1) NRT deregulation as 
a policy-making process; 2) community pharmacists as health care professionals providing 
guidance on NRT use; and 3) NRT users’ perceptions of NRT in SC.  
This multi-method study applied quantitative and qualitative methods. The study of 
NRT deregulation from the policy-making perspective was based on an inductive content 
analysis of all the publicly available documents and interviews of 12 Finnish Members of 
the Parliament (Study I). A nationwide representative survey of every second pharmacy 
owner and community pharmacist (n=2 291) was conducted a year after the deregula-
tion in 2006-2007 (Studies II & III). The NRT users’ perspectives of the role of NRT in 
SC were explored by analysing postings in the national internet-based discussion forum 
(STUMPPI) supporting SC (Study IV). This study was based on a qualitative analysis of 
smokers’	and	quitters’	postings	(n=24	481)	in	five	discussion	areas	during	2007-2012.
The NRT deregulation was politically communicated as a safe and evidence-informed 
decision promoting public health by advancing SC in Finland. On the basis of the analysis 
of	all	the	documents	and	interviews,	the	following	five	themes	emerged:	1)	how	deregula-
tion	may	influence	on	SC;	2)	appropriate	and	safe	use	of	NRT	products	 taking	 into	ac-
count the characteristics of these products. The debate extended beyond NRT and SC to 
become 3) a debate of the principles of who is allowed to sell medicines and what is the 
importance of professional advice for treatment outcomes; 4) debate on how evidence-in-
formed the decision was; and 5) the way the political process was carried out. Finally, the 
analysis revealed that two of the most important motives for the deregulation, poor NRT 
availability and NRT’s effectiveness in SC, were largely based on assumptions instead of 
actual	scientific	evidence.	
At the time of the pharmacy owners’ and community pharmacists’ survey in 2007, half 
of the respondents reported to be familiar with the Finnish SC Guideline. Guideline fa-
miliarity enhanced guideline implementation: in addition to counselling on NRT use, the 
pharmacists familiar with the SC guideline used other guideline-based SC methods more 
frequently compared with respondents unfamiliar with the Guideline. According to the 
survey	respondents,	 (n=2	291),	NRT	deregulation	had	sizeably	diminished	the	sales	of	
NRT at pharmacies as well as the contacts between NRT customers and community phar-
macists. In particular pharmacy owners’ motivation towards counselling NRT customers 
had decreased. However, community pharmacists still saw it as their duty to guide and 
support SC. 
                 3
4The studies conducted in the post-NRT deregulation period among community phar-
macists (III), and smokers and quitters (IV) found a great variety of NRT usage patterns. 
The most common usage pattern was the use of too low a dosage or too short a peri-
od compared with the instructions for NRT use. With both community pharmacists and 
smokers and quitters it was perceived to be possible that the use of NRT products can 
cause dependence on NRT. 
In the analysis of smokers’ and quitters’ internet-based discussions (IV) three major 
themes emerged related to NRT in SC: 1) distrust and negative attitude towards NRT; 2) 
neutral acceptance of NRT as a useful SC method; and 3) trust on the crucial role of NRT 
and other SC medicines. The negative attitude was related to the perceptions that NRT 
use maintains tobacco dependence, fear of NRT dependence or experience of not gain-
ing help from NRT use. NRT was perceived to be useful particularly in the initiation of 
SC attempts and in dealing with physiological dependence. The most highlighted factors 
of successful quitting were quitters’ own psychological empowerment and peer support 
from the discussion community. 
The	findings	of	this	study	suggest	that	NRT	deregulation	was	politically	presented	as	
a	significant	promotion	of	public	health.	In	contrast	to	this,	the	findings	among	smokers	
and quitters imply that simply the increased access and use of NRT may not be as cru-
cial in SC as suggested by different stakeholders during the deregulation process. Instead, 
many Finnish smokers and quitters saw NRT as less important in SC or held negative 
perceptions towards NRT use and feared dependence on NRT. Furthermore, the study 
provided evidence that in Finland NRT products are often used in a way which may not 
be	optimal	for	treatment	success.	These	findings	suggest	that	many	smokers	and	quitters	
could	benefit	from	personalized	support	for	NRT	use	which	would	include	behavioural	
components	and	a	plan	for	NRT	use	to	optimize	the	treatment	and	avoid	the	feared	de-
pendence on NRT. Community pharmacists could constitute an important countrywide 
public	health	resource	to	provide	such	counselling	and	personalized	SC	plans.	However,	
their motivation and expertise in NRT counselling decreased after the deregulation which 
means that health care may have lost one guideline-based resource in SC. 
The	findings	of	 this	study	highlight	 the	need	 to	 further	evaluate	 the	benefits	gained	
from the deregulation. There is also a future need to investigate how deregulation will re-
flect	in	the	following	matters	in	the	long	run:	1)	the	development	of	the	rate	of	smoking	
among the Finnish adult population, 2) what will be the role of NRT products in SC in 
terms of gaining permanent abstinence, 3) which SC services and interventions smokers 
and	quitters	prefer,	and	finally,	4)	community	pharmacists’	motivation	and	practices	to	
support SC. These aspects should be taken into account in policy-making when planning 
future SC services and interventions in Finland.
5Acknowledgements
This study was carried out at the University of Helsinki, Faculty of Pharmacy, Division 
of Social Pharmacy during 2006-2012. The planning of this study started already in the 
spring	2005	after	NRT	deregulation	was	publicly	suggested.	At	this	time,	I	was	finalizing	
my Master’s thesis on pharmacies’ participation in multidisciplinary SC collaboration. 
I own my very deepest gratitude to my dear main supervisor, Professor Marja Airaksinen, 
Head of The Clinical Pharmacy Group. I am so privileged for having the chance to learn 
from your outstanding expertise and to work with you for all these years. As my teacher 
and supervisor you have really empowered me to learn. In addition, you have always 
given me encouragement and support to go on. Marja, you are a real diamond and such 
a warm person! I am also so blessed to have you, Docent Kari Linden, as my other main 
supervisor. I thank you Kari for sharing your great expertise, constant support and the 
enormous amount of work you have done in supervising me. Despite how busy you have 
been you have always found time for my e-mails. I have also been so lucky to have you, Dr. 
Kirsi Pietilä, PhD, as my wonderful supervisor ever since my Master’s thesis. I thank you 
Kirsi for sharing your great expertise and for always being so supportive and encouraging. 
I’m most grateful to Docent Tellervo Korhonen, University of Helsinki and Dr. Kenneth 
Shermock, PhD, The Johns Hopkins Hospital, for pre-examining this work. Your highly 
valuable	 comments	 remarkably	 improved	 the	 final	manuscript	 of	 this	 thesis.	 You	 two	
are the kind of pre-examiners that I hope any PhD student would have. In addition, I 
especially	thank	you	Tellervo	for	your	kind	encouragement	in	the	final	phase	of	revising	
this thesis. 
  I most sincerely thank all the co-authors of this study: Tobacco Cessation Expert 
Patrick Sandström	and	my	first	Master’s	thesis	student	Mari Vasama, Msc (Pharm), are 
thanked for our great teamwork at the time of the Pharmacists and Tobacco survey. Dr. 
Hannes Wahlroos,	PhD,	is	acknowledged	for	allowing	me	to	learn	from	his	magnificent	
expertise in pharmaceutical policy. I thank Dr. Antti Silvast, PhD, for teaching me so 
much about qualitative analysis. Health Expert Maija Kolstela is acknowledged for all the 
help during the analysis of STUMPPI Forum.  
I warmly thank Dr. Vesa Jormanainen, MD, for making it possible for me work with 
the Pharmacists and Tobacco Survey. University Teacher Reijo Kärkkäinen, is acknowl-
edged for sharing his great expertise on public health and health policy and for encour-
agement. I owe special thanks to Richard Stevenson, Language Consultant, for helping 
me to survive in the jungle of the English language. Richard is especially acknowledged 
for his copious work with the proof-reading of this thesis. I most warmly thank Dr. Stina 
Parkkamäki, PhD, for her excellent comments given on my thesis manuscript, encour-
agement, peer support and help with the practicalities. Graphic designer Piia Viikari  is 
acknowledged	for	her	wonderful	work	with	the	final	layout	of	this	thesis.	I	wouldn’t	ever	
do without you Piia.
 I warmly thank the Association of Finnish Pharmacies, the Finnish Pharmacists’ As-
sociation and the Finnish Pharmacists’ Society and for their help at the time of the Phar-
6macists and Tobacco Survey. I most sincerely thank all the survey respondents and all the 
interviewed	Members	of	the	Finnish	Parliament	for	their	time.	The	Organization	for	Res-
piratory Health is acknowledged for allowing me to analyse the postings in the STUMPPI 
Forum and all the help while this analysis. I thank all the posters for the valuable insights 
to NRT and SC from the smokers’ and quitters’ perspective. The Association of Finnish 
Pharmacies,	Pfizer	Oy	Finland	and	The	Elli	Turunen	Fund	of	the	Finnish	Cultural	Foun-
dation	are	acknowledged	for	the	financial	support	for	this	study.
I	got	the	final	motivation	to	finalize	this	thesis	manuscript	because	of	the	wonderful	
possibility to continue doing research in a new project. For this I want to thank our great 
research group. Especially I thank my excellent boss, Professor Jarmo Hietala for his 
kind	 support	 and	understanding	while	 I	was	 doing	 the	 final	 corrections	 of	 this	 thesis.	
Dear Leena Saastamoinen, PhD, and Research Professor Anna-Mari Tuulio-Henriksson, 
are thanked for their warm support and encouragement in my path as a researcher. 
I thank for all the staff in the former Division of Social Pharmacy. It was lovely time for me 
to work with you all. Especially, I thank my peers and dear friends Dr. Marika Pohjanoksa-
Mäntylä, PhD, and Anna-Riia Holmström, PhD to come soon, for all our great collaboration 
and for sharing good and bad moments in research and life in general. 
I thank all my other dear friends and dear relatives for giving me strength to go on and 
for sharing life. I’m so happy to have you all in my life, even though I have not lately been 
very active in keeping contact myself. I especially thank my dear friends Katri Kaukoranta 
and Sanna Värränkivi for sharing joys and sorrows since our early days in Kuopio.
Finally, I would like to thank my nearest and dearest for everything. 
I’m so grateful to my dear mother- and father-in-law Varpu and Rauno Kurko for all 
the help with childcare and constant support. I thank you my dear “kälytin” Kirsi for 
friendship and help. You and your husband Petri Sola are wonderful. I’m so happy for all 
the great conversations we have had with you my dear friends Klaus and Johanna, PhD 
to come soon. You two are just superb. I especially thank you my darling Josu for all the 
peer support and for telling me why not to give up. 
This work would never be possible without my beloved parents, Ritva and Vilho 
Rajasilta. I thank you both and my dear grandmother Anni Rajasilta, from all my heart 
for always being there for me, supporting, listening and helping. Especially I want to 
express my gratitude and love towards you, my darling mother. Nobody in the whole 
world who has ever done so much for me as you have.  In addition being the best mother in 
the whole world, you have shown by your own example how to act as a real professionally-
orientated pharmacist and pharmacy owner. 
Finally I want to thank my two beloved K’s. You, my lovely smart and stubborn little 
daughter, Katariina are the love of my life. I thank you my dear Kaarlo for being my won-
derful husband in good and bad days for these last ten years. I especially thank you for be-
ing such an excellent father for Katariina and looking after her so much. I thank you two 
for your patience and love even though I have sometimes forgotten the importance of real 
life outside research.  
Lahti, May 2015 
Terhi Kurko
7Contents
Abstract ..................................................................................................................................................... 3
Acknowledgements ................................................................................................................................... 7
List of original publications ..................................................................................................................... 12
Definitions	of	the	key	concepts ................................................................................................................ 13
Abbreviations ............................................................................................................................................ 18
1 Introduction ....................................................................................................................................... 20
2 Smoking from a society and individual smokers’ perspective ............................................. 22
2.1 Smoking from a society perspective .............................................................................................. 22
2.2 Smoking from individual smoker’s perspective ............................................................................ 23
2.2.1 Nicotine as the cause of physiological tobacco dependence .............................................. 23
2.2.2 Behavioural, psychological and social aspects of tobacco dependence ............................ 24
2.2.3 Tobacco dependence as a chronic disease .......................................................................... 25
2.3 Brief overview of the tobacco control policy in Finland ............................................................... 26
3 Description of NRT products’ role in SC and its evolution ................................................... 28
3.1 Brief description of NRT products’ role in SC ............................................................................... 28
3.2 Recognition of nicotine addiction and the birth of NRT .............................................................. 29
3.3 The establishment and implementation of evidence-based SC guidelines .................................. 31
3.3.1 The establishment of evidence-based SC guidelines ........................................................... 31
3.3.2 SC guideline implementation and factors associated with it ............................................ 33
3.4 Community pharmacists’ role in counselling the use of non-prescription NRT .......................... 36
3.4.1 International experiences on pharmacists’ involvement in SC ......................................... 36
3.4.2 The Finnish experience on pharmacists’ involvement in SC ............................................. 37
3.5 NRT deregulation to general sales ................................................................................................. 39
83.5.1 International NRT deregulations ........................................................................................ 39
3.5.2 The Finnish NRT deregulation ............................................................................................ 40
3.5.3 The role of NRT after deregulation..................................................................................... 40
3.6 Widening NRT use to new user groups and the introduction of combination therapy ............... 41
3.7 NRT for harm reduction ................................................................................................................ 41
3.8 Advocating for a more liberal nicotine policy and market ........................................................... 43
4 Efficacy and effectiveness of OTC NRT ....................................................................................... 44
4.1	Evidence	on	NRT	efficacy	and	its	generalizability	to	real	life ....................................................... 44
4.1.1 Evidence on NRT efficacy ..................................................................................................... 44
4.1.2 Examples of differences between RCT and real life conditions ......................................... 45
4.1.2.1 Differences between NRT users in RCTs and real life ........................................... 45
4.1.2.2 Other differences between the two conditions...................................................... 45
4.2 Effectiveness of OTC NRT ............................................................................................................. 46
4.2.1 Different studies assessing the effectiveness of OTC NRT .................................................. 46
4.2.2 Contradictory evidence of the real life effectiveness of OTC NRT ..................................... 47
4.2.2.1 Studies supporting the effectiveness of OTC NRT ................................................ 47
4.2.2.2 Studies with mixed or non-supporting evidence on OTC NRT effectiveness ...... 48
4.2.3 Reasons for contradictory results and conclusions of the chapter ................................... 48
5 Key arguments related to NRT deregulation: what was the expectation and what has                    
    been achieved ....................................................................................................................................50
5.1 Evidence of the development of NRT use after deregulation ........................................................ 52
5.2 Change in NRT pricing after the Finnish deregulation................................................................. 53
5.3 How NRT use in quitting attempts has developed after deregulations? ...................................... 54
5.4 Smoking prevalence after NRT deregulations .............................................................................. 55
5.4.1 Evidence from the US, Australian and British smoking statistics .................................... 55
5.4.2 Evidence from the Finnish smoking statistics .................................................................... 56
5.5 Safety of OTC NRT ......................................................................................................................... 57
96 Real life NRT use: Why NRT deregulation is not directly reflected in 
    smoking statistics? .......................................................................................................................... 59
6.1 Smokers’ and quitters’ reasons not to use NRT ............................................................................ 59
6.1.1 Popularity of unassisted quitting ........................................................................................ 59
6.1.2 Unwillingness to use NRT ................................................................................................... 60
6.2 Concept of NRT adherence ............................................................................................................ 62
6.2.1 What is meant by the concept of adherent NRT use? ........................................................ 62
6.3 Real life NRT use patterns ............................................................................................................. 63
6.3.1 Use for a short period .......................................................................................................... 63
6.3.2 Use of too low a dosage ....................................................................................................... 63
6.3.3 Concurrent smoking and NRT use ..................................................................................... 63
6.3.4 Use of NRT for other purposes than quitting .................................................................... 64
6.4	Other	reasons	why	the	detection	of	the	influence	of	NRT	deregulation	on	smoking	statistics	is						
							difficult ........................................................................................................................................... 64
7 Counselling and NRT: evidence base and practical viewpoints ........................................... 65
7.1 Evidence-base related to the combination of counselling and NRT use ....................................... 65
7.2 What kind of counselling is needed in real life practice? .............................................................. 65
8 Summary of the key findings of the literature review (Chapters 3-7) ............................... 67
9 Aims of the study .............................................................................................................................. 69
10 Materials and methods ................................................................................................................. 70
10.1 Study context and design ............................................................................................................. 69
10.1.1 Brief description of the operationalization of the theoretical background ..................... 70
10.2	Data	sources	utilized .................................................................................................................... 70
10.2.1 Policy-making related to NRT deregulation .................................................................... 70
10.2.2 Community pharmacists’ survey ...................................................................................... 72
10
10.2.3 Internet-based discussions on NRT use ............................................................................ 73
10.3 Methods ........................................................................................................................................ 74
10.3.1 Qualitative studies utilizing inductive content analysis .................................................. 74
10.3.1.1 Steps in the data analysis ..................................................................................... 74
10.3.1.2 Policy-making related to NRT deregulation ....................................................... 74
10.3.1.3 Internet-based discussions on NRT use .............................................................. 75
10.3.2 Nationally representative survey among community pharmacists ............................... 75
10.3.2.1 The survey instrument ......................................................................................... 75
10.3.2.2 Statistical analysis ............................................................................................... 79
11 Results ................................................................................................................................................ 80
11.1 NRT deregulation from policy-making perspective ..................................................................... 80
11.1.1 NRT deregulation and public health .................................................................................. 81
11.1.2 Extensions of the debate: fundamental change in pharmaceutical policy and structures  
          related to policy-making ..................................................................................................... 81
11.2 Community pharmacists’ involvement in SC ............................................................................... 82
11.2.1 Community pharmacists’ familiarity with the Finnish SC Guideline .............................. 82
11.2.2 The implementation of the SC Guideline-based actions ................................................... 83
11.3	Reflections	of	NRT	deregulation	on	community	pharmacists’	perceptions	of	NRT	sales	and	their		
        professional role in SC .................................................................................................................. 85
11.4 How do Finnish smokers and quitters value NRT in SC? ............................................................ 87
11.4.1 Key explanations given to distrust and negative attitude towards NRT......................... 87
11.4.2 Neutral acceptance of NRT as a useful SC method ........................................................... 89
11.4.3 Trust in the crucial role of SC medicines ........................................................................... 89
11.4.4 Components of permanent success in SC .......................................................................... 89
11.5 NRT usage patterns in Finland ..................................................................................................... 90
11.5.1 Community pharmacists’ perceptions of NRT usage patterns ......................................... 90
11.5.2 Smokers’ and quitters’ perceptions of NRT usage patterns ............................................. 91
11.6	Key	findings	of	the	study .............................................................................................................. 91
11
12 Discussion ......................................................................................................................................... 93
12.1	Key	findings	in	relation	to	earlier	literature ................................................................................. 94
12.1.1 NRT deregulation from the political level ......................................................................... 94
12.1.1.1 The evidence base for the political decision of NRT deregulation ...................... 94
12.1.1.2 Evidence-informed decision-making and the NRT deregulation process .......... 95
12.1.2 NRT deregulation from health service providers’ level .................................................... 96
12.1.2.1 Community pharmacists’ involvement in SC ...................................................... 96
12.1.2.2 Community pharmacists’ perceptions of their professional role in SC after 
               NRT deregulation ................................................................................................ 97
12.1.3 NRT deregulation from the customers’ level..................................................................... 98
12.1.3.1 Explanation given to the negative attitude towards NRT ................................... 99
12.1.3.2 NRT usage patterns in Finland in the post-deregulation period ........................ 100
12.2 Methodological considerations .................................................................................................... 100
12.2.1 Qualitative studies .............................................................................................................. 101
12.2.1.1 Analysis of the political process of NRT deregulation ......................................... 101
12.2.1.2 Smokers’ and quitters’ perspective ...................................................................... 102
12.2.2 Community pharmacists’ survey ...................................................................................... 103
13 Conclusions, implications for further evaluation, research and health care services 105
13.1 Conclusions ................................................................................................................................... 105
13.2 Implications for further research and evaluation ........................................................................ 106
13.3 Implications for health care services ........................................................................................... 107
14 References ........................................................................................................................................ 109
Appendices 
12
a  This article has been reproduced with personal permission from John Wiley & Sons Inc. 
Provided by John Wiley and Sons and Copyright Clearance Centre. Licence number 3567101119394 
(February 13th 2015)
List of original publications
This thesis is based on the following original articles referred in the text by their Roman 
numerals. The articles are reproduced with the kind permission of the copyright holders. 
I Kurko T, Silvast A, Wahlroos H, Pietilä K & Airaksinen M: Is pharmaceutical poli-
cy evidence-informed? A case of the deregulation process of nicotine replacement 
therapy products in Finland. Health Policy 105 (2-3): 246-255, 2012.
II Kurko T, Linden K, Pietilä K, Sandstrom P & Airaksinen M: Community pharma-
cists’ involvement in smoking cessation: familiarity and implementation of the Na-
tional smoking cessation guideline in Finland. BMC Public Health 10: 444, 2010.
III Kurko T, Linden K, Vasama M, Pietilä K & Airaksinen M: Nicotine replacement 
therapy practices in Finland one year after deregulation of the product sales: has 
anything changed from the community pharmacy perspective? Health Policy 91 
(3): 277-285, 2009.
IV Kurko T, Linden K, Kolstela M, Pietilä K & Airaksinen M: Is nicotine replacement 
therapy overvalued in smoking cessation? Analysis of smokers’ and quitters’ com-
munication in social media. Health Expectations (On-line early view, DOI: 10.1111/
hex.12280). a 
13
Definitions of the key concepts 
Abstinence
According to the Glossary of the Cochrane Tobacco Addiction Group (2014) “Abstinence 
means period of being quit, i.e., stopping the use of cigarettes or other tobacco products”. 
Deregulation of nicotine replacement therapy products
Deregulation of nicotine replacement therapy products means a shift of the products’ 
sales channels from pharmacy-only to general sales. This means that the products can be 
purchased in a variety of sales outlets including grocery stores, supermarkets, kiosks and 
gas stations without the supervision or guidance of any health professional (Larsen et al. 
2004). The term ‘deregulation’ is often used as a synonym to OTC Switch which describes 
the change of the status of prescription (Rx) medicine to non-prescription one (World 
Health	Organization	2000).	However,	in	this	thesis	the	term	‘deregulation’ is used to de-
scribe	the	change	from	pharmacy-only	to	general	sales.	(See	also	the	following	definitions:	
‘Nicotine replacement therapy products’, ‘Over-the-counter medicine’ and ‘OTC condi-
tions for NRT purchase’). 
Efficacy 
Efficacy	means	how	the	studied	treatment	works	on	a	controlled	environment	where	the	
effects of the treatment, the study population and the circumstances are isolated from each 
other	by	a	well-planned	and	precise	study	design,	control	group,	randomization,	blinding	
and analysis (Rush 2009, Saturni et al. 2014). At best, these idealistic circumstances are 
achieved	in	randomized	controlled	trials	(RCTs),	which	are	known	as	the	golden	standard	
of	studies	aiming	at	investigating	the	efficacy	of	treatments	(Saturni	et	al.	2014).	
Effectiveness
Effectiveness means the assessment of therapeutic outcomes in conditions presenting 
real life (Rush 2009, Saturni et al. 2014) i.e., how the therapy works in practice. Studies 
assessing effectiveness in real life have high external validity, as these study designs can 
include all kinds of patients and environments and their characteristics may have an in-
fluence	on	the	results	(Saturni	et	al.	2014).	
Evidence-based intervention
According to The Centre of Evidence-based Intervention of University of Oxford (2015): 
“Evidence-based interventions or programmes are those which have been proven effec-
tive in multiple, high-quality randomised controlled trials”. In this thesis the term ‘evi-
dence-based SC intervention’ refers to those SC interventions which are proven to be ef-
fective in SC and recommended in the national treatment guidelines (see also Finnish SC 
Guideline). 
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Evidence-informed decision making
Evidence-informed decision-making means a procedure which aims to facilitate well-
informed, transparent and systematic processes in decision-making, taking into account 
the decision-making context (Dobrow et al. 2004, Oxman et al. 2009). Evidence-informed 
decision-making supports policymakers’ understanding of systematic processes ensuring 
the	 identification,	appraising	and	usage	of	 relevant	research.	Furthermore,	 if	evidence-
informed decision-making is followed in the decision-making process, evaluation of the 
decision is highly important (Jansen et al. 2009, Oxman et al. 2009). In this thesis the 
term evidence-informed decision making refers to the principles in political decision-
making. 
Finnish smoking cessation (SC) Guideline
In this thesis, The Finnish smoking cessation, SC, Guideline means the national Current 
Care Guideline of Tobacco Dependence and Smoking Cessation by the Finnish Medical So-
ciety Duodecim (2012). According to the Finnish Medical Society Duodecim (2014), “Cur-
rent Care Guidelines are independent, evidence-based clinical practice guidelines. These 
national guidelines cover important issues related to Finnish health, medical treatment 
as well as prevention of diseases. The guidelines are intended as a basis for treatment 
decisions and can be used by physicians, healthcare professionals and citizens”. 
Harm reduction
According	to	the	Cochrane	Tobacco	Addiction	Group	(2014)	harm	reduction	is	defined	as	
follows: “Strategies to reduce harm caused by continued tobacco/nicotine use, such as 
reducing the number of cigarettes smoked, or switching to different brands or products, 
e.g., potentially reduced exposure products (PREPs) or smokeless tobacco”.
Nicotine dependence
Nicotine is the substance responsible for the physiological dependence on cigarettes (US 
Department	of	Health	and	Human	Services	1988,	Benowitz	2009).	The	Expert	report	of	
Tobacco Advisory Group of the Royal College of Physicians (2000) has concluded “tobac-
co use to be self-administration of nicotine”. Therefore, nicotine dependence can be de-
fined	as	the	physiological	component	of	tobacco	dependence.	According	to	the	Finnish	SC	
Guideline (the Finnish Medical Society Duodecim 2012), nicotine dependence means per-
manent neurological changes caused by the use of nicotine containing products. Lack of 
nicotine administration causes withdrawal symptoms (Royal College of Physicians 2000). 
See	also	the	definitions	for	‘Tobacco addiction’ and ‘Tobacco dependence’. 
Nicotine Replacement Therapy product (NRT)
Nicotine Replacement Therapy, NRT, products are a group of nicotine containing phar-
maceutical products intended to reduce withdrawal symptoms caused by the abstinence 
of smoking, and thus, support SC (Silagy et al. 2002;2004,Stead et al. 2008; 2012).
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Non-prescription medicine
A	licensed	medicinal	product	sold	without	prescription	or	classification	governing	such	
medicines (Medicines Act 395/1987, 57 §, Ministry of Social Affairs and Health 2003, 
Medicines Act and Statues 2003, European Medicines Agency 2006). In this thesis ‘non-
prescription medicine’ means a licensed pharmaceutical product which is sold without 
prescription only at pharmacies.
Over-the-counter medicine (OTC medicine)
Over-the-counter medicine refers to licensed medicinal products which can be purchased 
without a prescription (Ministry of Social Affairs and Health 2003, European Medicines 
Agency 2006, Food and Drug Administration 2014). Traditionally, in the European Union, 
including Finland, non-prescription medicines are available only at pharmacies (Ministry 
of Social Affairs and Health 2003, Medicines Act and Statues 2003, European Medicines 
Agency 2006). In Finland all the over-the-counter medicines are sold at pharmacies with 
the exception of NRT products. Further according to Finnish medical legislation, commu-
nity pharmacists have a legislative duty to assure proper and safe use of all non-prescrip-
tion medicines by counselling (Medicines Act 395/1987, 57 §). Contrast to this in the USA 
and currently in many European countries OTC medicines are sold in addition to phar-
macies in food stores, supermarkets, kiosks and gas stations and without the supervision 
or guidance of any health care professional (European Medicines Agency 2006, Food and 
Drug Administration 2014). 
Over-the-counter, OTC, conditions for NRT purchase
The	definition	of	over-the-counter conditions used in this theses is adopted from the work 
of professor Shiffman and his colleagues (Shiffman et al. 2002a,b, Shiffman and Sweeney 
2008).	Their	definition	is	as	follows:	“OTC conditions in which smokers self-selected and 
used the products without any instructions or counselling, relying only on the product 
labels”. Furthermore, according to them, use under OTC conditions “implies use with 
no behavioural treatment, and also without personal instruction and structure, which 
could be seen as important contributions to efficacy”. 
OTC paradigm
According to Shiffman and Sweeney (2008), OTC paradigm means “to extend OTC 
treatments beyond acute use for acute symptomatic conditions to long-term use for 
treatment of chronic, asymptomatic conditions and for support of preventive lifestyle 
changes”.
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Pharmaceutical policy/medicines policy
According to Traulsen and Almarsdóttir (2005) “Pharmaceutical policy sets up the prin-
ciples that guide pharmaceutical policy making. It is plan or course of actions that influ-
ence, guide or determine future decision-making in the field of pharmaceuticals”. In the 
Finnish Medicines Policy 2020 strategy, the “joint objectives of the social and health care 
authorities and stakeholders in the field of pharmaceuticals are defined”. Most impor-
tantly,	the	strategy	defines	that	“pharmaceutical service is a part of the social and health 
service system” (Ministry of Social Affairs and Health 2011). 
Public health
According	to	World	Health	Organization,	WHO,	(2014a)	“public health refers to all or-
ganized measures (whether public or private) to prevent disease, promote health, and 
prolong life among the population as a whole. Its activities aim to provide conditions in 
which people can be healthy and focus on entire populations, not on individual patients 
or diseases.”
Self-medication
Self-medication “involves the use of medicinal products by the consumer to treat self-
recognized symptoms or disorders or the intermittent or continued use of medication 
prescribed by physician for chronic or re-occurring symptoms	(World	Health	Organiza-
tion 2000). In the Finnish Medicines Policy 2020 strategy the relationship between self-
care	and	self-medication	is	defined	as	follows:	“Self-care which is done by the use of non-
prescription medicine” (The Ministry of Social Affairs and Health 2011). 
Smoking cessation (SC)
According to WHO (2003): Smoking cessation, synonymous to treatment of tobacco de-
pendence “refers to a range of techniques including motivation, advice and guidance, 
counselling, telephone and internet support and appropriate pharmaceutical aids. The 
success of these interventions depends on their synergistic use in a broader context of 
comprehensive tobacco control programmes“. According the Glossary of the Tobacco 
Addiction Group of Cochrane Collaboration (2014) SC is synonymous to ‘quitting’ and 
is	defined	as	follows: “The goal of treatment is to help people achieve abstinence from 
smoking or other tobacco use, also used to describe the process of changing the behav-
iour.” 
Tobacco addiction
According to Grey et al. (2005): “Tobacco addiction is the umbrella term for compulsive, 
generally harmful pattern of drug self-administration as is characteristics of most ciga-
rette smokers”. It has been suggested that the term tobacco addiction should be used in-
stead of tobacco dependence (Grey et al. 2005, West and Hardy 2006). This is to under-
line the addiction as a holistic neurobiological condition including behaviour and feelings. 
However, in this thesis the term tobacco dependence is used, according to the Finnish SC 
Guideline (The Finnish Medical Society Duodecim 2012). 
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Tobacco control 
The umbrella term for all the acts in the battle against the global tobacco epidemic. WHO 
(2003c)	has	defined	Tobacco	control	as	follows:	“a range of supply, demand and harm 
reduction strategies that aim to improve the health of a population by eliminating or re-
ducing their consumption of tobacco products and exposure to tobacco smoke”. 
Tobacco dependence
Use of tobacco products causes tobacco dependence, which has physiological, psycho-
logical, behavioural and social aspects (US Department of Health and Human Services 
1988,	Royal	College	of	Physicians,	Benowitz	2009).	The	 international	diagnostic	classi-
fication	(ICD-10)	systems	of	the	WHO	has	classified	tobacco	dependence	and	the	with-
drawal symptoms caused by the abstinence of tobacco use as chronic conditions (World 
Health	Organization	1992,	2014b).	According	to	the	Finnish	SC	Guideline	(2012)	Tobac-
co dependence means a chronic disorder, which comprises of physiological, psychological 
and	social	aspects	(The	Finnish	Medical	Society	Duodecim	2012).	See	also	definitions	for	
Nicotine dependence and Tobacco addiction.
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Abbreviations
5A’s    Ask, Assess, Advise, Agree, and Assist
AFP    Association of Finnish Pharmacists 
ASH    Action on Smoking and Health
CNS    Central Nervous System
CT    Cold Turkey
DDD	 			Defined	Daily	Dose
EMA    European Medicines Agency
FDA    Food and Drug Administration (US)
FIMEA    Finnish Medicines Agency
FCTC    Framework Convention on Tobacco Control
FTND    Fagerström Test for Nicotine Dependence
ICD	 			International	diagnostic	classification
HSI    Heaviness of Smoking Index
MP    Member of Parliament
NICE    National Institute for Health and Care Excellence
NRT             Nicotine replacement therapy
OTC             Over- the-Counter
OTC NRT   Nicotine replacement therapy products sold in general sales
RCP   Royal College of Physicians
RCT	 		Randomized	Controlled	Trial
Rx                Prescription
SAHC          Social Affairs and Health Committee
S&H             Social Affairs and Health (Ministry or Parliamentary Committee)
SC                Smoking Cessation
UK   United Kingdom
USA   United States of America
WHO	 		World	Health	Organization
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1 Introduction
Tobacco control and promotion of smoking cessation (SC) are key global public health 
priorities	 (World	Health	Organization	2014c,	2015).	Globally,	 the	use	of	 tobacco	prod-
ucts	kills	six	million	people	each	year	prematurely	and	causes	significant	humanistic,	eco-
nomic	and	societal	hazards.	Actually,	the	use	of	tobacco	products	is	the	key	attribute	for	
most	of	the	serious	public	health	hazards	(US	Department	of	Health	and	Human	Services	
2014). There is no group of organs for which smoking would not be harmful and the evi-
dence of the harm accumulates continuously. Very recent evidence shows that even two 
thirds of regular smokers die prematurely due to their smoking (Banks et al. 2015). 
Nicotine	was	publicly	recognized	by	the	report	of	the	Surgeon	General	in	1988	for	the	
first	time	as	the	substance	responsible	for	causing	tobacco	dependence	(US	Department	
of Health and Health Behaviour 1988). Since then, a robust evidence-base has been gath-
ered identifying tobacco dependence as a chronic disease which requires several treat-
ment	episodes	and	comprehensive	support	(World	Health	Organization	1992,	Fiore	et	al.	
2008, Cummings and Mahoney 2008). Promoting different methods for supporting SC 
has been a central focus of tobacco control policy especially in Western countries.  
SC is one of the most effective ways to promote public health and reduce healthcare 
costs (Cromwell et al. 1997, Parrot and Godfrey 2004, Fiore et 2008, National Institute 
for	Health	and	Clinical	Excellence	2008,	World	Health	Organization	2014d).Traditionally	
all health care professionals are considered to have a key role in supporting the treatment 
of tobacco dependence. To increase their participation in SC, evidence-based guidelines 
have been established in many countries. These guidelines give detailed recommenda-
tions of the use of a wide range of evidence-based SC interventions, highlighting phar-
macotherapy and behavioural support as the cornerstone of SC treatment (Fiore et al. 
2008, Zwar et al. 2011, The Finnish Medical Society Duodecim 2012, National Institute 
for Health and Care Excellence 2013). 
Nicotine replacement therapy (NRT) products, having been in the pharmaceutical 
market for over three decades and sold without a prescription for a long period of time 
in many countries, are the most commonly used SC pharmacotherapy (Silagy et al. 2002; 
2004,	Stead	2008;	2012).	Since	the	very	first	years	in	the	pharmaceutical	market,	NRT	
products’	role	in	SC	has	been	influenced	by	the	constant	increase	in	information	and	un-
derstanding of tobacco dependence as a chronic condition and nicotine as the key agent 
causing	it.		NRT	products	were	the	first	prescription	(Rx)	medicines	used	in	SC	in	addi-
tion to behavioural counselling. Their use was highlighted as a part of the comprehensive 
treatment of tobacco dependence, but their availability was strictly regulated because of 
the potential risk of nicotine dependence (Elam 2012, Keane 2013).
During	the	past	decades,	 the	body	of	evidence	related	to	SC	and	NRT	products’	effi-
cacy	and	safety	has	increased.	This	increased	evidence	has	reflected	in	the	changing	role	
of	NRT	and	their	accessibility.	In	many	countries,	NRT	were	first	released	from	prescrip-
tion-only status to non-prescription medicines sold in community pharmacies. For this 
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reason, amongst various health professional groups, community pharmacists have espe-
cially been responsible to take care of supporting rational SC pharmacotherapy. The glo-
bal	role	of	pharmacists	in	SC	interventions	has	been	acknowledged	in	the	scientific	liter-
ature and in a few treatment guidelines (Fiore et al. 2008, Zwar et al. 2011, The Finnish 
Medical Society Duodecim 2012, National Institute for Health and Care Excellence 2013). 
In Finland, the international development to increase pharmacists’ participation in SC 
was	reflected	in	the	nationwide	efforts	to	increase	pharmacist’s	involvement	in	SC	in	the	
1990s and 2000s (Kurko et al. 2011).  
In many countries NRT products have been deregulated from pharmacy-only status 
to general sales, meaning sales at food stores, kiosks and gas stations, during the mid-
1990s to mid-2000s. These over-the-counter (OTC) deregulations can be perceived as 
an important starting point for new NRT usage patterns. Traditionally, non-prescription 
medicines are indicated for the treatment of minor and temporary conditions and symp-
toms	(World	Health	Organization	2000,	2003b).	After	their	deregulation,	NRT	products	
were	the	first	group	of	OTC	medicines	indicated	for	the	support	of	a	behavioural	life-style	
change and their use was recommended to last for several months (Shiffman and Sweeney 
2008).	For	this	reason,	the	NRT	deregulation	has	been	used	as	an	example	and	justifica-
tion for extending self-medication practices and the paradigm related to OTC medicines.
After NRT deregulation, NRT has assumed more and more consumer product-like 
characteristics as against a medicinal product intended to be used under the comprehen-
sive SC treatment procedure, including behavioural support from health professionals 
(Keane 2013). This development has currently accelerated, as many opinion leaders ad-
vocate	for	a	more	‘liberal	nicotine	policy’	(Le	Houezcek	et	al.	2011,	Fagerström	and	Bridg-
man 2014). This new nicotine policy relies on the principle that all nicotine containing 
products should be regulated according to the possible harmful health consequences in-
stead of the principle of regulating pharmaceuticals. 
This thesis concentrates on the deregulation of NRT products in Finland from pharma-
cy only status to general sales which took place in the beginning of 2006. This change was 
principally important in pharmaceutical policy and self-medication practices, as NRTs 
were and still are the sole group of pharmaceuticals sold outside pharmacies in Finland. 
Globally	the	Finnish	situation	is	unique,	as	specific	legislation	was	created	for	one	special	
group of pharmaceuticals. The literature provides limited information on the NRT dereg-
ulation, and there is no previous work assessing it from multiple aspects. Therefore, the 
overall aim of this thesis is to provide a comprehensive understanding of NRT deregula-
tion. 
This thesis consists of two parts: a literature review and an empirical section. The liter-
ature review provides the contextual framework for the empirical part (Chapter 10.1) but 
also	describes	the	factors	related	to	the	NRT	deregulation	and	its’	reflections	on	public	
health. It also covers the introduction of the role of smoking from the viewpoint of society 
and an individual (Chapter 2). Furthermore, it describes NRT products’ role in SC and its 
evolution	(Chapter	3),	NRT’s	therapeutic	value	on	the	basis	of	its	efficacy	and	real-world	
effectiveness (Chapter 4), health political argumentation and experience of the NRT de-
regulation (Chapter 5), evidence on NRT use in real life (Chapter 6) and the rationale for 
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combining counselling and NRT use (Chapter 7). 
The empirical part of the thesis investigates the NRT deregulation from the perspec-
tive of policy-making, health professionals and users of NRT products (Chapter 9, Stud-
ies I-IV). These perspectives were chosen because they are relevant for understanding 
the background and consequences of the NRT deregulation. Currently, the literature pro-
vides only sparse information on these subjects.
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2 Smoking from a society and individual  
 smokers’ perspective 
This	chapter	briefly	describes	smoking	from	a	society	and	individual	smokers’	perspec-
tive, the physiological mechanisms and the complexity of tobacco dependence disease. In 
addition, the key means of tobacco control in Finland are listed. The information given 
in this chapter serves as a background to understand the importance of SC from a public 
health perspective.  
2.1 Smoking from a society perspective
Smoking	 is	 closely	 related	 to	 the	cultural	and	social	environment,	which	 influences	 re-
markably on smoking behaviour (Hakkarainen et al. 2013, US Department of Health and 
Human Services 2014). A clear indication of this is the change in the general attitude to-
wards smoking, which has altered over the last 60 years in Western society (World Health 
Organization	2003a,	US	Department	of	Health	and	Human	Services	2014).	Six	decades	
ago smoking was only seen as a habit and often the prevailing culture supported its spread 
(World	Health	Organization	2003a,	Hakkarainen	2013,	US	Department	of	Health	and	
Human Services 2014). For instance in Finland, it is visible and has been acknowledged 
that the social status of tobacco products has radically shifted from that of harmless eve-
ryday consumption products to very harmful products, which are currently controlled by 
specific	legislation	aimed	at	ending	the	use	of	these	products	(Hakkarainen	2013).		
Tobacco	dependence	is	a	global	epidemic	(World	Health	Organization	2013,	2014d).	
The	World	Health	Organization,	WHO,	 has	 described	 the	 smoking	 epidemic	 as	 three	
waves,	from	the	first	wave	of	expansion	of	smoking	in	developing	countries	to	the	third	
wave of current decrease in Western countries. Currently, in the European Region the 
death rate attributable to smoking is globally highest, but WHO estimates that by 2030 
nearly 80% of tobacco attributed deaths will take place in low and middle-income coun-
tries	(World	Health	Organization	2013).	The	smoking	rate	varies	significantly	between	
European Countries, and across the population in different countries (World Health Or-
ganization	2013,	2014e).	According	to	meta-analysis	of	WHO	(2011)	smoking	is	far	more	
common among people with a low-income than a high-income. Actually, smoking is the 
key explanation for health inequalities between different social groups, causing a strong 
socioeconomic gradient between the wealthiest and poorest groups (Marmot et al. 2001, 
Jha et al. 2006). At least half of the socioeconomic differences in mortality in men aged 
35-69 years are explained by smoking (Jha et al. 2006). In Finland, it has been estimated, 
based on the evidence originating from Finnish population registers, that smoking is still 
the key reason explaining the difference in life expectancy between the most and least ed-
ucated	socioeconomic	groups	(Martikainen	et	al.	2013).	Especially	the	influence	of	smok-
ing in this difference is increasing among the Finnish women.
Smoking causes a tremendous economic burden for the society (World Health 
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Organization	2014f).	This	burden	is	explained	by	a	loss	of	productivity,	health	care	costs	
and personal suffering. Loss of productivity is explained by premature deaths, health 
problems and employee abstinence. The World Bank’s estimate (2011) suggests that 
smoking-related health care costs cover between 6% and 15% of all the annual health 
care costs in high-income countries. Other aspect of this economic burden is that the 
great majority (80%) of the world’s nearly one billion smokers live in low and middle 
income	countries	(World	Health	Organization	2011,	2014c).	Further,	among	the	poorest	
households, the share of families’ income spent on tobacco products is the largest, 
and	thus,	 the	use	of	 tobacco	products	causes	a	deficiency	of	necessities	 (World	Health	
Organization	2011).	
2.2 Smoking from individual smoker’s perspective
From	individual	smoker’s	perspective,	smoking	behaviour	and	thus	SC	are	influenced	by	
a great diversity of factors (Lerman and Niaura 2002, The Finnish Medical Society Duo-
decim 2006; 2012). The genetic differences explain a great deal of the variation in smok-
ing behaviour and the development of dependence (Lerman and Niaura 2002, Korhonen 
and	Kaprio	2012).	Further,	environmental,	behavioural	and	social	factors	influence	sig-
nificantly	on	tobacco	use	initiation	and	maintenance.	For	instance,	over	the	past	decades,	
the tobacco industry has in its marketing strategy spread the image of self-selected, inde-
pendent, enjoyable, adult-like behaviour, which has appealed so many individuals to ini-
tiate	smoking	(World	Health	Organization	2003d).	Many	smokers	still	associate	smoking	
with mostly positive images and tend to underestimate the harmful health effects (McKie 
et al. 2003, Katainen 2011). 
After the initiation, the habituation of smoking behaviour occurs, as it includes the re-
inforcing and rewarding effects of smoking, both in physiological and psychological sense 
(Royal College of Physicians 2000). Smoking is often associated with pleasure, a manner 
of coping in stressful events, social event or as a reward or refreshment (Royal College of 
Physicians 2000, McKie et al. 2003). Smokers have a great variety of reasons to continue 
to	smoke,	despite	them	knowing	about	the	health	hazards	(McKie	et	al.	2003,	Katainen	
2011). According to the results of the annual Health Behaviour and Health Survey among 
the Finnish Adult Population, over half of the smoking respondents would like to quit 
and nearly 40% had seriously attempted to quit (Helldán et al. 2013). However, quitting 
is	very	difficult	and	normally	several	quit	attempts	are	needed	before	permanent	SC	(The	
Finnish Medical Society Duodecim 2012). This is because of the existence of tobacco de-
pendence.
2.2.1 Nicotine as the cause of physiological tobacco dependence
Nicotine is the substance responsible for the physiological dependence on cigarettes (US 
Department	of	Health	and	Human	Services	1988,	Benowitz	2009).	The	Expert	report	of	
the Tobacco Advisory Group of the Royal College of Physicians (2000) has concluded “to-
bacco use to be self-administration of nicotine”. Nicotine inhaled from tobacco smoke is 
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adsorbed from lungs to blood circulation and administrated to the central nervous system 
(CNS) in 10 seconds from cigarette smoke (Royal College of Physicians 2000). 
		Already	the	very	first	nicotine-doses	bind	to	nicotine	receptors	and	thus	stimulate	the	
release of various neurotransmitters (Royal College of Physicians 2000, Mustonen 2004, 
Benowitz	2009).	Of	these	the	most	important	is	dopamine,	which	is	the	key	transmitter	
in producing pleasurable, reinforcing effects and thus maintaining drug dependence. In 
humans, even short term intake of tobacco products induces pleasure, stimulation, re-
duces	stress	and	anxiety	(Royal	College	of	Physicians	2000,	Mustonen	2004,	Benowitz	
2009, US Department of Health and Human Services 2014). The maintenance of these 
pleasurable effects is one explanation for the physiological tobacco dependence. There is 
evidence that even a short-term period of a few weeks of regular smoking increases the 
amount of nicotine receptors and changes the structure of nicotine receptors (Royal Col-
lege	of	Physicians	2000,	Benowitz	2009).	Furthermore,	the	continued	nicotine	adminis-
tration via smoking causes tolerance (Royal College of Physicians 2000, Mustonen 2004). 
This means that the smoker must use more cigarettes, or smoke them more intensively, to 
receive the rewarding effects of nicotine release. 
Withdrawal symptoms are experienced when the level of nicotine is lowered in the 
plasma	(Mustonen	2004,	Benowitz	2009).	These	withdrawal	symptoms	are	defined	as	
collection of signs and symptoms caused by the abstinence of the drug of which ones body 
is physiologically adopted (West and Gossop 1994, Royal College of Physicians 2000, 
West and Hardy 2006). The most common tobacco withdrawal symptoms include anxi-
ety, restlessness, poor concentration and irritability or aggression, increase in appetite, 
urge	to	smoke	and	night-time	awakenings	(Royal	College	of	Physicians	2000,	Benowitz	
2009). Most of these symptoms will disappear after a sustained abstinence of 4 weeks, as 
the smoker’s body reverts to its normal state (Royal College of Physicians 2000). Accord-
ing to current knowledge, relief of withdrawal symptoms caused by nicotine dependence 
is	the	key	action	mechanism	for	SC	pharmacotherapy,	including	NRT	(Henningfield	et	al.	
2009).  
A great variety of tests and scales exists for assessing the level of nicotine dependence 
for	clinical	practice	and	research	(Royal	College	of	Physicians	2000,	DiFranza	2010).	Of	
these, Fagerström Test for Nicotine Dependence (FTND) is the most commonly used scale 
in clinical practice. (Heatherton 1991, Royal College of Physicians 2000). It measures 
the	consumption	of	cigarettes	and	experienced	difficulty	to	tolerate	the	decrease	in	the	
nicotine level (Fagerström et al. 1989). Heaviness of Smoking Index (HSI) is developed 
on	the	basis	of	FTND	for	clinical	screening	purposes	(Kozlowski	et	al.	1994).	It	consists	of	
two questions, which assess daily cigarette consumption and the time of smoking of the 
very	first	daily	cigarette.
2.2.2 Behavioural, psychological and social aspects of tobacco dependence 
At the same time as the physiological nicotine dependence is developing, smoking behav-
iour becomes more conditioned and associated with the pleasurable physiological effects 
caused	by	nicotine	(Benowitz	2009).	This	behavioural dependence is associated with cer-
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tain manners, like rolling one’s own cigarettes or associating smoking with certain occa-
sions	(Royal	College	of	Physicians	2000,	Benowitz	2009).	
Psychological dependence develops for tobacco and nicotine use (Royal College of Phy-
sicians 2000, Mustonen 2004). For most smokers the pattern of cigarette use, in terms of 
daily consumption, routines related to smoking and amount of inhaled nicotine, remains 
constant and stable over time (Royal College of Physicians 2000). Part of the psychologi-
cal dependence, is to continue smoking to avoid withdrawal symptoms related to negative 
mood	(Royal	College	of	Physicians	2000,	Benowitz	2009).
Social dependence means associating the use of tobacco products with certain com-
pany and social events. Social dependence is important especially in the initiation phase 
of smoking (Royal College of Physicians 2000). Typically smoking starts at a very early 
age	and	the	social	pressure	is	a	key	mediator	in	learning	such	action	(Walsh	and	Tzelepis	
2007, Ollila et al. 2010, Finnish Medical Society Duodecim 2012). Later, smoking is asso-
ciated with the practices in the workplace and belonging to social group (Katainen 2011). 
Vice versa, in the cessation phase, belonging to a community supporting SC may be equal-
ly important in the initiation of a smoke-free lifestyle (Secker-Walker et al. 2002).  
 
2.2.3 Tobacco dependence as a chronic disease
There is robust evidence, that tobacco dependence should be seen as a chronic condi-
tion, which requires several treatment episodes and comprehensive support (Sims and 
Fiore 2002, Etter and Stapleton 2006, Cummings and Mahoney 2008, Fiore and Baker 
2011). Nicotine and tobacco dependence and the withdrawal symptoms caused by the ab-
stinence	from	tobacco	use	have	been	classified	as	chronic	diseases	by	two	international	
diagnostic	classification	systems	for	already	three	decades	(World	Health	Organization	
1992, American Psychiatric Association 1996).
Due to the highly addictive nature of tobacco products, tobacco dependence has been as-
sessed decades ago as “the most addictive and dependence-producing form of self-admin-
istrated gratification known to man” (Russell 1978). Later, dependence on tobacco prod-
ucts has been noticed to be equal to that on heroin and cocaine (Royal College of Physicians 
2000). As described above, nicotine is the key component of tobacco dependence (US De-
partment of Health and Human Services 1988). However, other substances in the tobacco 
smoke	(Benowitz	2009,	US	Department	of	Health	and	Human	Services	2014)	and	patterns	
related to smoking and its social position, are important as well (West and Hardy 2006). 
Tobacco dependence is widely investigated and there is a great variety of models explaining 
this neurobiological and psychological condition (West and Hardy 2006). 
For the reasons described above, also SC is not straightforward. It includes multiple 
aspects, which should be taken into account in planning supportive structures, suitable for 
individual smokers (Fiore et al. 2008, Fiore and Baker 2011). Furthermore, no consensus 
is reached on an exact model or theory explaining overcoming tobacco dependence. 
Instead, the SC behaviour of an individual smoker has been described by a great variety of 
different models (West and Hardy 2006). The most commonly and traditionally used one 
in clinical practise is the transtheoretical model of behavioural change (DiClemente et al. 
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1991),	which	characterises	smokers	and	quitters	into	five	different	stages	of	change.	The	
model	has	been	criticized	(West	2005)	and	also	it	has	been	as	a	start	point	for	developing	
more recent models explaining SC behaviour (Michie et al. 2011). Based on the information 
on these models and the nature of tobacco dependence, the great challenge in developing 
SC interventions is due to the relapse causing nature of tobacco dependence. 
2.3 Brief overview of the tobacco control policy in Finland 
Like any health promotion, the policies guiding tobacco control and SC have expanded 
to	every	level	in	the	society	(World	Health	Organization	2003a).	Tobacco	prevention	and	
SC have been priorities in the Finnish public health policy since 1976 when the Finnish 
Tobacco Act was enacted (Heloma et al. 2012). Prevention of the inequality between the 
socioeconomic groups has been the key reason to implement a long term tobacco control 
policy	in	Finland.	However,	the	policy	has	been	the	most	influential	among	the	wealthi-
est socioeconomic groups but it has been less capable of diminishing smoking among the 
lower socioeconomic groups (Helakorpi 2008). Finnish tobacco policy has partly suc-
ceeded as the smoking prevalence of men has halved over the last 30 years (Heloma et al. 
2012). In 2013 only 19% of Finnish men and 13% of women were daily smokers but there 
exists a strong socioeconomic gradient in smoking prevalence (Helldán et al. 2013).
 The	Finnish	Tobacco	Act	(1976)	has	emphasized	prevention	and	restrictions	on	smok-
ing, banning advertising and support for smoke-free environment. These goals were 
strengthened	in	2005	when	Finland	ratified	the	Framework	Convention	on	Tobacco	Con-
trol	public	health	treaty,	FCTC,	by	WHO	(World	Health	Organization	2014g).	During	its	
ten years existence this international treaty has been the key weapon in the battle against 
the	global	tobacco	epidemic	(World	Health	Organization	2015).	
Since October 2010 the Finnish Tobacco Act has aimed to end the use of tobacco prod-
ucts, making it internationally one of the strictest tobacco legislation (World Health Or-
ganization	2014g).	This	Finnish	devotion	is	in	accordance	with	the	international	aim	in	
tobacco control policy and science to totally end the use of tobacco products (Warner 
2013, Malone et al. 2014). These ‘end-game proposals’ give ideas how to expand tobacco 
control	to	the	broader	community,	utilize	innovative	strategies	to	finally	implement	a	to-
tal freedom from tobacco in the society (Warner 2013, Malone et al. 2014).  Key means 
in the Finnish endgame tobacco policy are effective legislation, prevention of tobacco use 
and intensive SC services (Hara and Simonen 2013, Ministry of Social Affairs and Health 
2014). 
Over the last decade, several amendments came into force to make the Finnish To-
bacco Control stricter (Heloma et al. 2012, Finnish Action on Smoking and Health 2014). 
These include extending the existence of smoke-free restaurants and other public areas, 
working places and municipalities, forbidding the visibility of tobacco products in the sale 
outlets and protection of minors. However, Finnish Tobacco legislation does not give re-
commendations	for	organizing	SC.	
	Instead,	state	and	community	level	health	care	is	responsible	for	organizing	SC	services	
in Finland (Sandström et al. 2009, Heloma et al. 2012). SC has mostly been guided by the 
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Finnish SC Guideline (The Finnish Medical Society Duodecim 2012). The Guideline was 
developed	by	a	multidisciplinary	expert	group	and	it	is	based	on	robust	scientific	evidence.	
It provides background information on tobacco and smoking as a health risk. Furthermore, 
the SC Guideline introduces a wide range of evidence-based SC interventions, which are 
applicable in various health care settings. The Guideline is distributed nationwide by free 
internet access along with online education supporting its implementation.
 Effective SC services can be produced both in local health care centres, occupational 
health care settings and in the private sector (Sandström et al. 2009, The Finnish Medical 
Society Duodecim 2012). The recommendations of the Finnish SC Guideline, are targeted 
to all health care professionals, but in the most current version (2012) physicians are in 
key position in encouraging and supporting SC. The key recommendations of the Guide-
line	for	all	health	professionals	are	the	provision	of	behavioural	support,	by	utilizing	the	
method of 5A’s (6K’s in Finnish practice): Ask, Advice, Assess, Assist, Arrange (Fiore et al. 
1996) on SC support and recommending effective pharmacotherapy (See Chapter 3.3). In 
Finland	there	are	three	first-line	SC	pharmacotherapies,	bupropion,	NRT	products	and	
varenicline. 
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3 Description of NRT products’ role in SC  
 and its evolution 
3.1 Brief description of NRT products’ role in SC
NRT products are a group of nicotine containing pharmaceuticals intended to reduce 
withdrawal symptoms caused by the abstinence of smoking and thus support SC (Stead 
et	al.	2012).	NRT	products’	use	is	based	on	the	idea	that	it	is	too	difficult	for	an	individual	
smoker to overcome simultaneously psychological and physiological tobacco dependence 
(Sees 1990). NRT products’ use can reduce most of the physiological and psychological 
withdrawal symptoms (Stead et al. 2012). 
In	the	Finnish	market,	there	are	currently	five	different	dosage	forms	of	NRT	products	
(Finnish Medical Agency 2015). Of these, the slow-release nicotine patch does not re-
place any of the behavioural activities related to smoking (Stead et al. 2012). However, the 
patch keeps nicotine level steadier without peaks, which can help especially in the physi-
ological withdrawal (Fiore et al. 2008). The more rapidly acting forms include nicotine 
gum,	lozenge,	oral	spray	and	inhaler,	which	can	release	nicotine	to	the	CNS	in	20	minutes.	
If	nicotine	is	swallowed,	 it	passes	first	pass	metabolia	in	the	liver	and	loses	its	efficacy.	
For this reason all oral NRT products are intended to be used so that nicotine is directly 
adsorbed from the oral mucosa (Elam 2012, Stead et al. 2012). All NRT products release 
nicotine into the body at a much slower rate and with a lower dosage than smoking does 
(Fiore et al. 2008, Stead et al. 2012).
NRT	products	are	the	most	utilized	and	investigated	SC	pharmacotherapy	(Silagy	et	al.	
2004, Shiffman and Sweeney 2008, Stead et al. 2008; 2012). This is due to their existence 
in the pharmaceutical market for over three decades, over-the-counter, OTC, status and 
their	proved	efficacy	and	safety	profile	for	various	patient	groups.	SC	guidelines	in	many	
Western	countries	recommend	NRT	use	as	being	the	first	line	gold	standard	SC	treatment	
(see for example Fiore et al. 2008, National Institute for Health and Clinical Excellence 
2008, Zwar et al. 2011, The Finnish Medical Society Duodecim 2012). NRT patch and 
gum	have	been	added	to	WHO	list	of	essential	medications	(World	Health	Organization	
2009a). These recommendations and decisions rely on the robust evidence of NRT prod-
ucts’	efficacy	and	safety	(Fiore	et	al.	2008,	Stead	et	al.	2012,	Cahill	et	al.	2014).	
Over the past decades, the role of NRT products in SC has changed (Figure 1). This 
chapter describes some key milestones related to NRT’s lifecycle, based on published lit-
erature. These milestones, are described along with the general development of the un-
derstanding and practises related to SC. Therefore also the development of the evidence-
based SC guidelines clinical SC practises and the role of health professionals supporting 
SC is described in the NRT lifecycle context. The key focus of this thesis is on the Finnish 
experience of NRT. However, as the most comprehensive published data on the lifecycle 
of NRT is from the United States of America (USA), the United Kingdom (UK) and Aus-
tralia, experiences from these countries are reviewed. 
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3.2 Recognition of nicotine addiction and the birth of NRT 
Already in the 1960’s reports from the Royal College of Physicians, RCP, in the UK (1962) 
and the US report from the Surgeon General (the US Department of Health and Human 
Services 1964) had published the idea of nicotine as the dependence causing agent in to-
bacco products (Elam 2012, Elam and Gunnarson 2012.)  However, most focus was put 
on the social and psychological dependence whereas physiological dependence was given 
less attention. At the same time, NRT gum was developed in Sweden (Elam 2012, Elam 
and	Gunnarson	2012).	The	original	first	Nicorette®	brand	name	with	 the	connotation	
of “Nico and Rätt” instead of “Nico ”and “Wrong” of tobacco use, describes well the ide-
ology	related	to	NRT	(Elam	2012,	Elam	and	Gunnarson	2012).	The	first	Nicorette® gum 
was	finally	registered	as	a	therapeutic	drug	to	treat	tobacco	dependence	in	1978	in	Swe-
den (Table 1). 
NRT is 
developed 
in Sweden 
(1970’s)
Rx 
-medicine,
part of SC 
therapy, 
(1980’s)
Available 
as non-
prescription 
medicine at 
pharmacies 
(mid 1980’s
- mid 1990’s)
Deregulated 
to OTC, 
general 
sales 
(mid-1990’s
- mid 2000’s)
NRT for 
harm 
reduction 
(mid 2000’s
- 2010’s)
New 
nicotine 
policy 
(suggested 
mid 2010’s)
Increase in 
access and 
liberality of 
the market
 Time
Figure 1. Development of NRT lifecycle during decades (modified from Shiffman and Sweeney 2008,  
 Le Houezcek et al. 2011, Elam and Gunnarson 2012, Keane 2013).
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Table 1.  Some milestones related to the lifecycle of NRT products in SC, modified from the review of  
 Keane (2013 ) and other cited literature.
NRT’s milestones 
(time period) Explanation (References in addition to Keane 2013)
Birth of NRT and pre-
market period (1960-1978)
NRT gum was developed in Sweden by Ove Fjörno’s Research Group from the 
traditional snus. The development was slow and complicated, as no earlier data 
existed on pharmacokinetics and pharmacodynamics of nicotine. Further challenges 
were caused by the thread of nicotine poisoning, finding the suitable administration 
route and the idea of increasing saliva’s pH. The first Nicorette® products were finally 
registered in 1978 by Leo© (Elam 2012, Elam and Gunnarson 2012). 
NRT was part of SC 
treatment plan (1978- early 
2000’s)
Establishing the first clinical 
SC guidelines (1996-1999)
NRT were released to 
pharmacies 
(during the 1990’s)
NRT use brought smokers into the medicalized network, which included the help of 
health professional. Nicotine in NRT products was separated from nicotine in tobacco 
products.
After understanding smoking as a chronic condition, in various countries clinical 
guidelines for treating tobacco dependence were established. These guidelines 
highlighted the importance of the combination of behavioural and pharmacological 
support in SC (Fiore et al. 1996, Commonwealth Department of Health and Aged Care 
1999).
NRT use was one element of the therapeutic regime recommended in SC guidelines. 
Like Henningfield (1995) described: “The very first idea of NRT use was associated with 
diagnosis, rational dosing, appropriate instructions, warnings and follow-up.” In most 
countries NRT were Rx medicines. 
NRT products became non-prescription medicines, sold only at pharmacies in many 
countries. Pharmacists had a specific role in supporting the rational use of NRT (Brock 
and Tailor 2007). 
NRT Deregulation
US 1996-2002
UK 1999-2001 
Denmark  2001
Australia 2005
Finland 2006
After the deregulation, the use of NRT products solely was highlighted and NRT were 
seen as the replacement. 
 
Due to the NRT deregulation the products’ role changed. In addition to being a 
pharmaceutical intervention meant for therapy, the products were also a safe consumer 
product, which use was dependent on consumers’ freedom to choose (Shiffman and 
Sweeney 2008).
Expanding NRT use to new 
indication areas (Harm 
reduction) and  populations 
(mid 2000’s)
Harm reduction included new strategies for NRT use such as cutting down to quit, 
reduction of the amount of smoked cigarettes and pre-cessation treatment (Lancaster 
et al. 2007). Harm reduction has been accepted as an official indication in the UK in 
2005, Australia 2007, Finland 2011 and in the US it is under FDA consideration (Raw 
2005, Lohi S. Personal information 2014, US Food and Drug Administration 2015).
Widening the population of whom to recommend NRT based on increased evidence on 
the safety of NRT (Britton et al. 2008, Fiore and Baker 2011). 
New nicotine market and 
new, more appealing NRT 
products suggested 
(2010’s-)
More appealing NRT products should be developed to contain more nicotine and 
release it more rapidly. The development should start from comparing the products 
to tobacco instead of placebo. Many public health experts yearn for the new nicotine 
market (Gray et al. 2005; Le Houeczec et al. 2011, Fageström and Bridgman 2014). 
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The NRT gum market expanded worldwide at the beginning of 1980’s. NRT gum products 
have been available on Rx since the early 1980’s in Europe, for instance in Finland since 
1983, and in the USA since 1984 (Sees et al. 1990, Amodei and Lamb 2008, Shiffman and 
Sweeney 2008, Keane 2013). In addition to an increase in neurobiological knowledge of 
nicotine	dependence,	the	existence	of	NRT	products	was	one	good	trigger	to	finally	and	
publicly announce the addictive nature of nicotine in tobacco products (Elam 2012, US 
Department	of	Health	and	Human	Services	1988;	2014).	This	was	done	for	the	first	time	
in the so called White-paper report of the Surgeon General in 1988 (p.9), which described 
nicotine as “the drug in tobacco that causes addiction.” 
In	the	1980’s,	the	body	of	clinical	trials	assessing	NRT	efficacy	increased	and	new	NRT	
formulations	were	also	invented	(Jarvis	et	al.	1987,	Buchkremer	1989).	Most	significantly,	
the slow-releasing NRT patch was developed in the USA (Rose et al. 1984). In the 1980’s 
and beginning of the 1990’s NRT products’ role was perceived ambiguous (Elam 2012, 
Keane 2013). The products were either perceived as therapeutic interventions, supporting 
SC, as the clean nicotine the products contain helps in overcoming withdrawal symptoms 
(Russell et al. 1980, Sees 1990, Keane 2013). However, NRT products could also be seen 
as a change in technology from tobacco products to a pharmaceutical product in deliver-
ing	nicotine	into	the	body	(Keane	2013).	These	perceptions	are	still,	in	the	2010’s,	influ-
encing in NRT use among smokers and quitters (see Chapter 6). 
3.3 The establishment and implementation of evidence-  
 based SC guidelines 
At the time NRT use was expanding in Western countries, tobacco dependence was un-
derstood to be a complex physiological and psychological condition (Russell et al. 1980, 
Jarvis et al. 1982). SC was expected to require the treatment of both these components 
(Table	1).	All	the	very	first	reviews	focusing	on	the	clinical	use	of	NRT	highlighted	that	in	
any circumstances the sole use of NRT gum only helps overcome withdrawal symptoms 
and the psychological work to gain SC the quitter must do themselves (Russell et al. 1980, 
Sees 1990). 
At this time West and Scheiders (1987) also noticed that ex-smokers experienced crav-
ings for smoking even years after quitting, when no traces of nicotine were left in their 
bodies.	This	finding	in	addition	to	the	declaration	of	the	Surgeon	General	(1988)	and	the	
recognition of tobacco dependence as a chronic disorder in the international disease clas-
sifications	highlighted	the	need	to	build	structures	and	practices	in	the	health	care	system	
to comprehensively support SC. 
3.3.1 The establishment of evidence-based SC guidelines 
 
To meet this comprehensive need to support SC, evidence-based clinical guidelines were 
globally established after the mid 1990’s (see for example: Fiore et al. 1996, Common-
wealth Department of Health and Aged Care 1999, McNeill et al.  2005, Raw et al. 2005). 
The	guidelines	give	detailed	instructions	on	how	to	organize	and	provide	services	meeting	
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the needs of individual smokers. For instance, in the USA in 1996 the Smoking Cessation 
Clinical Practise Guideline was published (Fiore et al. 1996). Its’ expert recommendations 
were	based	on	over	3	000	scientific	publications.	It	highlighted	the	dependence	causing	
nature of smoking and the existence of effective SC treatments, including NRT. 
In	the	UK,	the	first	SC	guideline	was	published	in	1998	(McNeill	et	al.		2005,	Raw	et	
al. 2005). In addition to presenting evidence-based practises, the British guideline was 
also equipped with the information on the cost-effectiveness of SC. This information sup-
ported the establishment of a new treatment service system for SC. In the UK the Nation-
al Institute of Clinical Excellence (NICE) has later published a detailed cost-effectiveness 
analysis of NRT products use for the society, which has altered practises of how NRT is 
distributed and reimbursed (West et al. 2005).  
In Australia altogether three clinical guidelines were established during 1996-1999 to 
increase physicians’ participation in implementing a National Tobacco Strategy (Com-
monwealth Department of Health and Aged Care 1999). 
In	Finland,	the	first	Finnish	SC	Guideline	was	published	in	2002	(The	Finnish	Medical	
Society Duodecim 2002). It and its later updates in 2006 and 2012 have been developed 
from the multidisciplinary viewpoint by the Finnish Medical Society. According to it, all 
healthcare	professionals	have	specified	SC	responsibilities,	and	the	local	cooperation	be-
tween them should facilitate SC by increasing and strengthening contacts with patients. 
All these guidelines and all their later updated versions in the 2000s and 2010s have 
underlined the importance of the role of all health care professionals in SC (Fiore et al. 
2008, National Institute for Health and Clinical Excellence 2008, Zwar et al. 2011, The 
Finnish Medical Society Duodecim 2012). Physicians have traditionally been the guide-
lines’ main target group, but the later versions of the SC guidelines highlight other health 
professionals and their multidisciplinary co-operation as well. 
 In the guidelines, the most highlighted interventions for health professionals are 
proactive assessment of smoking status, forms of behavioural support, different phar-
macotherapies and combining these treatments (Fiore et al. 2008, National Institute for 
Health and Clinical Excellence 2008, Zwar et al. 2011, The Finnish Medical Society Duo-
decim	2012).	As	NRT	products	were	the	first	group	of	pharmaceuticals	for	SC,	they	were	
found	to	be	a	significant	part	of	the	treatment	tools	for	health	care	professionals	(Russell	
1980,	Buchkremer	et	al.	1989,	Keane	2013).	This	role	is	reflected	also	in	the	recommenda-
tions in the guidelines (Table 2). 
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The existence of NRT as concrete SC supporting tools for health professionals, may also 
have motivated health care professionals to intervene within smoking and offer help 
(Russell et al. 1980, Buchkremer et al. 1989). For example, in Australia the implementa-
tion of national guidelines was assessed by a survey among physicians (Young and Ward 
2001). The most commonly followed, self-reported guideline recommendation was sup-
porting the use of NRT.  
3.3.2 SC guideline implementation and factors associated with it
Despite the existence of these evidence-based SC guidelines SC does not routinely take 
place in healthcare in the recommended way (Young and Ward 2001, Twardella and 
Brenner 2005, Ferketich et al. 2006,  Fiore et al. 2008, Sandström et al. 2009, Amemo-
ri 2012, Beenstock et al. 2012). Some studies of the implementation of the SC guidelines 
among different health care professional groups have been made (Young and Ward 2001, 
Twardella and Brenner 2005, Ferketich et al 2006, Sandström et al. 2009, Amemori 2012, 
Table 2. Examples of recommendations in the US Smoking Cessation Clinical Practise Guideline 1996  
 related to behavioural support on NRT use (modified from Fiore et al. 1996).
Examples of recommendations Examples of recommended activities
NRT patch and gum are efficient treatments 
when used along with psychosocial 
interventions.
Some examples of psychosocial interventions: 
l  Offer problem solving, skills facilitating SC treatments 
Include recognition of danger (urges to smoke), coping skills 
(identification of coping skills and problem solving practices), 
provide basic information on smoking
l  Arrange Quit day 
l  Arrange social support 
Clinician should tailor the dosage and duration 
of the NRT treatment to fit patients’ needs 
and give adequate information.
l  Notice precautions (pregnancy, cardiovascular diseases, side 
effects)
l  Heaviness of Smoking Index is recommended in assessing the 
level of nicotine dependence
l  Instructions for chewing technique (gum) or placing (patch) 
l  Instructions for scheduling the dosage
l  Information on possible side effects
If resources are feasible, clinician should meet 
the quitter at least four times. 
Individual SC treatment should last as long as 
resources are available.
l  Encourage the patient in the quit attempt  
l  Encourage the patient to discuss about the quitting process
l  Provide basic information on smoking and success on SC
OTC NRT* is accepted by FDA The introduction of OTC NRT does not reduce clinician’s 
responsibility to intervene with smoking, encourage NRT use or 
counselling the appropriate usage.
* In the US OTC NRT refers to general sales and sales from pharmacies as well
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Beenstock et al. 2012). There is strong evidence that changing healthcare professionals’ 
practices requires more effort than solely disseminating the guidelines; systematic ef-
forts are needed to promote their usage (Stone et al. 2002, Francke et al. 2008, Fiore et 
al. 2008). 
Lack of time (Manfredi and LeHew 2005, Pullon et al. 2005, Vogt et al. 2005 Fiore et 
al. 2008, Sandström et al. 2009, Amemori 2012), lack of health care professionals’ skills 
or	confidence	of	own	skills	in	offering	SC	counselling	(Vogt	et	al.	2005,	Wyne	et	al.	2006)	
have been reported as some of the key barriers for health care professionals’ adherence to 
the recommendations of SC guidelines. 
In the literature several facilitators of the implementation of SC guidelines are known 
(Table 3). Based on the systematic meta-review of Francke et al. (2008) these facilitators 
can	be	classified	into	those	related	to	the	guideline	content,	its	implementation,	patient	
and health care professional or working environment (Table 3). Examples of all these lev-
els are given in Table 3. 
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Table 3. Examples of facilitators of SC guideline implementation among health care professionals   
 based on published literature. The classification used is based on the systematic meta-review  
 of Francke et al. (2008).
Facilitators of SC guideline implementation (references in addition to Francke et al. 2008)
Guideline characteristics 
The aim of SC  guidelines is to make SC part of daily practise and adhering their recommendations does not 
require remarkable additional resources (Fiore et al. 2008, The Finnish Medical Society Duodecim 2012).
The SC guidelines include concrete tools and summaries making them easy to understand (Fiore et al. 2008, 
National Institute for Health and Clinical Excellence 2008, The Finnish Medical Society Duodecim 2012). 
Multifaceted implementation strategy
Free internet-access is given for most of the SC guidelines (Fiore et al. 2008, National Institute for Health and 
Clinical Excellence 2008, Zwar et al. 2011, The Finnish Medical Society Duodecim 2012).
Use of peers in dissemination (Smit et al. 2014)
Examples of educational strategies:
- Education focusing on motivational interviewing (Rosseel et al. 2011)
- Education with role plays (Secker-Walker et al. 2000)
- Education influencing on knowledge and attitudes (Rosseel et al. 2011) 
Smoker (Patient)
Patients’ motivation (no resistance to SC counselling) (Francke et al. 2008 Fiore and Baker 2011) 
The situation is ideal for SC counselling, for example: 
- Before an operation (Thomsen et al. 2010)
- During pregnancy (Melvin et al. 2000) 
SC counselling does not affect patients intimacy (Brewster et al. 2005, Beenstock et al. 2012).
Healthcare professional
Positive attitude (Smit et al. 2013)
Professional role and identity  (Amemori 2012, Amemori et al. 2013)
Experience showing that supporting SC is easy to remember or conduct (Amemori 2012, Amemori et al. 2013)
Confidence in one’s own counselling skills (Vogt et al. 2005)
Perception of accepting SC as a personal responsibility (Ratcshen et al. 2009, Sandström et al. 2009). 
Knowledge level (Beenstock et al. 2013)
Positive belief towards SC (Vogt et al. 2005)
Health professional being non-smoker (Ratcshen et al. 2009, Duaso et al. 2015).
Working place (environment)
Positive atmosphere and practice-wide commitment to SC (Pullon et al. 2005, Smit et al. 2013)
Multidisciplinary collaboration (An et al. 2008,)
Support from working place such as in daily care and encouragement over-time (Sandström et al. 2009, Rosseel 
et al. 2011)
Guarantee of needed resources (financial and other) (Pullon et al. 2005, Stacey et al. 2006)
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3.4  Community pharmacists’ role in counselling the use of  
 non-prescription NRT 
Together with the development of the SC guidelines, the status of NRT changed over time. 
In many European countries and in Australia NRT products were gradually released from 
prescription-only status to pharmacy-only sales, starting mostly from the mildest, 2mg, 
NRT	gum	round	the	1990s	(Paul	et	al.	2003,	Brock	et	al.	2007).	Though,	in	Switzerland	
NRT products were directly registered as non-prescription medicines in pharmacies al-
ready in the introduction year of NRT gum in 1978 (Elam 2012, Elam and Gunnarson 
2012). In Finland the smallest packages of NRT gum were switched to a non-prescription 
medicine a decade later, in 1988 and followed by larger packages in 1992 (The Finnish 
Medical Society Duodecim 2002). 
The non-prescription status of NRT was expected to facilitate contacts between quit-
ters and pharmacists and provide community pharmacists with a special role in counsel-
ling the rational use of NRT (Brock et al. 2007). Pharmacists are easily accessible by the 
public and they are often the only health care professionals whom the quitter meets (Hud-
mon et al. 2006, Brock et al. 2007).
3.4.1 International experiences on pharmacists’ involvement in SC 
NRT switches to non-prescription-medicines sold at pharmacies prompted the consider-
ation at the highest organisational level to increase pharmacists’ participation in promot-
ing SC. Globally the pharmacists’ role in supporting SC is part of the global health pro-
motion	efforts	by	the	WHO,	dating	back	to	the	1990’s	(World	Health	Organization	and	
EuroPharm Forum 1998). In the Second Global WHO meeting on the ‘Role of the Phar-
macists in the Health Care System’, held in Tokyo in 1992, pharmacists were seen as an 
important	resource	for	advancing	SC	(World	Health	Organization	and	EuroPharmForum	
1998). In Europe the pharmacies’ participation in SC is coordinated by EuroPharmForum, 
which is a coordination body of WHO Europe Regions and European Pharmacy Associa-
tions. In the strategy of Europharm Forum SC has been perceived as one key area in which 
to develop community pharmacists’ involvement in advancing public health.
According to the systematic reviews conducted, community pharmacists’ support may 
increase SC rates (Sinclair et al. 2004, Cramp et al. 2007, Dent et al. 2007, Saba et al. 
2014). This provides pharmacists with a good opportunity to develop evidence-based SC 
services	for	those	willing	to	quit.	There	is	evidence	that	many	customers	find	the	pharma-
cists’ role in supporting SC suitable (Hudmon et al. 2006). Still, community pharmacists 
could extent their participation in SC through several alternative actions and strengthen 
evidence-based practices (Aquilino et al. 2003, Paul et al. 2003, Chiang et al. 2006, Hud-
mon et al. 2006, Brock et al. 2007, Thannanithisak et al. 2008, Saba et al. 2014). 
However, in some countries the NRT switch to non-prescription medicine has been de-
bated	because	of	the	possible	safety	and	efficacy	concerns.	For	instance,	in	Germany	the	
medical authorities were re-considering whether the products should be reregulated to 
prescription status, even though German pharmacists were obliged to guide and counsell 
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the	use	of	NRT	(Hasford	et	al.	2003).	According	to	an	Australian	survey	a	significant	pro-
portion (40%) of the responding users of non-prescription NRT had not received any in-
structions from health care professionals (Chiang et al. 2006). Furthermore, a large pro-
portion of the respondents used NRT products in a non-optimal way.
3.4.2 The Finnish experience on pharmacists’ involvement in SC 
In Finland, pharmacists’ participation in SC originates from the international develop-
ment, most importantly the initiatives of Europharm Forum, as described above. Espe-
cially, the Association of Finnish Pharmacies (AFP), representing Finnish pharmacy own-
ers, has been proactively supporting pharmacists’ involvement in local SC networks and 
providing SC services since 1995 (Kurko et al. 2011). The SC coordination body within AFP 
involves representatives from other professional organisations and pharmacy schools to 
enhance the implementation of evidence-based SC practices and its evaluation. This de-
velopment was promoted by national training campaigns and SC counselling aid materi-
als (The Association of Finnish Pharmacies 2008). 
These systematic efforts to increase pharmacists’ participation in SC in Finland were 
reflected	in	the	Finnish	SC	Guideline,	published	in	2002	(The	Finnish	Medical	Society	
Duodecim 2002). According to the Guideline, the pharmacists’ role in SC is counsell, sup-
port and guide the rational and effective use of NRT in a local multidisciplinary SC team 
(See Figure 2). This means in practice that pharmacists are expected 1) to assess individ-
ual customer’s level of dependence in order to plan the treatment and 2) its follow-up ac-
cordingly. 3) They are also expected to recommend the use of non-pharmacological SC 
aids,	such	as	written	materials	or	internet	portals.	The	SC	Guideline	was	the	first	Finnish	
Current Care Guideline, which acknowledged the especial role of Finnish pharmacists in 
the	treatment	chain	of	chronic	disease.	After	the	release	of	the	SC	Guideline	AFP	organized	
country-wide educational campaigns, in nationally, regionally and locally and produced 
several educational materials supporting the implementation of the SC Guideline (Linden 
and Korhonen 2005). 
In addition to Guideline-based duties and requirements in SC Finnish pharmacies 
have offered different kinds of proactively developed SC services (Figure 2). For instance 
nearly all pharmacies have been proactive in recruiting participants to the national Quit 
and Win contest. Furthermore, in several regions around the Millennium pharmacies 
participated	in	multidisciplinary	local	SC	co-operation,	which	aimed	to	organize	better	
SC and tobacco prevention in these areas. The most sophisticated service available in 
Finnish community pharmacies is the individually tailored SC service, which is based on 
international models (Sinclair et al. 2002). 
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Though these services are offered by only a minority of pharmacies and they reach fewer 
customers compared to medication counselling (Figure 2). Furthermore, it is uncommon 
for community pharmacists to actively give quitting advice. According to the results of the 
annual survey of the Health and Health Behaviour of the Finnish Adult population by the 
National Institute for Health and Welfare, less than 2% of the respondents who smoked, 
had received an advice to quit from community pharmacists (Helldán et al. 2013). In con-
trast to this, nearly 40% of the smoking survey respondents received quitting advice from 
a physician and 30% from a public health nurse. 
However, compared with other countries the Finnish development of involving phar-
macists in SC around the Millennium was advanced.  For instance, in the USA similar 
Figure 2. The different tasks and services of Finnish community pharmacists ( modified and translated from the  
 Association of Finnish Pharmacies 2008).
Individually tailored 
SC service, offering 
cessation group 
courses (chargeable)
Campaigns at population level, active questions of smoking status and advice to quit as part of 
routine medication counselling
Participation on different SC related campaigns, educating the public 
of the health hazards related to smoking, CO- and micro-spirometer 
measurements, local multidisciplinary collaboration
Systematic support and follow-up of smoking: for 
example mini-interventions, active support of SC for 
high-risk patient groups, systematical follow-up of 
smoking status
Target 
group 
diminishes
Special 
services
Basic 
services
Actions and the minimum level of information required by the Finnish SC Guideline 
(2002, 2006) form the basic level of SC actions intended for all pharmacies as part of daily 
customer service:
Medication counseling and support of SC pharmacotherapy including non-prescription and prescription 
medicines
Minimum level of information required: familiarity with the rational use of NRT, with the 5A’s model and 
with the local SC services
Duties for staff pharmacists (B.Sc. and M.Sc.): 
- Take care of and support the rational use of SC pharmacotherapy 
- Offers also the non-pharmaceutical forms of SC support. 
Duties for pharmacy owners: 
- Participates in planning and implementation of the local treatment chain. Ensure of sufficient 
resources and education of pharmacists in SC
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kinds of educational activities to increase pharmacists’ activeness and support in SC were 
established after the mid 2000’s (Hudmon et al. 2006, Hudmon et al. 2007). In Australia, 
systematic training and pharmacy-based SC programs are just currently being established 
for the pharmacy profession (Saba et al. 2013). This need is highlighted by the recent ev-
idence	of	significant	gaps	in	evidence-based	SC	practice	among	Australian	pharmacists	
(Saba et al. 2013; 2014). In many European countries it is more common to involve phar-
macists in local campaigns, instead of a countrywide dissemination of SC actions (Brock 
et al. 2007). On the other hand, in Northern Ireland and Denmark, the community phar-
macy-based individually tailored SC service was implemented as a countrywide service 
structure in the mid 2000’s. 
3.5 NRT deregulation to general sales  
Internationally	 the	 distribution	 channels	 of	OTC	medicines	 vary	 significantly	 between	
countries	 (Mahecha	 et	 al.	 2006,	Mossialos	 et	 al.	 2008).	 Key	 functions	 influencing	 on	
these	differences	reflect	the	overall	content	of	pharmaceutical	policy,	 including	the	val-
ues, actors, structures and historical perspective. In this thesis, NRT deregulation means 
a shift from pharmacy-only distribution to general sales. Further, OTC NRT means NRT 
products which are sold in general sales. The following paragraphs describe NRT deregu-
lations in different countries in brief. 
3.5.1 International NRT deregulations  
The	first	and	most	investigated	NRT	deregulation	took	place	in	the	USA	in	August	1996,	
when the FDA approved nicotine gum for OTC sales. This was followed by releasing NRT 
patches	 in	1999	and	nicotine	 lozenge	in	2002	(Amodei	and	Lamb	2010,	U.S	Food	and	
Drug	Administration	2013).	The	US	deregulation	was	justified	by	the	idea	of	increasing	
access	and	utilization	of	NRT	products	and	thus	gaining	public	health	benefits	(Shiffman	
and Sweeney 2008, See Chapter 5). The US pharmaceutical policy has traditionally been 
very liberal, as all the non-prescription medicines are sold in general sales. NRT deregula-
tion was preceded by the deregulation of many prescription-medicines intended for tem-
porary use (Mahecha 2006). 
In the UK, the 2-milligram NRT gum was deregulated from pharmacy-only-status to 
general sales (equivalent to US OTC) in 1999 (Raw and McNeill 1999). Further, in May 
2001 the rest of NRT products were also added to general sales list. This was advocated by 
various	health	organizations,	with	the	idea	of	making	NRT	products	as	freely	available	as	
cigarettes (See Chapter 5). In the UK, at the same time as NRT deregulation, the world’s 
most comprehensive national SC policy was implemented (West et al. 2005). This policy 
consisted of the reimbursement of all prescribed SC medications, widely disseminated 
clinical guidelines and a nationwide spread of SC clinics, which offer behavioural support 
and medications. 
In the Nordic countries NRT products were deregulated from pharmacy-only to gen-
eral sales in Iceland in 1999, in Denmark in 2001 and in Norway in 2003 (Morgal and 
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Almarsdóttir 1999, Norreslet et al. 2005, Turakka and Paaskoski 2005). The NRT de-
regulation in these countries was a part of a wider deregulation of selected non-prescrip-
tion medicines. In addition, in Iceland and in Norway the ownership of pharmacies was 
liberalized.	Later,	in	2009	in	Sweden	the	pharmacy	monopoly	(Apoteket	Ab)	owned	by	
the Government, was dissolved and non-prescription medicines, including NRT products, 
were deregulated to general sales (Bardage et al. 2013).
3.5.2 The Finnish NRT deregulation 
In order to increase the availability and use of NRT products, the Finnish Parliament en-
acted a change in the prevailing medical legislation extending NRT sales to food stores, ki-
osks and gas stations from the beginning of February 2006 (Change in Medical Act 2006). 
At the time of the NRT deregulation process in 2005-2006, none of the strategic phar-
maceutical policy documents suggested deregulation of non-prescription medicines. On 
the contrary, the goal of the Ministry of Social Affairs and Health (S&H) was to include 
NRTs that were prescribed by the physician, in the reimbursement scheme in autumn of 
2004.	This	was	rejected	by	the	Ministry	of	Finance	for	monetary	reasons.	The	first	time	
the idea of NRT deregulation was mentioned, was in a speech of the Minister of S&H on 
March 12, 2005. 
 Already in May 2005 the Ministry of S&H had prepared the Government Bill 
(107/2005), which introduced NRT deregulation as a part of a larger package of chang-
es in medical legislation. The Amendment was enacted by the Finnish Parliament in De-
cember 2005. The Parliamentary Social Affairs and Health Committee (SAHC) expected 
the	Government	to	organize	monitoring	of	the	NRT	deregulation.	The	monitoring	report	
was completed one year after the deregulation was introduced (Ministry of Social Affairs 
and Health 2007). The monitoring group suggested further NRT deregulation to restau-
rants, which became smoke-free in the summer of 2007. This change was enacted, along 
with the new Tobacco legislation, in the autumn of 2010 (Ministry of Social Affairs and 
Health 2009). 
3.5.3 The role of NRT after deregulation 
After the NRT deregulations the products’ role solely in SC has been highlighted (Shiffman 
et al. 1997, Hughes et al. 2003, Hyland et al. 2005, Shiffman 2007, Shiffman and Sweeney 
2008, Hughes et al. 2011). After NRT deregulation, the need for healthcare profession-
als’	support,	which	was	highlighted	in	the	first	clinical	trials	and	guidelines,	is	given	less	
attention. Instead, smokers’ and quitters’, now self-respondent consumers’, freedom to 
choose and buy the products independently is highlighted (Shiffman and Sweeney 2008, 
Keane 2013). Furthermore, quitters do not want to be perceived as patients and they are 
reluctant to seek help from physicians in SC (Shiffman and Sweeney 2008). Some authors 
suggest that OTC NRT supports smokers’ and quitters’ self-esteem and capability (Mc-
Neill et al. 2001). This is also closely related to general tendency to widen the role of med-
ication users from patients to free consumers (Morgal and Almarsdóttir 1999). 
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The US deregulation of NRT to OTC has been suggested to present an important ex-
ample of the new “OTC paradigm” meaning to extend OTC treatments use beyond acute 
symptomatic conditions to long-term use for treatment of chronic, asymptomatic condi-
tions and for support of preventive lifestyle changes (Shiffman and Sweeney 2008). OTC-
NRT has been used as an important landmark on this road to increase the assortment 
of non-prescription and OTC medicines. In Europe the OTC paradigm has been used to 
justify the deregulation of orlistat from prescription to non-prescription status in 2008 
through	a	centralized	procedure	(European	Commission	2013)	It	has	also	been	noticed	
as a future direction of self-medicine practises (European Commission 2013). It is im-
portant	to	assess	how	this	new	paradigm	will	influence	on	self-care	and	non-prescription	
medicine practices. 
 
3.6 Widening NRT use to new user groups and the 
 introduction of combination therapy
Also during the 2000’s the use of NRT products has expanded into new indication areas 
and	patient	 groups	 compared	with	 the	first	 clinical	 guidelines	 (see	Table	 1,	Medicines	
and Healthcare Products regulatory Agency 2005; 2006, Fiore et al. 2008, Keane 2013, 
U.S Food and Drug Administration 2013). NRT products are recommended to new user 
groups, for whom NRT use was earlier considered to be contraindicated. These include 
individuals in the most vulnerable positions, like minors, pregnant and lactating mothers, 
the elderly and chronically ill (Fiore et al. 2008, Tonstad et al. 2009, Fiore and Baker 
2011). This relaxation is related to the increased information on the overall safety related 
to NRT products compared to the harm associated with continued tobacco use.  
Use of stronger NRT doses is also recommended in comparison with earlier advice. For 
instance, a combination therapy of different NRT products is recommended as a more ef-
fective treatment strategy than a single treatment (Fiore et al. 2008, National Institute of 
Clinical	Excellence	2012,	Cahill	et	al.	2013).	Efficacy	of	a	combination	therapy	may	be	ex-
plained by not only higher nicotine concentration but also the timing and form of nicotine 
delivery (Ebbert et al. 2010, Cahill et al. 2013; 2014).
3.7 NRT for harm reduction 
The	idea	of	harm	reduction	in	SC	is	to	minimize	the	amount	of	cigarettes	smoked	and	
thus the harm of tobacco use by the use of less toxic and carcinogenic nicotine substances 
(Stead	and	Lancaster	2007,	Le	Houezec	et	al.	2011).	Traditionally	quitting	is	perceived	as	
an orthodoxical absence of smoking (abrupt quitting). The instructions for NRT use have 
warned not to smoke during NRT use (the US Food and Drug Administration 2013). 
Significant	liberalization	of	NRT	products	has	taken	place	during	2005-2013	as	many	
regulatory authorities in different countries have approved more liberal, harm reduction 
indications for NRT products (Medicines and Healthcare Products regulatory Agency 2006, 
Royal College of Physicians 2007, National Institute for Health and Care Excellence 2013, 
the US Food and Drug Administration 2013, Lohi S. /Fimea, personal information 2014). 
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The	 ideology	 of	 harm	 reduction	 is	 justified	by	 the	 idea	 of	 tobacco	dependence	 as	 a	
chronic,	relapsing	disorder	(Le	Houezec	et	al.	2011).	In	the	mid	2010’s	harm	reduction	in	
SC is probably the hottest topic in tobacco science, accelerated by the radical expansion 
of	the	popularity	of	electronic	cigarettes	(World	Health	Organization	2014h).	Harm	re-
duction has its powerful supporters and opposites among scientists and stakeholders. SC 
specialists still differ in their perception on the safety of harm reduction strategies and 
recommending harm reduction to their patients (Beard et al. 2012). 
The most common strategies for harm reduction in relation to NRT use include cutting 
down before quitting, reduced smoking with NRT use and temporary abstinence (Nation-
al Institute of Clinical Excellence 2013, see Table 4). These strategies are recommended 
for smokers, who are either unable or unwilling to quit abruptly. These smokers may be 
highly dependent on nicotine or suffer from a chronic condition, for instance psychiatric 
disease, which makes quitting more complicated. 
Table 4. Examples of arguments for and against NRT use in harm reduction. 
Arguments for NRT use in harm reduction 
(References)
Arguments against NRT use in harm reduction 
(References)
Arguments related to harm reduction strategy generally
Harm reduction might decrease smoking and 
harms related to it (Hughes et al. 2006). 
Too ortodoxical tobacco policy, which only 
accepts total abstinence from all tobacco and 
nicotine products as a goal, may judge smokers 
unable to quit as failures (Gray et al. 2005, Le 
Houezec et al. 2011). 
A humanistic perspective highlights the need to 
help those smokers unable to quit, to minimize 
the health hazards (Le Houezec et al. 2011).
Harm reduction strategies may increase 
motivation in future quitting attempts (Hughes et 
al. 2006).
The effectiveness and the actual health benefits of 
harm reduction are still unclear (Hatsukami et al. 2004, 
Hughes et al. 2006, Stead and Lancaster 2007).
In a long-term follow-up study of over 20 000 
participants only total abstinence was associated 
with reduced mortality from tobacco related diseases 
(Godtfredsen et al. 2002). 
Harm reduction may diminish smokers’ motivation 
towards quitting if reduction is seen as an alternative to 
SC (Hughes et al. 2006). 
Harm reduction can benefit the tobacco industry as a 
means to dialogue with public health experts and also 
expand its business (Peeters and Gilmore 2015).
Arguments related to specifically on NRT use in harm reduction 
NRT products are, due to their safety, purity and 
high standard required by medication regulatory 
authorities, idealistic harm reduction products 
(Gray et al. 2005, Le Houezec et al. 2011, Keane 
2013).
 
Most of the evidence for harm reduction is from 
NRT studies (Stead and Lancaster 2007).  
Originally NRT products were developed from 
pharmaceutical needs to give therapeutical 
replacement for nicotine, but not to replace the habits 
and behaviour related to smoking (Jarvis 1982, Keane 
2013).
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The	evidence	for	the	efficacy	of	harm	reduction	and	the	practises	related	to	it	are	con-
tradictory (Table 4). According to the systematic Cochrane review on harm reduction, the 
use of NRT products nearly doubled the odds on reducing the number of smoked ciga-
rettes per day by 50% (Stead and Lancaster 2007). However, only a minority of the study 
participants were able to maintain this reduction of smoking for a longer period.  
3.8 Advocating for a more liberal nicotine policy and market 
NRT products are currently marketed and regulated as medical products, not as a substi-
tute	for	cigarette	smoking	(Le	Houezec	et	al.	2011).	However,	currently	many	stakehold-
ers	and	scientists	advocate	for	a	far	more	liberal	nicotine	policy	(Le	Houezec	et	al.	2011,	
Fagerström and Brigdman 2014). This sort of policy would relax NRT regulation, change 
NRT’s status to non-medical products and increase their doses and rates of nicotine de-
livery to act as a better substitute for tobacco use. Currently better acting NRT products, 
which	would	better	fit	the	needs	related	to	smoking	behaviour,	are	already	developed	and	
discussed (Shabab et al. 2013, Fagerström and Brigdman 2014). 
Furthermore, some stakeholders suggest, that all nicotine containing products should 
be regulated under the same regulatory authority, which focuses on the harmfulness of 
nicotine containing products, instead of the current separated regulation for tobacco and 
nicotine	products	(Le	Houezec	et	al.	2011,	Elam	and	Gunnarson	2012).	This	would	lead	
to a new nicotine market, whose regulation would be based on the products’ harmful-
ness. As a result, the most harmful products would be the most regulated, most unattrac-
tive and most inaccessible. These discussions of a new regulation for the nicotine market 
are also related to recent evolvement and expanding popularity of e-cigarettes (Bell et al. 
2012,	Etter	et	al.	2014,	World	Health	Organization	2014h).	
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4 Efficacy and effectiveness of OTC NRT 
During the NRT deregulation debates the concepts of efficacy and effectiveness of OTC 
NRT were much discussed (see Chapter 5). Therefore it is important to describe what 
these concepts mean and what the actual evidence-base of the real world effectiveness of 
OTC NRT is. The aim of this chapter is to describe the differences between these two con-
cepts,	their	assessment,	and	report	the	evidence	of	OTC	NRT	efficacy	and	effectiveness	
and	the	aspects	related	to	the	generalizability	of	this	evidence	in	real	life.	
Efficacy means how the treatment studied works on a controlled environment. In this 
environment the effects of the treatment, the study population and circumstances are 
isolated	from	each	other	by	the	well	planned	and	precise	design,	control,	randomization,	
blinding	and	analysis	(Rush	2009,	Saturni	et	al.	2014).	Efficacy	is	associated	with	high	
internal validity, as the effects of confounders are controlled. At best, these idealistic cir-
cumstances	are	achieved	in	randomized	controlled	trials,	RCTs,	which	are	called	the	gold-
en	standard	of	studies	aiming	to	investigate	efficacy	of	a	treatment	(Saturni	et	al.	2014).	
Traditionally	most	SC	pharmacotherapy	 investigations	have	 focused	on	 the	 efficacy	 in	
a clinical trial environment (Zhu et al. 2012).  This is mostly due to the requirements of 
medical authorities for gaining marketing permissions. 
In	contrast	to	efficacy,	effectiveness means the assessment, how therapy works on real 
life conditions (Rush 2009, Saturni 2014). Studies assessing effectiveness under real life 
conditions (real life studies) have high external validity, as the study designs permit the 
inclusion of different kinds of patients and environments allowing their characteristics to 
influence	in	the	results	(Saturni	et	al.	2014).	Real	life	studies	are	especially	important	for	
assessing	the	generalizability	of	findings	from	RCTs	and	for	locating	rare	phenomena	re-
lated	to	the	studied	treatment.	On	the	other	hand,	it	is	much	more	difficult	to	control	con-
founding factors in real life studies than in RCTs’. For this reason, real life studies do not 
usually have high internal validity and cannot assess causal relationships as rigorously as 
RCTs can (Rush 2009, Saturni et al. 2014).
4.1 Evidence on NRT efficacy and its generalizability 
 to real life
4.1.1 Evidence on NRT efficacy
Based	on	the	robust	scientific	evidence	on	efficacy	NRT	use	is	stated	as	the	gold	stand-
ard in SC treatment (Lemmens et al. 2008, Stead et al. 2012, Cahill et al. 2014). The most 
cited	source	of	 information	on	NRT	efficacy	is	provided	by	the	high-quality	systematic	
reviews produced by the Cochrane Collaboration. The Cochrane Collaboration is an in-
ternational,	non-profit	and	independent	organization,	which	produces	and	disseminates	
high-quality evidence-based information on different health care interventions (Hart-
mann-Boyse et al. 2013, The Cochrane Tobacco Addiction Group 2014). 
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The Cochrane Collaboration has its own, Cochrane Tobacco Addiction Group (2014), 
which	assesses	the	efficacy	of	different	SC	interventions,	including	pharmacotherapy,	be-
havioural methods and society level interventions. The Tobacco Addiction Group has as-
sessed	NRT	products’	efficacy	in	altogether	four	versions	of	the	systematic	review	during	
2000-2012 (Silagy et al. 2002; 2004, Stead et al. 2008; 2012, see Appendix 1). This as-
sessment	is	based	on	over	120	RCTs	and	the	confidence	intervals	of	the	findings	are	very	
narrow, implying high reliability (Lemmens et al. 2008, Stead et al. 2012). All the ver-
sions of the Cochrane review have concluded the use of NRT to increase SC rate by 50-
70% compared with placebo, regardless of the duration of the therapy, the intensity of ad-
ditional support provided or setting (Silagy et al. 2002; 2004, Stead et al. 2008; 2012). In 
the	meta-review	assessing	the	efficacy	of	different	SC	interventions,	NRT	efficacy	assess-
ment was considered as the strongest (Lemmens et al. 2008).
4.1.2 Examples of differences between RCT and real life conditions
Information	on	NRT	efficacy	is	widely	used	to	justify	OTC	NRT’s	effectiveness	in	real	life	
(Shiffman and Sweeney 2008, Fiore et al. 2008, National Institute on Clinical Excellence 
2012).	There	are	also	specific	RCTs,	mimicking	OTC	conditions	and	comparing	these	to	
Rx conditions (Shiffman et al. 2002a, Hughes et al. 2003). However, often the RCT re-
sults cannot be directly extrapolated to real life due to several differences between RCT 
and real life conditions (Walsh 2008, Zhu et al. 2012, Saturni et al. 2014). 
4.1.2.1 Differences between NRT users in RCTs and real life
Motivation can be expected to be highly essential in lifestyle changes such as SC (Zhu et 
al. 2012). When NRT trial participants and NRT users in real life are compared, there are 
differences between their motivations towards behavioural change (Walsh 2008, Zhu et 
al. 2012). For instance, in many NRT trials mass media advertisements are used in re-
cruitment, though there is evidence that study participants, recruited from advertisement, 
have better motivation towards quitting compared with all quitters (Silagy et al. 2004, 
Stead et al. 2008, Walsh 2008). Trial participants have better levels of adherence towards 
NRT use than the NRT users in real life, partly due to the follow-up and guidance pro-
vided	in	the	trial	(Walsh	2008,	Zhu	et	al.	2012,	Henningfield	et	al.	2012).	In	real	life	poor	
adherence towards NRT treatment and abrupt discontinuation of the therapy are cited as 
one	key	reason	for	poor	real	life	benefits	of	NRT	use	(see	Chapter	6.2).	
4.1.2.2 Other differences between the two conditions 
In most of the trials included in the Cochrane Review on NRT, participants’ rate of initial 
dependence	has	been	assessed	and	the	treatment	has	been	modified	accordingly	(Stead	et	
al. 2012). In real life, the OTC NRT users have to choose the treatment option themselves 
and sometimes they have not taken the level of nicotine dependence into account in that 
choice (Walsh 2008). For ethical reasons, trial participants have often received NRT free 
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of charge (Hughes et al. 2003, Walsh 2008, Hughes et al. 2011). In real life, smokers and 
quitters have to pay for the products themselves. There is evidence, that total or partial 
reimbursement of NRT increases the use of NRT (West et al. 2005, Selby et al. 2008, Sha-
hab et al. 2009, Reda et al. 2012). 
In addition, due to the trial protocol, even in trials with limited counselling, the study 
participants in NRT and placebo groups have frequent contacts with the clinical research 
centre (Stead et al. 2012, see Appendix 1). Although the participants in NRT and placebo 
groups have received similar counselling, there is evidence, that the number of SC ses-
sions	held	has	an	influence	on	the	adherence	towards	NRT	use	and	the	rate	of	success	
(Walsh et al. 2008, Stead et al. 2012, Zhu et al. 2012). Furthermore, in many trials NRT 
use is accompanied by multiple components, such as initial counselling or written NRT 
use	instructions,	follow-up	visit	or	audiotapes	on	SC	and	self-reflective	diaries	(Shiffman	
et	al.	2002	Hughes	et	al.	2003).	These	components	make	it	difficult	to	directly	compare	
the effects of NRT use in trials with real life (Hughes et al. 2003, Walsh 2008). This mat-
ter also highlights the need for real life effectiveness studies.
4.2 Effectiveness of OTC NRT 
Currently, the interest towards and the existence of real life studies is constantly increas-
ing in many therapeutic areas (Rush 2009, Saturni 2014). Studies assessing the effective-
ness of OTC NRT have been progressive, as many of these were conducted soon after the 
US deregulation, near Millennium (Shiffman et al. 1997, Pierce and Gilpin 2002, Thorn-
dike et al. 2002, Hughes et al. 2003, Hyland et al. 2005a). Currently, no study address-
ing the population based effectiveness of OTC NRT has been conducted in Finland. For 
this reason, the evidence on effectiveness is based on international evidence in countries, 
where NRT has been deregulated to general sales. 
4.2.1 Different studies assessing the effectiveness of OTC NRT
To gain an understanding of the different studies assessing the effectiveness of OTC NRT, 
a non-systematic literature search and a narrative literature review was conducted during 
March-June 2014. Studies were searched from the Scopus database via the University of 
Helsinki with full coverage for Medline and 98% coverage for Embase. 
The studies included in this review (Appendix 2) were chosen to provide either exam-
ples of different kinds of study designs or because they were among the most cited ones. 
When	considering	the	generalizability	of	this	non-systematic	review	for	Finland,	it	should	
be noted that none of these studies directly compared the effectiveness of NRT bought 
from a pharmacy with those from other sales outlets.
Effectiveness of OTC NRT in real life has been investigated through different 
population-based study designs and data collection methods (Appendix 2). Some of these 
studies compare data before and after NRT deregulation (Pierce et al. 2002, Thorndike et 
al.	2002,	Hyland	et	al.	2005a)	and	some	only	after	deregulation	(Alberg	et	al.	2012,	Kazka	
et	al.	2013,	Kotz	et	al.	2014).	
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In most of the included studies users of OTC NRT are compared with non-users and 
the key outcome has been tobacco abstinence though some studies have assessed smoking 
reduction or adherence to NRT as well (Alperg et al. 2005, Balmford et al. 2011, Shabab 
et al. 2011). Most of the studies are conducted in the USA (Shiffman et al. 1997, Pierce 
and Gilpin 2002, Thorndike et al. 2002, Hughes et al. 2003, Hyland et al. 2005a, Reed et 
al.	2005,	Shiffman	and	Sweeney	2008,	Henningfield	et	al.	2009,	Hughes	et	al.	2011).	The	
high number of studies from the USA is because the local pharmaceutical market is the 
largest and most advanced. 
4.2.2 Contradictory evidence of the real life effectiveness of OTC NRT
4.2.2.1 Studies supporting the effectiveness of OTC NRT 
There	 is	 one	meta-analysis	 assessing	 the	 efficacy	 of	NRT	 in	 an	OTC-like	 environment	
(Hughes et al. 2003, Appendix 2). Despite this meta-analysis being based on RCTs as-
sessing	efficacy	instead	of	effectiveness,	it	compared	the	effects	of	sole	use	of	NRT	and	
NRT with counselling in mimicked real life conditions. For this reason it was included in 
this non-systematic literature review. The meta-analysis was based on four studies com-
paring OTC NRT and Rx NRT patch and it did not include any studies of other dosage 
forms (Hughes et al. 2003). The meta-analysis showed OTC NRT patch yielding similar 
six months quit rates compared with Rx-NRT patch. This review is much cited in NRT lit-
erature	and	it	has	often	been	used	as	a	justification	for	the	effectiveness	of	NRT	deregu-
lation.	However,	the	conclusions	and	generalizability	of	this	meta-analysis	have	been	de-
bated (Walsh 2008).
There	is	also	one	qualitative	review	summarizing	evidence	on	OTC-NRT	effectiveness	
from population-based studies (Hughes et al. 2011). It included altogether 11 retrospec-
tive cohort studies, in which the cohort members using OTC-NRT were compared with 
non-NRT users. The authors of the review also located seven pre- and post- OTC-NRT 
studies. These studies compared the quit rates before and after deregulation. Due to the 
heterogeneity between the included studies, the authors were unable to conduct a meta-
analysis.	They	summarized	the	key	findings	by	four	different	methods	and	finally,	based	
on their assessment, found OTC NRT to be effective in real life (Appendix 2).   
 Some prospective cohort studies conducted over the last ten years, have found evi-
dence supporting the real life effectiveness of OTC NRT (Hyland et al. 2005a, West and 
Zhou	2007,	Balmford	et	al.	2011,	Kazka	et	al.	2013,	Appendix	2).	These	studies	have	sev-
eral methodological strengths, including broad and representative data collection and 
longitudinal analysis. In addition the authors have been able to control many confound-
ing factors in the effectiveness assessment. Furthermore, some US studies based on NRT 
sales data (Shiffman et al. 1997) or combining sales data to a tobacco survey (Reed et al. 
2005) have found evidence supporting the effectiveness of OTC NRT.  
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4.2.2.2 Studies with mixed or non-supporting evidence on OTC NRT effectiveness
There are mixed results for the effectiveness of different NRT forms (Appendix 2). For in-
stance, the study of Hyland et al. (2004) found that NRT gum was effective but the patch 
was	not.	In	contrast	to	this,	the	study	of	Kazka	and	co-authors	(2013)	found	evidence	of	
the effectiveness of the OTC patch but not for any oral NRT dosage forms.
There are also several studies showing no evidence to support the effectiveness of OTC 
NRT in real life (Pierce and Gilpin 2002, Thorndike et al. 2002, Gilpin et al. 2006, Al-
berg	et	al.	2005,	Alpert	et	al.	2012,	Kotz	et	al.	2014,	Appendix	2).	The	most	cited	ones	are	
the large population-based surveys in California (Pierce and Gilpin 2002) and in Mas-
sachutess (Thorndike et al. 2002) comparing data before and after the US NRT deregu-
lation.	Based	on	their	findings,	the	use	of	NRT	significantly	increased	after	deregulation,	
but	this	did	not	reflected	as	a	reduction	in	the	population-based	smoking	rate.	These	stud-
ies indicate that OTC NRT use was associated with less successful SC attempts compared 
to Rx-NRT. 
The prospective cohort study of Alpert et al. (2012) found that the likelihood of relapse 
in SC was most common among study participants who used NRT without any profes-
sional support. The study limitations were large loss to follow-up during four years fol-
low-up	and	possible	recall-bias	of	the	study	participants.	Therefore,	the	findings	of	this	
study, and especially the very critical conclusions drawn by the authors, were debated 
among	the	scientific	community	(Beard	2012,	Stapleton	2012).	
	 	A	 recently	published	retrospective	cohort	 study	 from	the	UK	(Kotz	et	al.	2014)	as-
sessed the real life effectiveness of different SC pharmacotherapies solely or combined 
with behavioural support from population based data (See Appendix 2). The authors con-
sidered England to be the only country in the world where this kind of study could be con-
ducted. This is because, according to the authors, “England has the most extensive and 
comprehensive coverage of different SC methods and use of SC medicines is the highest 
in the whole world” (Kotz	et	al.	2014).	Further,	at	the	time	of	the	data	collection,	NRT	has	
been	OTC	medicine	in	England	for	a	decade,	which	indicates	a	stabilized	market.	NRT	
products can be purchased by Rx or as an OTC medication, which allowed the authors to 
compare these two groups of NRT. Based on the results of over 10 000 respondents, OTC 
NRT was not found effective in SC. In contrast to this, the combination of Rx-NRT with ei-
ther tobacco specialist’s behavioural support or health professional’s brief advice were as-
sociated with an increased success rate compared to no medication use. However, the use 
of	OTC	NRT	yielded	a	poorer	rate	of	success	than	no	SC	medicine	use	(Kotz	et	al.	2014).	
 
4.2.3 Reasons for contradictory results and conclusions of the chapter
The contradictory results on OTC NRT effectiveness can not entirely be explained by study 
setting, design or methodology used. In addition, the role of confounding factors must 
also be taken into account. Of these, the most important in population-based retrospec-
tive cohort studies is the confounder of respondents’ ability to recall their last quitting at-
tempt	(Henningfield	et	al.	2009,	Borland	et	al.	2012).	It	is	easier	to	remember	quitting	at-
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tempts in which some form of support, medical or behavioural, was used, compared with 
attempts without assistance (Borland et al. 2012). The latter ones are more likely to be 
spontaneous	and	short,	which	makes	them	more	difficult	to	remember.	This	factor	may	
increase the amount of reported unsuccessful quitting attempts, in which pharmaceutical 
aids	is	utilized	(Shiffman	et	al.	2008c).	
In addition, the more dependent smokers are on cigarette use, the more likely they 
are to use pharmacotherapy in their quitting attempts (Cummings et al. 2004, Shiffman 
et al. 2005, Shiffman et al. 2008c, Hung et al. 2009, Balmford et al. 2009, Borland et al. 
2012). This can cause confounding by indication (Shiffman and Sweeney 2008, Borland 
et al. 2012). This means that as the participants have self-selected their treatment instead 
of	randomized	allocation,	the	proportion	of	dependent	smokers,	who	are	at	the	highest	
risk for failure, is over-presented among NRT users. Therefore NRT users do not show a 
larger success rate than non-users. On the other hand, the motivation towards quitting 
may be higher among those who decide to use SC treatment (Cummings et al. 2004, Shiff-
man et al. 2008c). 
In conclusion of this chapter, the evidence-base of the effectiveness of OTC NRT is con-
tradictory. As there is a variety of study types, sampling methods and ways to control con-
founding factors in OTC NRT studies, this is natural. As more studies of OTC NRT effec-
tiveness are published, the knowledge of confounding factors increases and these matters 
can be better taken into account in future study designs (Shiffman et al. 2005, Rush et al. 
2009	Borland	et	al.	2012,	Alpert	et	al.	2012,	Kotz	et	al.	2014).		
Finally,	when	efficacy	and	effectiveness	are	compared,	it	is	important	to	remember	that	
many	SC	interventions	in	real	life	may	have	much	lower	effectiveness	than	efficacy	proven	
in clinical trials (Curry et al. 2003, Lemmens et al. 2008, Zhu et al. 2012). This degrading 
of effectiveness in real life compared with a RCT environment is typical for all drug thera-
pies	(Saturni	et	al.	2014,	Henningfield	et	al.	2009).
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5 Key arguments related to NRT 
 deregulation: what was the 
 expectation and what has been    
 achieved 
Like described in Chapter 3, NRT deregulation took place in many countries during the 
mid-1990s and the early 2000s (Table 5). The fundamental reason in common with all 
countries, was to enhance public health by diminishing smoking. It was expected that the 
wider	availability	of	NRT	would	significantly	increase	NRT	utilization.	This	in	turn	would	
significantly	increase	quit	attempts,	in	turn	these	attempts	would	increase	SC	and	thus	
provide	significant	public	health	benefits	(Shiffman	et	al.	1997,	McNeill	and	Raw	2002,	
Shiffman	and	Sweeney	2008,	Government	Bill	107/2005).	These	public	health	benefits	
would consist of saved lives, diminished burden of disease and premature deaths and cost 
savings for the society and for individuals. 
Currently over a period of ten to twenty years after the NRT deregulation in various 
countries, evidence has been gathered from different viewpoints to gain a more compre-
hensive	understanding	how	OTC	NRT	has	reflected	in	SC	in	real	life	and	on	the	safety	of	
OTC NRT. The aim of this chapter is to describe this evidence. Although NRT deregula-
tions have taken place in many countries, most published evidence originates from the 
USA following some evidence from the UK and Australia. For this reason, this chapter 
mostly reports the experiences originating from these countries in addition to Finland. 
51
Table 5. Key arguments supporting the NRT deregulation and a summary of how these arguments are fulfilled in the   
 selected countries based on literature.
Key arguments justifying 
NRT deregulation 
Countries in  
which this 
argument was 
presented
How this argument was fulfilled 
based on published evidence? 
(Number of the chapter focusing 
on this matter) 
References 
Increase in NRT availability 
Limited access to NRT especially 
compared to the access of tobacco 
products. 
Comparison of the number and 
opening hours of pharmacies 
compared to places, which sell 
tobacco.
Australia, 
Finland, the UK, 
the USA
YES
Number of sales outlets has increased 
after deregulations (5.1).
Shiffman et al. 1997, 
Mcneill et al. 2001, 
West and Zhou 
2007, Shiffman and 
Sweeney 2008, 
Finnish Medical 
Agency and Social 
Insurance Institution 
2013
Increased NRT utilization
 
Low use of NRT before 
deregulation 
Use of NRT will increase due to the 
deregulation
Australia, 
Finland, New 
Zealand, the UK, 
the USA
YES 
NRT sales data from different countries 
suggests that the use of NRT has doubled 
after deregulation (5.1).
The use has significantly increased 
but it is still considered modest in quit 
attempts (see 5.3).
Shiffman et al. 
1997, Paul et al. 
2003, Shiffman  et 
al. 2008c, Shiffman 
and Sweeney 2008, 
Scollo et al. 2012, 
Amodei and Lamb 
2008, Helldán et al. 
2013, Finnish Medical 
Agency and Social 
Insurance Institution 
2013
Deregulation will lower NRT 
prices
Australia, the UK, 
the USA
YES
Prices have decreased in Finland, but the 
long term development is unclear (5.2).
Aalto-Setälä and 
Alaranta 2009
Sole use of OTC NRT is effective 
NRT is efficient and OTC NRT is 
effective in real life
OTC NRT products are effective 
without additional counselling 
Australia, 
Finland, New 
Zealand, the UK, 
the USA
UNCLEAR
 
There is robust evidence on NRT efficacy 
(4.1). However, population based 
studies have yielded mixed results of 
effectiveness (4.2).
Counselling is still highlighted in NRT 
guidelines and SPCs (7.1).
Hughes et al. 2003, 
Shiffman and 
Sweeney 2008, 
Hughes et al. 2011
Decreased smoking 
Use of OTC NRT will lead to an 
increase in SC attempts. 
Increased SC attempts, in which 
OTC NRT is used, will lead to more 
successful quitting.
Decreased smoking due to 
increased NRT use will present 
significant public health benefits.
Australia, the UK, 
the USA
UNCLEAR
NRT Efficacy is considered to remain 
similar in Rx and OTC conditions. There 
are mixed results of effectiveness from 
population based studies (4.2). Smoking 
statistics are unable to detect remarkable 
effects of the NRT deregulation to 
smoking prevalence (5.4).
Shiffman et al. 1997, 
McNeill et al. 2001,  
Government Bill 
107/2005, Amodei and 
Lamb 2008, Shiffman 
and Sweeney 2008,  
Scollo et al. 2012 
OTC NRT is safe 
Most common safety concerns: 
Evolvement of serious side effects 
Dependence on NRT, 
Possible abuse are not evident
Worldwide 
evidence from 
different studies
YES
There is little evidence of serious side 
effects, dependence on NRT or abuse of 
NRT (5.5). 
Klesges et al. 2003, 
Johnson et al. 2004, 
Burton et al. 2006, 
Rainio et al. 2011, 
Mills et al. 2013
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5.1 Evidence of the development of NRT use 
 after deregulation
Based	on	evidence	from	various	countries,	the	use	of	NRT	has	sizeably	increased	after	the	
NRT deregulation (Shiffman et al. 1997, Paul et al. 2003 West et al. 2005, Finnish Medi-
cal Agency and Social Insurance Institute 2013). The US sales statistics suggest that after 
the NRT deregulation, the use of NRT gum and patch has doubled compared with the use 
before deregulation (Shiffman et al. 1997, Reed et al. 2005, Amodei and Lamb 2008). 
In the UK, NRT gum of 2mg was deregulated to general sales in 1999 and the rest of 
NRT forms in 2002. In 2001, all SC medications were included in the reimbursement 
scheme. These changes together resulted in dramatic increased the use of SC medications 
in the UK from the 28% in 1999 to 61% in 2002, based on sales data and a population 
based survey (West et al. 2005). However, compared with other regulatory changes lead-
ing to the increase in SC medications use, NRT products deregulation was not associated 
with	a	statistically	significant		increase	in	SC	(West	et	al.	2005).	
In Finland, on the basis of the Finnish wholesale statistics of medicines (Finnish Phar-
maceutical Data Ltd. /Personal information 2008), the sales of NRT products amounted 
26 million Euros in 2005 (retail price including value added tax of 8%). Since 1995, the 
sales increased approximately by 10% annually. During 2006, the NRT sales increased 
by 20% compared with the previous year and 30% of the sales occurred outside pharma-
cies (National Agency of Medicines and Social Insurance Institution 2006). In 2013 the 
wholesale sales of NRT products amounted to 34 million Euro for other sales outlets and 
7 million Euro for pharmacies (Finnish Medicines Agency Fimea and Social Insurance 
Institution 2014). When measured in wholesale sales NRT products were the most sold 
group of non-prescription medicines in Finland in 2013. 
	Defined	daily	doses	(DDD)	are	the	international	unit	of	average	medicine	consump-
tion	(World	Health	Organization	and	Norwegian	Institute	on	Public	Health	2009).	Based	
on the measurement of DDDs consumed, the use of NRT in Finland has nearly doubled 
after deregulation (Figure 3). According to sales statistics from 2013, a majority (80%) of 
the sales are made in the outlets outside pharmacies (Finnish Medicines Agency Fimea 
and Social Insurance Institution 2014). The most commonly sold product forms are the 
smallest packages of the mildest NRT gum (Ministry of Social Affairs and Health 2007). 
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5.2 Change in NRT pricing after the Finnish deregulation
One key argument for NRT deregulation in Finland was the expected decrease in NRT pric-
es, because after deregulation products pricing became free (Government Bill 107/2005). 
This change was found especially important because of the strong socioeconomic gradient 
in the smoking behaviour. Before NRT deregulation, NRT products pricing was guided by 
the Medical legislation, of which one key principle is that all medications have the same 
Figure 3. Development of NRT sales in Finland during 2005-2013. (Sources: National Agency of   
 Medicines and Social Insurance Institution 2007, Finnish Medicines Agency Fimea and Social  
 Insurance Institution 2010, 2012, 2014).
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regulated price in all Finnish pharmacies (Medicines Act 1987). Finnish pharmacies are 
obliged to pay a pharmacy fee for the sales of all medicines, which on average was 7% of 
the pharmacy turnover at the time NRT deregulation took place (Act on Pharmacy Fee 
1166/2005). 
After deregulation NRT products pricing became free and pharmacies were released 
from the pharmacy fee for the NRT products. According to an analysis of NRT prices, con-
ducted immediately following deregulation in 2006, NRT prices decreased by an average 
of 15 percent units in all sales outlets in urban areas (Aalto-Setälä and Alaranta 2007). 
The products were most inexpensive in supermarkets and most expensive in gas stations. 
The assortment of NRT products was largest at pharmacies and the most modest in ki-
osks. How much of the development was due to recentness of this change and how the 
pricing behaviour develops in long turn needs though further investigation.  
5.3 How NRT use in quitting attempts has developed 
 after deregulations?
Population-based studies have provided evidence that increased use of NRT products 
has also increased the number of quit attempts which included NRT use (Shiffman et 
al. 1997, Pierce and Gilpin 2002, Thorndike et al. 2002, Hyland et al. 2005a, Reed et al. 
2005, Amodei and Lamb 2008, Shiffman and Sweeney 2008, Zhu et al. 2012). There are, 
though,	more	contradictory	findings	relating	to	how	much	NRT	is	used	in	quit	attempts	
and how much for other purposes (Amodei and Lamb 2008). Based on the US sales sta-
tistics, Shiffman and his colleges (1997) suggested, that the number of NRT assisted quit-
ting attempts has more than doubled after NRT deregulation (from 2.5 million in 1995 to 
5.8 million in 1997). 
However, it can be questioned is it a reliable assessment to directly draw the number of 
quit attempts from sales statistics (Walsh and Penman 2000, Amodei and Lamb 2008). 
This is because the mere purchase of a product does not guarantee success in quitting 
or even that the product is used in a quit attempt. On the other hand, West and his col-
leagues (2005) suggested that, if NRT usage patterns remain stable over the monitored 
sales period, the assessment from sales data is a valid measure for assessing NRT use in 
quit attempts. 
In Finland, the National Institute for Health and Welfare (2014) conducts an annu-
al representative survey called Health Behaviour and Health among the Finnish Adult 
Population (AVTK). The surveys, annually conducted, are comparable since 1978 mak-
ing them the most important follow-up instruments of health behaviour among Finnish 
adults. According to the results of this survey NRT use in quit attempts has steadily in-
creased during 2005 and 2013 (Figure 4). In 2005, before NRT deregulation, 13.5% of the 
adult population who smoked during past year, had used NRT for quitting (Helakorpi et 
al. 2005). In 2013 the corresponding rate was 17.4% (Helldán et al. 2013). 
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5.4 Smoking prevalence after NRT deregulations
In	various	 countries,	 it	was	 expected	 that	NRT	deregulation	will	 lead	 to	 significant	 re-
duction in smoking rates (Table 5). However, the evidence from many countries suggests, 
that NRT deregulation is not directly projected in national smoking statistics (Cummings 
and	Hyland	2005,	West	et	al.	2005,	Amodei	and	Lamb	2008,	Wakefield	et	al.	2008,	Zu	
et al. 2012, see Figure 5). 
5.4.1 Evidence from the US, Australian and British smoking statistics
Based on the US smoking statistics, the prevalence of cigarette smoking (24.7%) has re-
mained constant, when comparing the year before the NRT deregulation (1995) and the 
year after (1997) (Centers for Disease Control and Prevention 2007, Amodei and Lamb 
2008). In the USA ten years after the NRT deregulation (in 2006) the smoking rate was 
20.8% (Centers for Disease Control and Prevention 2007, US Department of Health and 
Human Services 2014), with a decline of 3.9% over ten-year period. Compared with the 
12.5% drop in the smoking rate over ten-year period of 1974-1985, the increased availabil-
ity	of	NRT	after	deregulation	did	not	significantly	reduced	smoking.	
The nationwide, representative National Health Interview study has collected data on 
Figure 4. Development of NRT use in quit attempts in Finland during 2005-2013, according to the data  
 originating from the Health and Health Behaviour among the Finnish Adult Population   
 -survey by the National Institute for Health and Welfare (Helakorpi et al. 2006, 2007, 2008,  
 2009, 2010 and 2011, Helldán et al. 2012, 2013).
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the	US	SC	rates	since	1991	(Zu	et	al.	2012).	According	to	its	findings,	the	annual	SC	rate	is	
between 4-5% when measured by abstinence continuing at least three months during past 
year (Zhu et al. 2012). According to this study, the SC rate varies from year to year with a 
constant upward trend (Zu et al. 2012). The most positive trend was a reduction in smok-
ing	during	1991-1999	but	during	1999-2002	there	was	a	significant	drop	in	the	SC	rate.	In	
1995, before NRT deregulation, 45.8% of smokers made a quit attempt, whereas in 1997, a 
year after deregulation, 40.8% of smokers made a quit attempt (Centers for Disease Con-
trol and Prevention 1997; 1999, Amodei and Lamb 2008). 
The review of Cummings and Hyland (2005) reported a time series analysis of the na-
tional US tobacco consumption and NRT sales from the period of 1976 to 1998. The anal-
ysis	found	no	statistically	significant	evidence	for	the	idea	that	the	deregulation	of	NRT	
patch and gum products was associated with decreased cigarette consumption. In con-
trast to this, the introduction of the NRT patch in 1992 was followed by a modest decrease 
in cigarette consumption. 
In Australia NRT product sales were deregulated to supermarket sales in 2005 (Eller-
man et al. 2011). The Australian Self-Medication industry (2008) has visibly lobbied for 
the gradual deregulation of NRT products. According to the Australian National Drug 
Strategy Household Survey, the prevalence of regular smoking in Australia was 22% in 
2004. In 2007, it was 21% and in 2010 it was 20%, indicating of a drop of one percent over 
a successive three-year period (Winstalley and White 2012).
		In	the	UK	smoking	has	significantly	decreased	between	the	1970s	and	mid-1990s.	Af-
ter that the decrease in the smoking rate has been much slower. The average annual de-
cline of smoking rate has been 0.4% during 1999-2005 (Cancer Research UK 2014). It has 
been	suggested	that	the	sizeable	increase	in	the	use	of	SC	medications	during	1999-2002	
(soon after NRT deregulation) in the UK has at most optimistically resulted in an annual 
reduction of smoking prevalence of 0.1% (West et al. 2005). This reduction is considered 
so marginal, that it is impossible to reliably detect it in annual smoking prevalence sur-
veys. 
 
5.4.2 Evidence from the Finnish smoking statistics
The development of the smoking rate in Finland, originating from the health indicators 
of	the	National	Institute	for	Health	and	Welfare	(indicator	bank	SOTKAnet®	2014),	is	
described in Figure 5. Before NRT deregulation in 2005, the proportion of daily smok-
ers (smoking rate) in Finland was 22.2%. In 2013 the smoking rate was 16.7%. As noticed 
from the Figure 5, in addition to NRT deregulation, various other changes in the Finnish 
Tobacco legislation have been enacted after 2006. In addition, in Finland the general at-
titude against tobacco has been strengthened all the time (Hakkarainen 2014). For these 
reasons	it	impossible	to	directly	assess	the	influence	of	NRT	deregulation	on	the	decline	
in the smoking rate in Finland. However, there is no compelling evidence supporting the 
expectation	that	NRT	deregulation	will	solely	lead	to	a	significant	reduction	in	smoking	in	
Finland. Additional reasons why the increased NRT use after deregulation is not directly 
reflected	in	smoking	statistics	are	described	in	Chapter	6.	
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Figure 5. Development of the smoking rate (proportion of daily smokers) among the Finnish adult population 
 (25-64 years old) during 2000-2013 (drawn from the indicator bank SOTKANET® by the Finnish   
 National Institute for Health and Welfare, ©;THL) and the most important changes in the Finnish   
 tobacco legislation near the NRT deregulation and after it (Finnish Action on Smoking 2014).
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5.5 Safety of OTC NRT
At the time of NRT deregulation safety concerns were raised (Table 5). As nicotine is a va-
soconstructive substance, especially the possible existence of serious cardiovascular ad-
verse effects was concerned (Greenland et al. 1998). According to a meta-analysis of 35 
studies (Greenland et al. 1998), it is unlikely for NRT to cause cardiac events. Also the re-
sults of more recent network meta-analysis suggest that it is unlikely that the use of NRT 
would cause serious cardiovascular events (Mills et al. 2013). 
Further, as nicotine is the key dependence causing agent in tobacco products, it was 
worried, would OTC NRT cause dependence among the population (Table 5). According 
to population-based studies the prevalence of dependence on any NRT product is low, ap-
proximately 1% of all NRT users (Hughes, et al. 2004, Hughes et al. 2005). On the other 
hand, it has been suggested that persistent use and dependence on NRT are under-inves-
tigated phenomena and therefore, they can be more prevalent than is currently expect-
ed (Dome 2011). Less than 10% of smokers use NRT for long-term (> 1 year) (West et al. 
2000, Sims and Fiore 2002, Hajek et al. 2007). There is evidence, that the smokers, who 
are more dependent on tobacco, use NRT for longer periods (Hajek et al. 2007, Shiffman 
et al. 2008c). The long-term use of NRT is also recommended as a therapeutic option for 
highly dependent smokers (Fiore and Baker 2011, The Finnish Medical Society Duodecim 
2012). The long-term use of NRT is considered as a much safer option compared with to-
bacco use. However, it has also been stated that long-term use over a number of years may 
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not be the best solution for everyone (Dome 2011, Grando 2014)
Possible	abuse	of	NRT	products,	was	presented	as	a	significant	safety	threat	related	to	
NRT deregulation (Table 5). In population-based studies, NRT use among non-smokers, 
both adult and adolescents, is very rare (Klesges et al. 2003, Etter 2007b, Gerlach et al. 
2008, Rainio et al. 2010). For instance, a largely distributed internet-based survey during 
2004-2006	was	only	able	 to	detect	five	never-smokers,	who	were	using	NRT	for	years	
(Etter	2007a).	Though	marginal,	these	findings	imply	that	nicotine	dependence	may	be	
initiated from the use of NRT gum as well. 
 Studies conducted among US and Finnish minors have provided evidence that it is rel-
atively easy for minors to purchase OTC NRT products (Klesges et al. 2003, Johnson et 
al. 2004, Rainio et al. 2010). Due to the easy access and powerful advertisement of NRT, 
non-smoking minors may consider NRT as a magic pill for SC (Al-Delaimy et al. 2006). 
Though, in Finland among adolescents the most common purpose for the use of NRT was 
just to try (Rainio et al. 2011), there is no compelling evidence, that NRT products are 
widely abused.  
In addition to these worries, the relationship between pure nicotine and cancer has dis-
cussed	among	the	scientific	community	(Dome	2011,	Grando	2014).		Most	recently,	the	
opinion	article	of	Grando	(2014)	synthetized	the	preclinical	evidence	in	literature	relat-
ed to this matter. The author suggested that the association between nicotine and cancer 
could not be excluded. In addition, the individual differences in the expression of nico-
tine receptors should better be taken in to account. Although these concerns were mostly 
related to e-cigarettes, Grando (2014) recommended that in future the dose- and time-
dependent effects of nicotine and differences between administration routes should be 
further investigated.  
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6 Real life NRT use: Why NRT 
 deregulation is not directly reflected in  
 smoking statistics? 
As described in Chapter 5, after the NRT deregulations in many countries the radical in-
crease	in	the	use	of	NRT	is	not	directly	reflected	in	the	smoking	statistics	(Cummings	and	
Hyland	2005,	Amodei	and	Lamb	2008,	Henningfield	et	al.	2009,	Zhu	et	al.	2012).	This	
contradiction between sales data and the development of the smoking rate can be ex-
plained by at least four factors related to NRT use in real life. First, despite the deregula-
tion, many individuals are not using NRT in their quit attempts (Shiffman and Sweeney 
2008, Amodei and Lamb 2008, Zhu et al. 2012). Secondly, NRT may be used in a sub-
optimal way in a quitting attempt, making that attempt ineffective (Amodei and Lamb 
2008, Zhu et al. 2012). Thirdly, NRT is used in a way that is not related to quitting. Fi-
nally there are other reasons for this discrepancy. This chapter describes these reasons in 
more detail.
6.1 Smokers’ and quitters’ reasons not to use NRT 
As described in Chapter 2, nicotine dependence is a chronic condition, requiring com-
prehensive treatment. Therefore the evidence-based clinical guidelines underline the im-
portance of comprehensive support, which consists of pharmacotherapy and behavioural 
components (Fiore et al. 2008, The Finnish Medical Society Duodecim 2012). Especially 
the use of pharmacotherapy is highlighted, because there is such a robust evidence-base 
for its use (See Chapter 4). Despite this, the use of pharmacotherapy is not the only way 
to succeed in a SC attempt. Actually at the population level the most common way to quit 
is to do it unassisted. 
6.1.1 Popularity of unassisted quitting 
During the period of radical decrease in smoking in the 1970s and 1990s in many Western 
countries, unassisted quitting synonymous with quitting cold turkey (meaning no use 
of any evidence-based behavioural or pharmaceutical methods) has been the predomi-
nant way to quit (Fiore et al. 2008, US Department of Health and Human Services 2014). 
Even though during the past twenty years, SC treatments have been greatly developed, 
unassistant quitting is still the most common way to quit (Cokkinides et al. 2005, Fiore 
et al. 2008, Gross et al. 2008, Chiang and Chapman 2010, Yeomans et al. 2011, Hung et 
al. 2011).      
There are many reasons for the popularity of unassisted quitting (Table 6). Smokers 
and quitters may prefer the use of non-traditional SC aids, highlight the importance of 
their own willpower or are reluctant to seek assistance (Hammond et al. 2004, Gilpin et al. 
2006, Gross et al. 2008, Hung et al. 2008, Medbo et al. 2011, Marques-Widall et al. 2011). 
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Further, according to population-based studies, many quitters just perceive quitting cold 
turkey far more helpful than other methods (Hammond et al. 2004, Hung et al. 2009). 
For these reasons, some authors have also suggested that unassisted quitting should be 
more	recognized	as	an	equally	good	way	to	quit	compared	with	assisted	quitting	(Cheong	
et	al.	2007,	Chapman	and	MacKenzie	2010,	Alpert	et	al.	2012).	However,	this	perception	
is	contrasted	by	 the	evidence,	which	suggests	 that	unassisted	quitting	produces	signifi-
cantly lower permanent abstinence rates compared with assisted quitting (Hughes et al. 
2004a, Fiore et al. 2008, National Institute of Clinical Excellence 2012). 
6.1.2 Unwillingness to use NRT 
The	review	of	Zhu	et	al.	(2012)	suggested	that	the	use	of	SC	medicines	is	influenced	by	
healthcare providers’ interests, costs and marketing efforts. Health care professionals’ 
proactive role in SC, including the recommending of SC medicines, has been promoted in 
the great body of SC guidelines (See Chapter 3.3).  However, some studies suggest, that 
health professionals’ false perceptions may still hinder the prober use of NRT (Amodei 
and Lamb 2008, Beard et al. 2012, Zhu et al. 2012). OTC NRT is widely marketed in most 
of the Western countries, and there is contradictory evidence, how marketing efforts are 
reflecting	 in	 the	actual	use	 (Tauras	et	 al.	2005,	Wakefield	et	 al.	2008).	NRT	products’	
price	is	seen	as	a	significant	obstacle	to	the	use	and	reason	to	discontinue	the	use	early	
on. Reimbursement by health insurance increases to some level the use of NRT (West et 
al. 2005, Kaper et al. 2008).  
In addition, NRT users’ perceptions of NRT explain why these products are not used in 
SC or they are used in a non-optimal way (Table 6). Many smokers and quitters have mis-
information or fears towards NRT use, which hinder NRT use. 
  It has also been questioned, are the current nicotine replacements enough appealing 
for quitters (Cummings and Mahoney 2008, Shiffman 2010, Caldwell et al. 2012, Fager-
ström	and	Bridgman	2014).	Because	the	current	NRT	products	do	not	sufficiently	mim-
ic	smoking	behaviour,	some	smokers	find	NRT	unappealing	and	unrewarding	(Caldwell	
et al. 2012, Fagerström and Bridgman 2014). Further, the current administration routes 
through oral mucosa or skin, do not release nicotine fast enough to respond to withdraw-
al symptoms (Caldwell et al. 2012, Ferguson and Shiffman 2014). On the other hand, the 
key principle in the development of NRT products has been the slow nicotine release rate 
compared with tobacco products, so avoiding the products ability to maintain nicotine de-
pendence (Elam 2012, Keane 2012). 
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Table 6. Examples of smokers’ and quitters’ reasons for not using NRT and suboptimal use of NRT. 
Examples of smokers’ and quitters’ reasons for not using NRT and suboptimal use of NRT (Reference) 
Reasons related to popularity of quitting without any assistance
l  Cold turkey is effective (Hung et al. 2011, Medbo et al. 2011).
l  Own willpower far more important  (Hammond et al. 2004, Vogt et al. 2008).
Reasons related to perceptions on NRT
l  Lack of awareness (Hammond et al. 2004, Kaper et al. 2005), though in more recent publications, most 
smokers are aware of NRTs (Bansal et al. 2004, Ferguson et al. 2011).
l  Disbelief in efficacy (Bansal et al. 2004, Cummings et al. 2004, Hughes et al. 2009, Ferguson et al. 2011).
l  Misunderstanding of treatments action and safety (Etter and Pernager 2001, Bansal et al. 2004; Hammond 
et al. 2004, Van der Rijt  and  Westernik 2004, Vogt et al. 2008). Misinformation of safety and/or efficacy 
may be even more significant barrier to use than cost (Ferguson et al. 2011). 
l  Fears of adverse effects and existing mild AE’s (Etter and Pernager 2001, Bansal et al. 2004, Vogt et al. 
2008, Hughes et al. 2009). Most common adverse effects are headaches, skin irritation, nausea, 
gastrointestinal complaints and insomnia (Mills et al. 2013). 
l  Fear of NRT dependence (Etter and Pernager 2001, Bansal et al. 2004, Cummings and Mahoney 2008, 
Hughes et al. 2009).
l  Prior experiences (Hammond et al. 2004, Van der Rijt and Westernik 2004). Though prior experiences can 
also diminish negative attitudes towards NRT use (Etter and Pernager 2001, Bansal et al. 2004, 
Cummings et al. 2004).
Reasons related to NRT purchases
l  Access (McNeill et al. 2001, Shiffman and Sweeney 2008, Fiore and Baker 2011). Though very easy access 
(delivery at home) and possibility to familiarization of NRT forms or NRT free of charge did increase use, 
but was not associated with quitting (Mooney et al. 2006, Walker et al. 2011). 
l  Costs (Cummings and Hyland 2005, Kaper et al. 2005, Hughes et al. 2009). Including SC medications in the 
reimbursement scheme in the UK significantly increased their use (West et al. 2005). Increase in cost may 
decrease appropriate use (Sims and Fiore 2002).
l  Relaxed licensing, which allowed the ‘cut down to quit use of NRT’, did not increase significantly OTC NRT 
use in the UK (Shabab et al. 2009).
Reasons related to early discontinuation of NRT use
l  Relapse back to smoking (Burns and Levinson 2008, Balmford et al. 2011). 
l  Side effects (Burns and Levinson 2008, Balmford et al. 2011). 
l  Perception of NRT not helping (Burns and Levinson 2008, Balmford et al. 2011). 
l  No longer need for NRT and quitting successfully (Burns and Levinson 2008, Balmford et al. 2011). 
l  Low motivation for use, situational or other reasons (Balmford, et al. 2011).
l  Lack of money or NRT cost (Burns and Levinson 2008, Balmford et al. 2011). 
l  Purchase by prescription was an important predictor of longer use (Gilpin et al. 2006).
l  Patch is used for longer than gum  (Paul et al. 2003).
l  Withdrawal symptoms (Sims and Fiore 2002).
Examples of use for too a short time 
l  A majority uses NRT for a shorter time than recommended  (8- 12 weeks) (Shaw et al. 1998, Sims and 
Fiore 2002, Paul et al. 2003, Gilpin et al. 2006, Shiffman and Sweeney 2008, Walsh 2008, Balmford et al.  2011).
l  In the first population-based study, assessing early discontinuation of NRT use, the median usage period 
was only 10 days and only 12% of the participants who attempted to quit used NRT for eight weeks or more 
(Burns and Levinson 2008).
Examples of use with too a small dosage
l  NRT users typically use only about 50% of recommended doses of SC medicines (Shiffman et al. 2008a,b). 
Level of adherence is associated with success rate of SC.
l  19% of quitters who used NRT gum used at least the minimum recommended daily dose (Shiffman et al. 
2002a). These quitters were more successful in abstinence in the sixth week compared to those not using 
the product with the recommended dose. 
l  Increased use of nicotine lozenge was associated with a significant increase in SC, so that each additional 
lozenge used would increase of the likelihood of six weeks abstinence by 10% (Shiffman et al. 2007b).  
Examples of concurrent use of NRT and cigarettes (dual use)
l  NRT is used to temporary replace when smoking is not allowed (Shaw et al. 1998, Sims and Fiore 2002).
l  Concurrent use of NRT inhaler or NRT gum and tobacco is common in population based studies (Hughes 
et al. 2004b, Hughes et al.  2005, Beard et al. 2013).
l  NRT use for smoking reduction or temporary abstinence is common. NRT use in these attempts was 
associated with previous quit attempts (Beard et al. 2012, 2013).
l  Reduction in cigarettes smoked is most common pattern of use for non-cessation reasons (Hughes et al. 
2005). This is recommended  as cessation strategy for patients unwilling to quit (Fiore and Baker 2011).
l  Although rare, the off-label use of an inhaler is related to a repeatedly concurrent use with tobacco or 
inhaler use for non-cessation reasons (Hughes et al. 2005).
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6.2 Concept of NRT adherence  
Adherent	use	of	NRT	treatment	will	significantly	increase	the	likelihood	of	achieving	SC	
in clinical, hospital- based and community settings (Shiffman et al. 2002, Shiffman et al. 
2007a, Burns and Levinson 2008, Shiffman et al. 2008a,b, Raupach et al. 2008). The low 
rate of adherence partially explains why in many population-based studies OTC NRT use 
has yielded much lower abstinence rates than could be expected from clinical trials (Curry 
et al. 2003, Raupach and van Schayck 2011, Raupach et al. 2014). However, while the con-
cept	of	adherence	to	NRT	is	difficult	to	determine,	some	background	information	related	
to it is given in the next paragraphs. 
6.2.1 What is meant by the concept of adherent NRT use? 
Increasing adherence to medications has been called the key mediator to improve the ef-
fectiveness	of	all	current	pharmacological	treatments	(World	Health	Organization	2003e).	
For	SC	behaviour	and	NRT	use	there	are	some	specific	characteristics,	which	make	the	
assessment	of	adherence	and	practices	improving	it	more	difficult	compared	with	other	
long-term conditions (Hollands et al. 2011, Raupach et al. 2014). For instance, it can be 
more	difficult	to	persuade	smokers	unwilling	to	use	SC	medicines	to	use	them	compared	
with medicine users of other therapeutic areas (Hammond et al. 2004, Shiffman et al. 
2005, Shiffman et al. 2008c, Hollands et al. 2011).
Currently,	there	is	lack	of	uniform	definition	for	good	adherence	of	SC	medication	or	
measurement of the good adherence (Raupach et al. 2014). There is no consensus on what 
is the optimum therapeutic period of NRT use (Sims and Fiore 2002, Cumming and Ma-
honey	2008).	The	majority	of	relapses	take	place	either	during	first	eight	days	or	during	
three	first	months	after	a	quitting	attempt	(Hughes	et	al.	2004a,	Cummings	and	Mahoney	
2008, Fiore and Baker 2011). The current recommendations of the optimum treatment 
period	of	three	months	are	originating	from	the	RCT’s	assessing	the	efficacy	and	safety	
for regulatory purposes (Sims and Fiore 2002, Cummings and Mahoney 2008). In RCTs 
NRT	efficacy	is	typically	assessed	during	the	period	of	use	for	12	weeks	(Cummings	and	
Mahoney	2008,	Fiore	et	al.	2008).	On	the	other	hand,	some	smokers	could	benefit	using	
oral NRT forms for over six months (Fiore and Baker 2011). Also a great variety of differ-
ent	NRT	forms	makes	it	difficult	to	define	the	level	of	optimum	dosage.	For	this	reason,	
most studies have only used post-hoc measurement for adherent dosing (Raupach et al. 
2014).  
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6.3 Real life NRT use patterns 
The way NRT products are used in real life can partly explain why their increased use has 
not	been	reflected	in	a	sizeable	drop	on	the	smoking	statistics.	Therefore	NRT	use	pat-
terns in real life are described in brief below. 
6.3.1 Use for a short period 
Despite the lack of consensus of the optimum therapeutic NRT use period, among the 
most common reasons for relapse in real life NRT studies, is that individuals are not us-
ing pharmacotherapy long enough to overcome withdrawal symptoms (Sims and Fiore 
2002, Hughes et al. 2004a). In contrast to RCT’s, in population-based studies the major-
ity of the study participants uses OTC NRT for less than four weeks (Etter and Pernager 
2001, Thorndike et al. 2002, Hyland et al. 2005a, Pierce et al. 2006, Burns and Levinson 
2008, see Table 6). There is also evidence, that OTC NRT is used for a far shorter period 
than prescription NRTs (Pierce et al. 2006). 
6.3.2 Use of too low a dosage 
NRT is also used with too low a dosage (See examples in Table 6). NRT users typically use 
only about 50% of the recommended doses (Shiffman et al. 2008a,b). Especially this is 
related to all the oral forms of NRT. Sometimes the products are also used with the wrong 
technique or with refreshments, which hinders the adsorption of nicotine. Furthermore, 
some NRT users tend to underestimate their level of dependence and use the mildest oral 
NRT form (Shiffman et al. 2008c). 
The same reasons, why NRT is not used at all, also partly explain why many NRT 
users tend to use NRT for only a very short time or with inadequate dosing (Table 6). In 
addition to these, in population-based studies a variety of reasons to discontinue use in 
the early stages have been reported. Of these reasons, the most common one has been the 
reinitiation of smoking (Burns and Levinson 2008, Balmford et al. 2011). 
  
6.3.3 Concurrent smoking and NRT use 
Traditionally the concurrent use of NRT and smoking is forbidden in the instructions 
for NRT use and it is considered as a reason for NRT treatment failure (Shaw et al. 1998, 
Sims and Fiore 2002). In population-based studies this concurrent (dual) use of an NRT 
inhaler or NRT gum and tobacco is common (Thorndike et al. 2002, Hughes, et al. 2004, 
Hughes et al. 2005, Burns and Levinson 2008 Beard et al. 2010, Balmford et  al 2011). 
Currently smoking reduction with NRT patch as a preceding SC is recommended as a 
NRT use strategy, especially for patients who otherwise would not be able to quit (Royal 
College of Physicians 2007, Wang et al. 2008, Sims and Fiore 2011). In Finland, this in-
dication	was	officially	accepted	for	NRT	gum	for	the	first	time	in	August	2011	(Personal	
information from Lohi S. /Fimea 2014). Some evidence suggests that smoking reduction 
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can lead to successful SC (Wang et al. 2008, Baker et al. 2010). However, this use should 
be combined with counselling by a health care professional and a well-planned strategy 
for how to reduce smoking (Wang et al. 2008, Sims and Fiore 2011).
6.3.4 Use of NRT for other purposes than quitting 
There is some evidence, that NRT products are used for other purposes than quitting 
(Sohlberg et al. 2001, Hammond et al. 2008). In a survey conducted in Minnesota in 1999 
about 20% of NRT users did not make a quit attempt while they used NRT (Solhberg et 
al. 2001). Similarly, one third of all NRT users in a four-country study used NRT for pur-
poses other than for quitting (Hammond et al. 2008). These purposes were a reduction in 
the number of cigarettes smoked and temporary abstinence. 
In	Denmark,	after	NRT	deregulation,	NRT	use	has	significantly	increased	but	this	has	
not	been	associated	with	a	significant	decrease	in	smoking	(Laegestyrelmittelsen	2005).	
According to a report by the Danish Health Authorities, Sundhetsstyrelssen, (2006) less 
than half (42%) of the NRT users used products for quitting. Whereas 24% used NRT for 
smoking reduction and 19% reported being dependent on NRT. According to the survey 
of the Health and Health Behaviour among Finnish adult population in 2013 (Helldán 
et al. 2013) 6.5% of the respondents, who smoked during past year, had used NRT other 
purposes than quitting, whereas in 2005 the corresponding rate was 2.9% (Helakorpi et 
al. 2005). 
6.4 Other reasons why the detection of the influence of   
 NRT deregulation on smoking statistics is difficult 
There	are	also	additional	reasons	why	the	influence	of	NRT	deregulation	is	difficult	to	de-
tect in smoking statistics. Most importantly, SC is a multifaceted phenomenon, which is 
influenced	by	several	developments	taking	place	in	the	society.	Based	on	the	literature,	
smoking prevalence among adults has been found to be dependent on the number of ado-
lescent smokers who continue to smoke into their adulthood, the number of smokers who 
die, the number of quit attempts and on quitters’ ability to remain abstinent (Hatsukami 
et al. 2008, Hughes 2011, US Department of Health and Human Services 2014). All these 
factors	influence	on	the	smoking	rate	concurrently,	making	it	hard	to	detect	the	influence	
of one intervention on the overall smoking rate.  
Finally, according to the hardening hypothesis, those smokers who are still smoking 
in the 2010s are those most dependent on tobacco and for them achieving SC is most dif-
ficult	(Warner	and	Burns	2003,	Hughes	2011).	Furthermore,	the	most	dependent	smok-
ers	are	those	most	likely	to	use	SC	pharmacotherapy	(Henningfield	et	al.	2011).	This	pat-
tern could partly explain why the decline of smoking has been in most Western countries 
less radical than it was two decades ago. However, the evidence-base on this hypothesis 
needs more detailed assessment before the impact of more dependent smokers on smok-
ing prevalence can be determined (Hughes 2011). 
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7 Counselling and NRT: evidence base   
 and practical viewpoints 
7.1 Evidence-base related to the combination of 
 counselling and NRT use 
All	 the	very	first	reviews	focusing	on	the	clinical	use	of	NRT	highlighted	that	NRT	use	
should be well planned and instructed (Russell et al. 1980, Sees 1990). In addition, behav-
ioural support should be offered. According to these reviews, without behavioural support 
the treatment would not succeed. These recommendations were based on the addictive 
nature of nicotine and understanding about the complexity of behavioural change. 
Two of the most recent updates of Cochrane review (Stead et al. 2008; 2012) highlighted 
the	beneficial	role	of	sole	NRT	use	in	the	quitting	process	independent	of	any	substantial	
support (Appendix 1). However, the update from 2012 of the review also detected a few 
studies comparing OTC NRT to placebo. According to the pooled results of these studies 
the effect of NRT on SC remained positive. However, the authors noted that in those 
studies the control groups had very low success rates compared with control groups in 
other settings (Appendix 1). This matter implies the need for counselling related to NRT 
use.  
Similarly, two other Cochrane Reviews have provided evidence supporting the addi-
tional effects of NRT use and behavioural support (Stead and Lancaster 2012a,b, see Ap-
pendix 1). These reviews focused on the combined effects of behavioural support and SC 
medications compared with sole medication use. The reviews detected small but statisti-
cally	significant	beneficial	effects	of	increased	support	in	advancing	SC.	
The current US Clinical Practice Guideline is based on the meta-analyses of over 6 000 
scientific	publications	(Fiore	et	al.	2008).	Based	on	its	evidence	NRT	efficacy	is	the	best	
among those smokers who also receive behavioural support in addition to NRT use (Ap-
pendix 1). Similarly, the systematic review and meta-analysis assessing long-term (> 2 
years)	benefits	of	the	use	of	NRT	found	the	highest	quit	rates	among	those	smokers,	who	
had received more intensive behavioural support in special SC centres (Etter and Staple-
ton 2006). 
 
7.2 What kind of counselling is needed in real life practice?
In	the	scientific	literature	various	aspects	are	presented	why	the	counselling	provided	by	
health professionals for the use of NRT products is important in the real life. These are 
listed as follows: (1) Nicotine dependence is a chronic condition and its treatment needs 
comprehensive long-term strategy (Chapter 2). (2) Counselling combined with the use of 
NRT supports smokers’ motivation towards quitting and remaining abstinent (Fiore et al. 
2008). Quitting motivation is highly dependent on cognitive and behavioural components 
which	include	perceived	self-efficacy	and	the	ability	to	learn	new	habits,	planning	strate-
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gies for overcoming temptations to smoke and maintain the decision. Often behavioural 
support provided in NRT trials and recommended in various clinical guidelines aims to 
strengthen quitters’ empowerment (Zhu et al. 2012). This comprehensive SC support can 
help in the prevention of relapses and maintaining the permanent lifestyle change. 
(3) Counselling of NRT use increases smokers’ and quitters’ understanding how NRT 
works and how to use it properly (Fiore et al. 2000, Cummings and Hyland 2005, Fiore et 
al. 2008, Raupach and van Schayck 2011). As described in Table 6, there is a great body of 
evidence suggesting that many NRT users have inadequate information about the prod-
ucts,	which	hinders	NRT	use.	It	has	been	suggested	that	NRT	users	would	benefit	from	
receiving	customized	medicine	information	which	addresses	their	perceptions	related	to	
NRT (Vogt et al. 2008, Amodei and Lamb 2008, Fiore and Baker 2011, Raupach and van 
Schayck 2011). (4) Health professionals’ counselling is also needed to increase quitters’ 
interests towards NRT use (Amodei and Lamb 2008, Amodei and Lamb 2010, Raupach 
and van Schayck 2011). (5) Further, among NRT users there is a need to increase adher-
ence towards NRT by different methods (Amodei and Lamb 2008, Holland et al. 2011, 
Raupach and van Schayck 2011). (6) For NRT products, there are many dosage forms 
and	administration	routes.	For	this	reason	NRT	users	can	benefit	from	the	help	of	health	
professionals, who can tailor the most suitable form of NRT therapy and give practical in-
structions on the use of the different drug forms. (7) The use of NRT for pre-cessation and 
planned smoking reduction with NRT use should be combined with the counselling from 
health care professionals (Wang et al. 2008). Otherwise there is a great probability that 
these strategies do not succeed.  
 (8) Finally, there are individual differences in the duration of withdrawal symptoms. 
This	matter	can	notably	influence	on	treatment	success	(Sims	and	Fiore	2002).	For	this	
reason the therapy of physiological dependence must be treated individually instead of 
one	size	fits	all	considerations	(Sims	and	Fiore	2002,	Fiore	et	al.	2008,	National	Institute	
on Clinical Excellence 2012, Raupach and van Schayck 2011). 
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8 Summary of the key findings of the 
 literature review (Chapters 3-7)
NRT products have been on the market for over three decades. During this time the role of 
NRT	has	significantly	altered	as	the	evidence-base	of	the	products	has	steadily	increased.	NRT	
deregulations, having taken place in several countries during mid-1990s to mid-2000s, can 
be perceived as a starting point for a new pattern of NRT use. The deregulation changed NRT 
products’ role from medicines towards consumer products (Shiffman and Sweeney 2008, 
Keane 2013). This development is currently accelerated, as many stakeholders advocate for a 
far more liberal nicotine policy. NRT deregulation has also been used as a successful example 
for extending self-medicine practices and the paradigm related to OTC use towards the treat-
ment of long-term conditions (Shiffman and Sweeney 2008). 
There	is	compelling	evidence	of	NRT	efficacy.	However,	several	factors	may	hinder	general-
izing	this	information	to	real	life,	especially	in	terms	of	the	use	of	OTC	NRT.	The	effectiveness	
of OTC NRT in SC has been investigated and debated even very recently (Albert et al. 2012, 
Kaszka	et	al.	2012,	Kotz	et	al.	2014).	Currently,	the	evidence-base	of	the	effectiveness	of	OTC	
NRT in real life is contradictory. 
In Finland, based on the data of the Finnish Statistics on Medicines, during the post NRT 
deregulation period, NRT products’ sales have nearly doubled and the great majority of NRT 
purchases are made through other sales channels rather than from pharmacies (Figure 3). This 
dramatic increase in NRT sales after deregulation is similar to international experiences (Shiff-
man et al. 1997, West et al. 2005, Laegestrylmittelsen 2005). However, in Finland, according 
to the annually conducted survey of the Health and Health Behaviour among the Adult Popu-
lation, NRT use in quit attempts has increased by 3.9% units during the post-deregulation pe-
riod 2005-2013 (Helakorpi et al. 2005, Helldán et al. 2013, Chapter 5.3). This increase is not so 
sizeable	compared	with	the	dramatic	increase	in	NRT	sales.	
The most important reason for NRT deregulations worldwide has been the expectation that 
NRT	deregulation	would	lead	to	a	significant	reduction	in	the	prevalence	of	smoking.	Current-
ly however, there is no compelling evidence supporting that expectation (see Chapter 5.4). In 
Finland,	according	to	the	SOTKANET®	database	by	the	National	Institute	for	Health	and	Wel-
fare, the smoking rate among the Finnish adult population has decreased by 5.7% units during 
the period of 2005-2013 (Figure 5, Chapter 5.4). During the post-deregulation period, several 
amendments in the Finnish Tobacco legislation have taken place, making the Finnish legisla-
tion	globally	one	of	the	strictest.	The	introduction	of	these	new	norms	makes	it	difficult	to	di-
rectly estimate the effects of NRT deregulation on smoking prevalence in Finland. However, 
the smoking prevalence has been steadily decreasing during the past decades and there has not 
been any detectable acceleration of that development after NRT deregulation.   
According to the literature there are several reasons why the NRT deregulation has not re-
sulted	directly	in	a	sizeable	decrease	in	the	smoking	rate.	For	example,	the	NRT	usage	patterns	
in real life are not always optimal. To illustrate, the use of too low a dosage or too short a treat-
ment period compared with the instructions, is common. Finally there are several reasons why 
health care professionals’ counselling of the use of NRT products remains important. 
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9 Aims of the study 
The overall objective of this study was to explore reasons for the NRT deregulation to gen-
eral	sales	in	Finland	in	2006	and	the	reflections	of	this	change	on	SC	practices.	This	study	
concentrates on exploring NRT deregulation from three perspectives: 1) NRT deregula-
tion as a political process, 2) community pharmacists as health care professionals guiding 
NRT use, and 3) NRT users’ perceptions of NRT in SC.    
The	specific	study	aims	are	the	following:
To identify and describe the key dimensions of the political argumentation 1) 
in the debate leading up to the NRT deregulation in Finland (I).
To explore the familiarity and implementation of the Finnish SC Guideline 2) 
in Finnish community pharmacies, factors relating to Guideline familiarity, 
implementation and provision of SC services (II).
To assess the Finnish pharmacy owners’ and staff pharmacists’ perceptions 3) 
on the role and usage patterns of NRT products about one year after the de-
regulation (III). 
To gain an understanding how smokers and quitters value NRT in SC (IV).4) 
To explore what kind of NRT usage patterns existed in Finland in the post-5) 
NRT deregulation period (2006-) (III, IV).
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10 Materials and methods 
10.1  Study context and design
This study applied both qualitative and quantative methods (Table 7). As NRT deregula-
tion is a relatively new and widely debated phenomenon in Finland, it was explored from 
three selected perspectives. These perspectives were chosen because they are relevant to 
understand the background and consequences of the NRT deregulation. In addition, pre-
vious literature provides only sparse information on these subjects. Therefore, this study 
aims	to	describe	the	reason	for	the	change	and	its	reflections,	instead	of	assessing	the	pos-
sible causal relationship related to public health.
Various	data	sources	and	methods	were	utilized	in	this	study	(Table	7).	This	triangu-
lation of different study settings, multiple data sources and methods is conducted to pro-
vide a more comprehensive and deeper understanding of the investigated phenomenon 
(Smith 2002).
  
Table 7. Methods used in the substudies (I-IV).
Study Methods Data sources utilized Analysis 
      
I Document analysis and twelve 
personal, open-ended theme 
interviews in spring 2006.
All publicly available documents of 
the legislative process introducing 
NRT deregulation. 
Interviews of Members of the 
Finnish Parliament.  
Qualitative analysis:
Inductive content analysis 
of the arguments related 
to NRT deregulation. Two 
independent analysis, which 
were compared and merged 
were conducted during 2011.
II, III Nationally representative postal 
survey among a random sample of 
Finnish community pharmacists 
(including pharmacy owners and 
staff pharmacists) conducted in  
November 2006- April 2007.
Responses of the Finnish 
community pharmacists including 
staff pharmacists and pharmacy 
owners.
Response rate 54% 
50% for pharmacy owners, 53% for 
staff pharmacists
Quantitative analysis: 
Descriptive statistics, Qhi-
Square, Logistic Regression 
analysis were conducted 
during 2007-2009.
IV Analysis of internet-based postings 
made by smokers and quitters 
on NRT products in the period of 
January 2007-January 2012 in the 
Finnish national SC supporting 
Stumppi Forum. 
The postings made by Stumppi 
Forum participants on the five 
selected Internet discussion areas 
in the Forum.  
Altogether the data collection 
and analysis was based on 24 481 
postings in these areas.
Qualitative analysis: 
Inductive content analysis 
of the postings, concerning 
NRT use or comparing NRT 
to other SC methods, was 
conducted during October 
2011- March 2012.
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10.1.1 Brief description of the operationalization of the theoretical background
Especially	 in	 the	 first	 study	 the	 principle	 of	 evidence-informed decision-making was 
utilized	as	a	theoretical	background.	It	means	a	procedure,	which	aims	to	facilitate	well-
informed, transparent and systematic processes in decision-making, taking into account 
the decision-making context (Dobrow et al. 2004, Oxman et al. 2009). As this qualitative 
study was inductive in its nature, the conceptual background helped to choose the unit of 
analysis, category building, and grouping but and also in the abstraction phase (Elo and 
Kyngäs 2008, Appendix 3). This study also served as a framework for the later studies 
(III, IV). 
The studies II and III focused on community pharmacists’ involvement in SC and their 
perceptions of NRT use and deregulation. In the study (II) the concept and the literature 
of SC guideline implementation among health professionals was used as the theoretical 
background	(See	Chapters	3.3,	3.4).	This	theoretical	framework	was	operationalized	in	
the study by assessing the concepts of guideline familiarity and implementation. More 
detailed	description	of	the	operationalization	of	the	key	concepts	to	measured	variables	is	
given in Appendix 3 and in Chapter 10.3.2. 
For the studies (III, IV) the literature on real life NRT use (Chapter 6) was used as the 
conceptual framework. This literature was used as one starting point for developing the 
survey	instrument	utilized	(III).	This	concept	was	operationalized	to	concrete	variables	in	
the forms of statements regarding pharmacists’ perceptions on real life NRT use. In addi-
tion, key concepts related to the political debate on NRT deregulation (analysed in Study 
I)	were	operationalized	in	this	study	as	the	concrete	statements	concerning	pharmacists’	
perceptions on deregulation (see Appendix 3 and Chapter 10.3.2). 
In the last study (IV) among Finnish smokers and quitters, the literature on NRT use 
patterns and on different internet communities and facilities supporting participants’ em-
powerment and self-management was used as a background for the idea of the study (van 
Udel-Kraan et al. 2008, Armstrong et al. 2009, Seale et al. 2012). These concepts also 
helped to understand the topics covered within smokers’ and quitters’ discussions. 
10.2 Data sources utilized 
10.2.1 Policy-making related to NRT deregulation
All	the	official,	publicly	available	documents	relating	to	the	Amendment	of	Medicines	Act	
on presenting NRT deregulation were analysed (Figure 6, phases 4-9, 11). Most of them 
can be accessed online via the Finnish Parliament’s homepage, from which they were 
downloaded verbatim. The Statements of Interest Groups were received from the Minis-
try of S&H in February 2010. Altogether the documents consisted of 402 pages (Figure 
6). 
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1. Minister of Social Affairs and Health introduced the idea of 
reimbursement for NRT  (August 31st, 2004)
2. NRT reimbursement is rejected by Ministry of Finance. Reason: 
lack of money (Autumn 2004)
3. The Speech of Minister of Health: NRT deregulation 
         (March 12th, 2005)
4. First draft of Government Bill by Ministry of S&H (51 pages) 
         (April 29th, 2005)
5. The Statements of Interest Groups (n=33, altogether 179 pages) 
(by May 18th, 2005)
6. The Government Bill (107/2005) to the Parliament Preliminary 
Debate in the Plenary Session 
         (7 pages) (September 8th, 2005)
7. The Bill to the Handling of Committee of Social Affairs and Health 
(SAHC) (September 8th, 2005). The Hearings of the Stakeholders’ 
statements (n= 27 altogether 123 pages). The Bill to the Handling 
of the Constitutional Law Committee
8. The Statement of the Parliamentary SAHC 
        (19 pages) (December 2nd, 2005) 
9. The general debate in the plenary sessions 
         (December 7-8th, 2005) (altogether 25 pages) 
         I Vote (December 8th ) 
         II Vote (December 12th)
10. President confirms the Amendment of the Medicines Act (22/2006) 
(January 13th, 2006)
11. Follow-up by the Working Group on Monitoring of the sales 
of NRT preparations (April 13th, 2006– February 28th, 2007) 
Memorandum (49 pages) (February 28th, 2007)
12. Amendment of Medicines Act: Widening the sales of NRT products 
to restaurants. (September 19th, 2010)
Figure 6. The legislative process of introducing NRT deregulation, and the  
 documents analysed in the study (bolded).
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The	main	focus	of	the	analysis	was	on	the	official	documents,	but	to	obtain	additional	in-
formation and enrich viewpoints, personal, open-ended theme interviews of twelve Mem-
bers of Parliament (MPs) were made shortly after the deregulation was enacted in Feb-
ruary-May 2006.  The recruitment criterion for the interview was that the representative 
had a clear interest in health policy (e.g., background as a health professional or member-
ship of the Parliamentary SAHC). The number of interviewees was balanced according to 
the	size	of	each	Parliament	Group.	Altogether	20	MPs	were	sent	an	e-mail	request	and	
12 MPs accepted it. Six of them had voted for and six against the deregulation. The inter-
views took place in the Parliament Building and lasted between 25 to 90 minutes. All the 
interviews were conducted by the same researcher (TK). The interview discussions satu-
rated after the ninth interview. More detailed description is given in the original publica-
tion I. 
10.2.2 Community pharmacists’ survey 
The survey questionnaire was mailed to a national, random sample of every second Finn-
ish community pharmacist (n=2291), including pharmacy owners (n=289) and staff phar-
macists (n=2002) in November 2006. The sample was drawn from the member registers 
of the three national pharmacists’ professional associations (Table 8). At the time of the 
survey, these registers covered 100% of the Finnish pharmacy owners and 93% of the 
staff pharmacists with B.Sc. (Pharm.) and M.Sc. (Pharm.) degrees. Because 7% of the staff 
pharmacists	did	not	belong	to	a	professional	organization,	they	were	not	contacted.	
The respondents were drawn randomly by choosing every second pharmacist, who 
were not refusing to give their contact information for research purposes, from a list in 
which they were presented in an alphabetic order based on their surnames. All the re-
spondents had equally good chances to be chosen as a study participant. For the statistical 
analysis all the received responses were combined (see also Chapter 10.3.2 and the origi-
nal publications II and III for a more detailed description). 
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10.2.3 Internet-based discussions on NRT use 
Since 2004 The Organisation for Respiratory Health in Finland has maintained an In-
ternet portal called STUMPPI,	financed	by	the	government-based	Slot	Machine	Associa-
tion of Finland (RAY). The STUMPPI website (2014) is constantly updated and it con-
tains a lot of current information on tobacco consumption and SC. The website provides 
free services for registered and unregistered quitters and health professionals. Among 
the	services	included	are	ten	discussion	areas,	each	with	a	different	focus.	The	five	most	
popular discussion areas were selected for this study. These were SC Medications and 
Replacement Therapies; Pre-Contemplators; Contemplators; Action; and Maintenance. 
The selected discussion areas were those concentrating most clearly on the role of NRT in 
different stages of SC process. More detailed description of the selection of these areas is 
given in the original publication IV. 
Table 8. Community pharmacists invited in the study (II-III).
Professional organization  
N= total number of members at the time the 
study was planned 
%= the proportion the members of the 
professional organization covered in 2005
Sample 
(Every 2nd pharmacist 
from the alphabetic 
member list)
Responses 
received (n) 
Response rate
All community 
pharmacists 
N= 5053 nall= 2291 
n
final
= 1932+282= 2214*
1190 
54%
Pharmacy owners Association of Finnish Pharmacies 
N= 584 
100% of all pharmacy owners
nall= 289
n
final
= 282* 
140
50%
Staff pharmacists total N= 4469
93%
nall = 2002
n
final
= 1932* 
1050 
 53% 
M.Sc. Pharmacists Finnish Pharmacists’ Association, 
N1= 369 
and  
Finnish Pharmacists’ Society,
 N2= 379
Coverage of N1+N2 = 
92% of all M.Sc. pharmacists 
n1= 184
n2= 190 
n1+2  = 374
n
final
 = 366*
217
 59%
B.Sc. Pharmacists Finnish Pharmacists’ Association  N= 3256
93% of all B.Sc. Pharmacists 
n= 1628
n
final
 = 1566*
833
53%
* after excluding unreached recipients and inadequate responses (see the Figure 7, outline of the study for further information)
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10.3 Methods  
10.3.1 Qualitative studies utilizing inductive content analysis 
While assessing the perspective of pharmaceutical policy-making (I) and NRT users (IV), 
inductive	 content	 analysis	was	utilized.	This	method	pays	 special	 attention	 to	 the	 cru-
cial	aspects	of	the	textual	material	and	produces	classifications	based	on	the	content	of	
the material (Sandelowski 1993, Graneheim and Lundman 2004, Elo and Kyngäs 2008). 
This study investigated rarely explored phenomena and the aim was to gain authentic in-
sights into studied perspectives. Therefore, inductive content analysis was the most suit-
able analysis method.
10.3.1.1 Steps in the data analysis 
Before	conducting	the	analysis	the	unit	of	analysis	was	fixed	(see	also	Appendix	3).	In	the	
study of the NRT deregulation as a political process, it was one or more sentences con-
taining one policy argument for or against NRT deregulation. A policy argument was de-
fined	as	an oral or written statement that advocates the adoption of a policy or justifies 
decision to adopt a policy (Ball 1995). In assessing the STUMPPI Forum participants’ 
perceptions unit of analysis was one or more sentences concerning opinions, perceptions, 
experiences or expectations related to NRT use or comparing NRT with other SC methods 
(Rx medicines or non-pharmaceutical methods, including cold turkey). 
In both studies, the materials were carefully read through several times to ensure the 
comprehension of their fundamental features. Then all the materials were re-read. For 
each sentence, relevant to research questions, a short code, true to its original expression, 
was created. The codes covering similar or nearly similar meaning were combined. These 
were grouped again to form categories, which were named according to their overall con-
tent (Graneheim and Lundman 2004, Elo and Kyngäs 2008). Later, the categories were 
again	grouped	to	form	broader	categories,	and	finally,	preliminary	themes.	
10.3.1.2 Policy-making related to NRT deregulation
The	analysis	of	the	political	documents	was	started	from	the	first	draft	of	the	Government	
Bill and continued to further documents in chronological order (Analysis 1). The debates 
held in the Parliament and the 12 interviews were analysed in a similar way to the docu-
ments (Analysis 2). The analysis was started with the documents of the Parliamentary 
debates in chronological order and followed by the interviews of the MP’s in the order in 
which they were conducted. Finally, the two analyses (1&2) were compared and merged. 
In doing so, it was noted that both the analysis resulted in similar themes. More detailed 
description of the analysis is given in the original publication I, Figure 2. 
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10.3.1.3 Internet-based discussions on NRT use 
In the internet-discussions-based study of smokers’ and quitters’ perceptions on NRT use 
the data collection and analysis took place simultaneously. It was started by reading sys-
tematically through all the postings made during January 2007 and January 2012 in the 
discussion areas of SC Medications and Replacement Therapies and Pre-Contemplators. 
All	the	postings	relevant	to	the	research	question	were	copied	verbatim	onto	two	specific	
MS-Word	files.	For	each	posting	only	one	code	per	viewpoint	was	created,	but	one	post-
ing could include several viewpoints and yield several codes. On basis of these postings on 
the	two	areas,	the	first	coding	scheme	was	created.	The	data	collection	continued	to	the	
three further areas and 20% of the discussions were read. The data saturated in the Main-
tenance area after 8% of the threats were read. More detailed description of the analysis 
is given in the original publication IV.  
10.3.2 Nationally representative survey among community pharmacists 
10.3.2.1 The survey instrument 
The survey instrument was designed to cover several aspects of SC practices in communi-
ty pharmacies, the implementation of the national Finnish SC Guideline and pharmacists’ 
perceptions on NRT deregulation. The survey instrument was based on an earlier Finnish 
survey conducted among physicians and nurses to assess their attitude towards smoking 
and actions taken in SC (Jormanainen et al. 1997, Barengo et al. 2004). The instrument 
was	modified	to	include	community	pharmacists.	Figure	7	describes	the	development	and	
conduction of the survey. In Appendix 4 the questions used in the studies II&III are trans-
lated into English. 
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Development of the survey instrument
A Finnish nationwide survey for physicians and nurses as a
basis (Barengo et al. 1997, Jormanainen et al. 1997);
modification to pharmacy context based on the literature
review
Pre-testing
two pharmacies
(2 pharmacy owners and 10 staff pharmacists)
Assuring face-validity
Phase 1
November 2006: Mailing of the survey to 2291 participants,
(289 pharmacy owners; 2002 staff pharmacists, of which
1628 B.Sc. and 374 M.Sc.)
Phase 1b
December 2006: An electronic reminder via the national
pharmacy intranet to every Finnish pharmacy.
827 responses obtained (response rate 36%), of which 126
from pharmacy owners and 701 from staff pharmacists
Phase 2
January 2007: A reminder with a repeat questionnaire sent
to all the respondents. 409 additional responses received, of which 
17 from pharmacy owners, 392 from staff pharmacists.
Cumulatively 1236 responses (response rate 54%)
Phase 2b
March 2007: A reminder via the national pharmacy intranet:
19 additional responses received, of which 1 from a
pharmacy owner and 18 from staff pharmacists
Total of 1255 responses received (response rate 55%)
1190 responses included in the analysis.
Response rate 54%
65 responses excluded:
36 of respondents not 
working in a community 
pharmacy, 29 empty or 
inadequate responses.
12 recipients were not 
reached:
The surveys of 12 recipients 
were returned by the postal 
service because addresses 
of the recipients
were unknown.
Figure 7. Outline of the national survey among community pharmacists.
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Operationalization of the key concepts to variables  used in the survey instrument
The	variables	utilized	in	the	study	were	based	on	literature	reviews	on	the	following	top-
ics: background variables (Cabana et al. 1999, Cooke 2000, Stone et al. 2002, Francke 
et al. 2008, Prior et al. 2008); guideline dissemination (Cabana et al. 1999, Cooke 2000, 
Young and Ward 2001, Stone et al. 2002, Ward et al. 2002, Francke et al. 2008, Prior et 
al. 2008), key SC duties of community pharmacist given in the Finnish SC Guideline and 
literature on pharmacists role in SC (Hudmon et al. 2006, Brock et al. 2007, Association 
of Finnish Pharmacies 2008). Some variables measuring pharmacists’ support in SC were 
modified	from	earlier	studies	of	lifestyle	changes	conducted	among	Finnish	health	care	
professionals (Barengo et al. 1997, Jormanainen et al. 1997, Jallinoja et al. 2007). 
As	the	 familiarity	with	a	guideline	 is	 the	first	step	 in	 implementation	(Francke	et	al.	
2008) the structured key question of the implementation of the Finnish SC Guideline (the 
original publication II) was as follows: “How familiar are you with the SC Guideline”. The 
duties expected by the SC guideline for community pharmacists were used as a basis for 
the measuring of SC actions taken at community pharmacies. These actions were opera-
tionalized	in	a	set	of	questions	assessing	the	frequency	of	recommending	guideline-based	
pharmacological and non-pharmacological SC treatment options to the smoking phar-
macy customers and respondents’ participation in continuing SC education (see Appen-
dix 3&4). In addition to these variables, participation in local SC multidisciplinary team-
work was used as a background variable (see original publication II) for familiarity with 
the guideline and measuring its implementation.
In addition the Likert-type of statements on NRT usage patterns were based on a lit-
erature review of the topic (See the original publication III, Table 1). Another set of state-
ments	concerning	the	influence	of	deregulation	on	pharmacy	owners’	and	staff	pharma-
cists’ motivation to serve and counsel customers purchasing NRT products was based on 
the	political	debate	on	the	possible	effects	of	the	deregulation.	The	conceptualization	of	
these	 literature	 reviews	 and	 the	 operationalization	 of	 the	 key	 outcome	 variables	 is	 de-
scribed in Appendix 3. 
Modifications of the key variables  for the analysis
The	background	 variables	 utilized	 in	 the	 study	 are	 presented	 in	Table	 9.	All	 the	 back-
ground variables were used in their original format, with two exceptions. The variable 
related	to	pharmacist’s	participation	in	continuing	SC	education	was	reclassified	as	a	di-
chotomic variable (yes/no) for the statistical analysis. In addition the pharmacy’s loca-
tion	by	province	was	re-classified	to	four	regions:	Southern,	Eastern,	Western	and	North-
ern (combination of options Oulu and Lapland) Finland. Before conducting the statistical 
analysis,	the	background	variables	were	categorized	to	characteristics	of	the	responding	
pharmacist; characteristics of his/her workplace; and SC actions that have taken place at 
his/her workplace according to the systematic meta-review of Francke et al. (2008). 
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Table 9. Characteristics of the respondents (n= 1190) and all Finnish community pharmacists in 2006 (n= 5053).   
 Variable
Respondents  
(n=1190)
All 
community 
pharmacists  
(n= 5053)
% n % n
Variables associated with the respondent
Professional status
B.Sc. Pharmacist (Staff pharmacist) 70 833 72 3654
M.Sc. Pharmacist (Staff pharmacist) 18 217 16 815
  Pharmacy owner (M.Sc. degree or higher) 12 140 12 584
Total 100 1190 100 5053
Specialization of the respondent*
Asthma 25 272 14 706
Diabetes 21 230 13 680
Cardiovascular diseases 20 221 12 613
Participation in continuing education in SC
In-house training 48 568 na na
Continuing education (CE) 25 302 na na
In-house training by a drug company 40 477 na na
CE by a drug company 33 398 na na
Not participated  20 229 na na
Variables associated with the respondent’s working pharmacy 
Location by province
Southern Finland 39 459 41 2087
Western Finland 33 392 35 1773
Eastern Finland 15 174 12 604
Northern Finland       13 157 12 589
Total 100 1182 100 5053
Annual prescription volume 
< 40 000 21 252 16 782
40 000–80 000 38 452 34 1751
80 001 ≥  41 475 50 2520
Total 100 1179 100 5053
Ownership
Privately owned 94 1108 91 4589
University owned 6 75 9 464
Total 100 1183 100 5053
* Based on the professional programs run by the AFP since late 1990’s to assure community pharmacies’ contribution to the 
national public health goals. Information available on pharmacists working in privately owned community pharmacies (missing 
data from the two university owned pharmacies covering about 11% of the total prescription volume). 
na = not available
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In the question assessing the SC Guideline familiarity for the analysis the options “I have 
read the Guideline carefully through” and “I am familiar with its main principles “were 
combined to make up a group of respondents ”Familiar with the Guideline.” The remain-
der	of	the	respondents	were	categorized	as	”Unfamiliar	with	the	Guideline”.	
In the Likert–type statements measuring respondents’ perceptions of the importance of 
SC and healthcare’s role in it, assessing pharmacists’ perceptions on NRT role or NRT 
deregulation	 the	 options	 “Always”	 and	 “Almost	 always”	were	 reclassified	 as	 “Always”;	
options “Strongly agree” and “Agree” to “Agree”; and correspondingly “Disagree” and 
“Strongly disagree” to “Disagree”. 
In all statements of the study, B.Sc. and M.Sc. pharmacists shared similar views and 
thus their responses were combined. The same applied to in the case of pharmacy own-
ers and staff pharmacists with the exception of the set of statements covering how ex-
tending	NRT	sales	has	influenced	on	their	perceptions.	More	detailed	descriptions	of	the	
evidence-base	for	the	key	questions,	its	operationalization	to	concrete	variables	and	the	
modification	of	the	variables	for	analysis	is	given	in	original	publications	(II&III).	
10.3.2.2 Statistical analysis 
The statistical analysis of the studies was based on bivariate (original publications II, III) 
and	multivariate	 analysis	 (II).	The	 statistical	 significance	 in	 the	bivariate	 analysis	was	
tested	by	Chi	Square	test.	P-value	of	<0.05	was	considered	statistically	significant	in	study	
II and p-value of < 0.01 in study III. 
In assessing the factors associated with the guideline familiarity (II), the multivariable 
analysis, logistic regression was applied to control for a concomitant effect of the back-
ground variables selected for the analysis on the basis of the bivariate analysis (Hidalgo 
and Goodman 2013). The main outcome variable measuring respondents’ familiari-
ty	with	the	SC	Guideline	was	dichotomized	(1=Respondent	familiar	with	the	Guideline;	
0=Unfamiliar). The Spearman’s correlations between the background variables were cal-
culated to avoid possible multicollinearity. Of the two variable pairs with a correlation 
co-efficient	of	0.6	or	more,	(respondent’s	age	and	graduation	year;	and	”Smoking	pass	in	
use” and ”Pocket card to support SC counselling in use”), respondent’s age and use of a 
SC pocket card were included in the regression analysis. A backward step-wise logistic re-
gression	analysis	was	conducted.	The	final	model	did	not	include	interaction	terms.	The	
associations between the outcome and background variables were described by Odds Ra-
tios calculated from the B-estimates, and p-values (see Table 3 in the original publication 
II). 
All the statistical analyses were conducted by the SPSS analytical software, version 15 
(SPSS Inc., Chicago, IL). More detailed description of the statistical analysis is given in 
original publications II and III.
80
11 Results
This	 chapter	 summarizes	 the	 key	findings	of	 the	 original	 studies	 (I-IV).	They	 are	 also	
summarized	in	Figure	12	(Chapter	11.6).	
11.1 NRT deregulation from policy-making perspective
Key arguments for the NRT deregulation were assessed by using the analysis of politi-
cal documents and MP’s interviews of the NRT deregulation as a political process. Ac-
cording to the Interest groups’ statements given for the Ministry S&H and for the Finn-
ish Parliament, NRT deregulation was widely supported. However, most of the Interest 
Groups’ statements contained several arguments against deregulation. The Head of the 
Parliamentary	Committee	of	Social	Affairs	and	Health	characterized	the	political	process	
of NRT deregulation as a colourful debate. This debate is analysed in depth in this study. 
As	result	of	the	analysis,	the	debate	comprised	of	five	central	themes,	which	are	conceptu-
alized	in	Figure	8.	Key	findings	related	to	each	theme	are	described	in	the	following	para-
graphs. 
V Deregulation as a political process
The process
● Lack of collaboration
● Contradiction 
● Hasty preparation 
I NRT access and deregulation
to advance SC
Increase in NRT access, sales and use
● Availability compared to tobacco
● Food stores vs. pharmacies
● Decrease in prices
Public health
● Starting point and aim
NRT increases cessation
● Outcomes: cessation or not
● Is cessation process or impulsive
● Other tools to advance cessation
II Characteristics of NRT
Counseling NRT use
● Necessary or not
● More important than NRT
Efficacy vs. effectiveness
● Different in real life?
Safety and risks
● NRT is safe
● Risks: addiction, abuse, misuse
Use in real life
● Underuse as a problem
III Principal change in 
prevailing
medical legislation
Principles in distribution of 
medicines
● NRT as start point
Pharmacies vs. stores unfair
● Competition
● Duties of pharmacies
● Duties of food stores
Health, Tobacco or Commercial 
Policy
Medicalization
IV Use of evidence in decision making
Evidence vs Assumptions
● Impossible to estimate/ investigate key outcomes before or after
Figure 8.  Key themes of the political debate leading to NRT deregulation emerged from analysis of the 
 documents and interviews. Reproduced with the kind permission of Elsevier (originally published in I).
Government Bill 
● Minister of Social Affairs and Health 
● Party discipline 
License system and monitoring 
● Role of municipalities
● License for tobacco sales
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11.1.1 NRT deregulation and public health  
Throughout the debate on NRT deregulation, there was a broad consensus that smoking 
is	a	major	public	health	hazard.	Protection	of	public	health	was	used	as	a	starting	point	for	
arguments both for and against NRT deregulation (Themes I&II, Figure 8). The objective 
of	the	deregulation	was	to	significantly	improve	access	to	NRT	products,	decrease	prices,	
and	thus,	increase	their	use	(Theme	I,	Figure	8).	This	was	justified	by	inadequate	NRT	ac-
cess and use, when the number and opening hours of food stores and community pharma-
cies, i.e., the availability of NRT products and tobacco, were compared. In the debate the 
argument of poor NRT availability was questioned, because the pharmacy network was 
regarded as extensive enough to provide NRT for SC.    
Increased access to NRT products was expected to increase the number of NRT pur-
chases and quitting attempts, and to make quitting easier, more impulsive and straight-
forward.	The	 significance	of	 increasing	NRT	purchases	 and	 their	use	 in	 cessation	was	
highlighted	but	also	criticized,	because	of	the	nature	of	SC	as	a	long-term	process.	It	was	
also brought up that only succeeded SC attempts were crucial for public health.  
Furthermore, the appropriate and safe use of NRT products, when taking into account 
special characteristics of NRT products, was highlighted in the debate (Theme II, Figure 
8). A key part of this was the debate on the effectiveness of sole NRT use without any be-
havioural components or counselling. It was also discussed whether the information on 
NRT	efficacy	from	RCTs	is	equivalent	to	effectiveness	in	real	life.	The	Government	Bill	
stated that NRT is safe and the deregulation would not create any safety risks. On the oth-
er hand, deregulation was seen as a remarkable threat to drug safety. Possible misuse and 
abuse of NRT products, especially by minors and athletes, were the most debated safety 
concerns. 
11.1.2 Extensions of the debate: fundamental change in pharmaceutical policy 
and structures related to policy-making 
The political debate extended beyond NRT and SC to become a debate on the principles 
of pharmaceutical policy and structures guiding the policy-making process. An important 
part of the debate was, who is allowed to sell medicines and what is the importance of pro-
fessional advice to treatment outcomes. NRT deregulation was initiated as a fundamental 
change	in	Finnish	pharmaceutical	legislation	because	NRTs	were	the	first	and	sole	medic-
inal products intended to be sold outside pharmacies and, as such, without professional 
advice. Furthermore, the general principle in deregulating the distribution of non-pre-
scription	medicines,	instead	of	enacting	specific	legislation	for	one	medicine	group,	was	
raised. In addition, due to the required license system for the sales of NRT, the deregu-
lation made the sales of NRT products more regulated than the sales of tobacco (Theme 
IV, Figure 8). 
The NRT deregulation proposal was strongly presented as a part of the health and to-
bacco	 legislation,	 supporting	public	health.	 It	was,	however,	 criticized	as	being	a	 com-
mercial policy, separate from prevailing health and pharmaceutical policy, deliberately 
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aiming to increase the commercial aspect of medicine use. It was even stated to be an at-
tempt to weaken health care’s role in SC by losing NRT as a resource if sold outside phar-
macies.
The	proposal	for	deregulating	NRT	was	equipped	with	evidence	on	NRT	efficacy	and	
foreign experiences on NRT deregulation. However, two of the key arguments support-
ing deregulation, the poor NRT availability and the effectiveness NRT deregulation in 
SC,	were	not	justified	by	any	evidence.	Instead	both	the	key	reasons	were	based	on	an	as-
sumption	in	the	Government	Bill.	Furthermore,	the	influence	of	NRT	deregulation	on	SC	
was seen to be impossible to evaluate. These matters raised questions of how evidence-
informed the decision was (Theme IV, Figure 8). 
 The way the political decision-making process was carried out was also debated from 
several	aspects	(Theme	V,	Figure	8).	The	Government	Bill	was	criticized	because	it	was	
prepared in only one ministry, so lacking wider collaboration. Further, the claims of the 
key authority of medicines regulation, National Agency for Medicines, were not given any 
attention. It was debated that the change in legislation should have been processed at a 
slower pace because it contained so many proposals which were changing principles in 
the prevailing legislation. 
Party discipline was seen as the central force supporting the deregulation and accord-
ing	to	some	interviewed	MPs	the	decision	personalized	to	the	Minister	of	S&H.	The	proc-
ess was also seen as very contradictory, as some evidence was interpreted differently by 
different stakeholders. A more detailed description of the analysis of the NRT deregula-
tion as a political process and examples of original citations is given in original publica-
tion I.
11.2 Community pharmacists’ involvement in SC
11.2.1  Community pharmacists’ familiarity with the Finnish SC Guideline 
In this study almost half (47%) of the responding pharmacists (n=1190) were familiar 
with the Finnish SC Guideline (Table 2, original publication II). Based on the bivariate 
analysis conducted, the following variables related to individual pharmacists’ character-
istics	positively	 influenced	the	familiarity	with	the	SC	Guideline:	specialization	 in	asth-
ma, ever smoked 100 or more cigarettes, participation in continuing SC education, being 
a pharmacy owner, and being older and pharmacists’ positive perceptions of SC (Table 
2, original publication II). Of the background variables related to respondent’s working 
pharmacy, its location by province and dispensing counter design were associated with 
the Guideline familiarity (Table 2, original publication II). All the variables measuring 
availability of SC services at the respondent’s working pharmacy, such as offering indi-
vidually tailored SC service, having a guideline on NRT dispensing, participating in local 
multidisciplinary SC collaboration, were associated with the Guideline familiarity (Table 
2, original publication II). 
In the multivariate analysis, nine out of the 21 variables were found to have a statisti-
cally	significant	association	with	the	SC	Guideline	familiarity.	The	highest	ORs	were	found	
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in the variables related to  respondents’ own perceptions of the personal skills and knowl-
edge in SC (OR 3.8); perceptions of customers value NRT counselling (OR 3.3); and regu-
lar	use	of	the	pocket	card	in	SC	counselling	(OR	3.0;	all	variables,	p≤0.001)	(Table	3,	the	
original publication II). However no characteristics related to pharmacists’ work place, 
like	geographical	location	or	dispensing	design,	influenced	on	Guideline	familiarity.	
11.2.2 The implementation of the SC Guideline-based actions 
Implementation of the guideline-based SC actions and services were more common 
among the respondents familiar with the SC Guideline (Table 10). The familiarity with 
the Guideline was strongly associated with respondents’ working pharmacy’s participa-
tion in local multidisciplinary SC actions, the frequency of applying the 5A’s Intervention 
with smoking customers and the discussion about SC with customers who have higher 
risk factors or buy SC medicines. These actions were not so commonly taken compared 
with recommending NRT gum or patch, which were reported by almost all respondents 
despite their Guideline familiarity (Table 10). Similarly, nearly all the respondents report-
ed that they always discuss SC with customers who spontaneously refer to his/her smok-
ing. The same applies to supporting smoker’s own quitting decision which was made by 
more than 60% of the respondents.
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Table 10. Implementation of the Finnish SC Guideline -based SC actions / services among the pharmacists familiar and   
 unfamiliar with the Finnish SC Guideline. 
The Finnish SC Guideline based actions and services 
Familiar 
with the 
Finnish 
SC 
Guideline 
(n= 512)
Unfamiliar 
with the  
Finnish SC 
Guideline 
(n= 625)
p-value* 
Workplace involvement in local multidisciplinary SC actions % %
Participation in a joint training 15 5 < 0.001
Considered joint practices 12 5 < 0.001
Have joint practices  5 2 < 0.001
Recommends SC Guideline based pharmacological treatment   
Nicotine gum 94 96 0.450
Nicotine patch 86 80 0.01
Nicotine inhaler 22 20 0.345
Bupropion (Zyban®) 15 10 0.08
Recommends SC Guideline based non-pharmacological tools
Own quitting decision 68 62 0.020
Written SC support material 56 41 < 0.001
Participation in the “Quit and Win” competition 26 23 0.242
Social support of family and/or friends 17 14 0.120
Telephone-based SC support 12 8 0.09
Pharmacy’s  individually tailored SC service 10 6 0.006
Group therapy 9 5 0.027
Internet-based SC support 7 4 0.080
Advise to see a  public health nurse 4 3 0.104
Follows at “least often”** the 5A’s Intervention with smoking customers
Advised to quit during the month prior the survey 12 3 < 0.001
Told about how smoking effects medication during past month 10 2 < 0.001
Asked about  smoking during past week 9 2 < 0.001
Assessed quitting date during past month  2 1 < 0.001
Discusses always*** about smoking with customers who..
self-refer to their smoking 94 91   0.101
are pregnant 45 32 < 0.001
buy SC medicines  35 17 < 0.001
suffer from a smoking-related disease 18 7 < 0.001
 
 * Between the groups familiar and unfamiliar with the SC Guideline
 ** Reclassified from the options: “always” , “often”, “at least with every second customer”, “sometimes, never”. 
“Often”  was considered as option “often or more frequently”
*** “Always” from the original answering options: ”always”, “sometimes”, “never” 
    self-r fe  to their smoking
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11.3 Reflections of NRT deregulation on community 
 pharmacists’ perceptions of NRT sales and their 
 professional role in SC 
The responding pharmacy owners (n=140) and staff pharmacists (n=1050) had different 
views	on	the	influence	of	the	deregulation	on	the	sales	of	NRT	products	and	on	counsel-
ling customers on the use of these products, one year after the deregulation (Figure 9). 
Of the pharmacy owners, 30% and 17% of the staff pharmacists saw that their own mo-
tivation to counsell clients buying NRT products had diminished. Respectively, 19% of 
the owners and 5% of the staff pharmacists saw the importance of the NRT products in 
SC had diminished. The majority (83%) of the pharmacy owners agreed that the sales of 
NRT products had decreased at their pharmacy after the deregulation (Figure 9). 54% of 
the owners had also noticed that clients came to the pharmacy for advice on NRT use, but 
bought the products elsewhere. 
Despite the decreasing sales, the pharmacy owners and staff pharmacists shared the 
opinion that it is their duty to support SC and that the clients valued the NRT counselling 
provided by pharmacists. They also considered professional service as a more important 
means	of	competition	than	the	price	competition	with	the	stores.	A	sizeable	proportion	
of the owners (44%) reported devotion to training in their pharmacy to support SC coun-
selling, and almost a quarter (23%) of staff pharmacists indicated this devotion at their 
pharmacy in the recent past. 
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Figure 9.   The influence of the NRT deregulation on staff pharmacists’ and pharmacy owners’ perceptions on 
 NRT sales and their professional role in SC. Reproduced with the kind permission of Elsevier (originally  
 published in III).
The sales of the NRT products have diminished 
in my working place(p<0.001)
Pharmacists (n=1033)
Owners (n=138)
Clients obtain the medical counselling of NRT 
from pharmacy, but buy the products elsewhere (p<0.001)
Pharmacists (n=1033)
Owners (n=138)
In my working place there has lately been devotion 
to education supporting SC counselling (p=0.001)
Pharmacists (n=1032)
Owners (n=139)
Because of the deregulation of NRT products, 
their role in SC has diminished (p<0.001)
Pharmacists (n=1032)
Owners (n=139)
Because of the deregulation of NRT products, my 
motivation towards the medication counselling of NRT use 
has diminished (p=0.002)
Pharmacists (n=1035)
Owners (n=139)
The counselling of NRT use is  more important in the 
competition in their markets than the possible cheaper 
prices in other sale channels (p=0.001)
Pharmacists (n=1033)
Owners (n=139)
It is pharmacists’ duty to offer SC support (p=0.131)
Pharmacists (n=1041)
Owners (n=139)
Clients value the counselling related to the NRT products 
(p=0.478)
Pharmacists (n=1030)
Owners (n=139)
0 % 100 %
Agree No opinion         Disagree
              45    25                       30
                                    83         4     14
         29                         31                                40
                       54                                 25                   20
      23               12                                  65
                  44                       9                       47
5        18                77
      19                22                                      58
   17           8             74
        30         12                  58
         79                                           12       9
    70   12          18
                   95                                              32
                 93                      6  1
                                       89                     7   4
                                    86                   8     6
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11.4 How do Finnish smokers and quitters value NRT in SC?
The NRT users’ perceptions of NRT were assessed by analysing smokers’ and quitters’ 
internet-discussions in the national STUMPPI Forum in the period 2007-2012. As result 
three major themes explaining how NRT is perceived as a SC method emerged. These 
themes	are	conceptualized	in	Figure	10.	Authentic	examples	of	the	postings	are	given	in	
original publication IV, Supplementary Table 1. At the time of NRT deregulation (Chap-
ter 11.1) the NRT role was highlighted. However, in the smokers’ and quitters’ discussions 
the most common theme that emerged was a negative attitude towards NRT use (Theme 
1, Figure 10), offset by acceptance of NRT use early on as a necessary aid in SC (Theme II, 
Figure 10). 
11.4.1 Key explanations given to distrust and negative attitude towards NRT 
The frequently emerged explanation for the negative attitude towards NRT use was the 
fear of NRT use either maintaining tobacco dependence or causing NRT dependence. In 
the postings, nicotine was suggested as the substance responsible for dependence on to-
bacco products. For this reason several posters even saw NRT use as equal to smoking. 
Total freedom from nicotine was highlighted in the postings as the ultimate goal of all SC 
attempts and this freedom should be achieved at an early stage. 
In	the	postings,	the	more	beneficial	effects	and	successful	use	of	prescription	SC	medi-
cines (bupropion and varenicline) over NRT were partly explained by the absence of nic-
otine while using these medications. Similarly the cold turkey quitting (CT), was partly 
explained by the abstinence of nicotine. Among the posters this culminated in the idea of 
NRT use in quitting as a less right way, and thus, NRT users are not real quitters as long 
as they continue to use NRT.
In the analysed discussions, the use of NRT products was found unhelpful and unnec-
essary for several other reasons. These include discussion participants’ self-reported ex-
periences of not gaining help from NRT use or of adverse effects caused by NRT, general 
aversion towards medicines and sometimes high prices. Further, a few participants even 
saw, that the need for NRT has been misinterpreted because of the overestimated physi-
ological nicotine dependence. NRT products were also seen as a business and usage in-
structions with high doses and long-term use only as pharmaceutical manufacturers’ at-
tempt	to	gain	more	financial	profit.		
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11.4.2 Neutral acceptance of NRT as a useful SC method 
Posters having a neutral attitude towards NRT use found this therapy helpful. Though, it 
was highlighted that no medication guarantees successful quitting, and the actual work to 
maintain SC should be done by the quitters themselves. In this approach, the importance 
of NRT use in the beginning of the SC process was highlighted. 
In	the	discussions,	the	most	common	justification	for	NRT	use	was	the	perception	that	
NRT use is always a better option than continuing smoking and NRT products are medi-
cines intended for SC. Therefore, their use is highly recommendable. Several posters, in-
cluding those with self-reported heavy tobacco dependence and long tobacco history, re-
ported how they had gained help from NRT use and NRT use had encouraged them to try. 
Also health professionals’ recommendations and research results were presented as a jus-
tification	for	NRT	use,	though	these	were	not	as	prominent	justifications	as	participants’	
personal experiences.
Several participants gave advice to others to relieve their fear of possible NRT depend-
ence.	They	recommended	first	 to	concentrate	on	mastering	tobacco	dependence.	Later,	
there would be time to quit NRT use in small steps. NRT was found to be a safer and more 
natural option compared with prescription SC medicines.
11.4.3 Trust in the crucial role of SC medicines 
Though, the idea of medication use to achieve SC was mainly balanced, some posters 
highlighted the crucial role of medication in SC. These perceptions were especially associ-
ated with prescription medicines though trust on NRT was expressed but less frequently. 
Sharing information on the characteristics and recommending medicines to other partic-
ipants was the way this perception emerged. Medicine use in quitting was also reported 
being experimental and difference between true decision and medication use attempts 
was established. Experimental NRT purchases were one example of this behaviour.
11.4.4 Components of permanent success in SC 
In the discussions the most highlighted component of successful quitting was quitters’ 
psychological empowerment. This included one’s own decisiveness and motivation to 
maintain a new smoke-free lifestyle. A clear difference was made between physiological 
nicotine dependence and psychological dependence as the components of tobacco de-
pendence. Psychological dependence was admitted to be the hardest part of SC. To con-
centrate on its management, one needed relief from physiological withdrawal symptoms, 
which NRT use could make tolerable. The concentration on psychological dependence in-
cluded building up new smoke-free self-image, learning a totally new lifestyle, daily hab-
its, and mentally making a permanent change. More detailed description of the results of 
the study is given in original publication IV. 
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11.5 NRT usage patterns in Finland
The data describing different usage patterns in Finland is gathered from two studies, with 
quantative (III) and qualitative approach (IV). 
11.5.1 Community pharmacists’ perceptions of NRT usage patterns
Of NRT usage patterns, almost all, 98%, of the responding pharmacists agreed that it is 
possible to get addicted to NRT products (Figure 11). A high proportion (86%) of the re-
spondents indicated that NRT products have been misused, misuse meaning use for too 
Figure 11.   Pharmacists’ perceptions of the usage patterns of NRT products (all the respondents n=1190). 
   Reproduced with the kind permission of Elsevier (originally published in III).
100 %
It is possible to get addicted to NRT products (n= 1169)
I have noticed that NRT products have been misused 
(use for too short a time or too low a dosage) (n= 1177)
I have noticed that NRT products have been used with 
the wrong technique (n= 1177)
NRT products can be used to replace cigarettes when 
smoking is not allowed (n= 1175)
Mere NRT products are not enough for quitting 
(n= 1169)
NRT products can be used to diminish the adverse 
effects smoking causes on one’s health (n= 1174)
I have noticed that customers use cigarettes and NRT 
products concurrently (n= 1177)
I have noticed that minors have abused NRT products 
(n= 1174)
Agree No opinion         Disagree
0 %
86                8      6
75               17           8
72           12            16
70           7             23
63       12                25
59              25                   16
98   1
11         36                53
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short a time or too low a dosage. Furthermore, three quarters of the respondents agreed 
that	the	products	are	used	with	the	wrong	technique.	One	reflection	of	deregulation	was	
that a majority of the respondents perceived that NRT products could be used for harm 
reduction	purposes	though	these	were	not	official	indications	of	NRT	at	the	time	of	the	
survey	was	conducted.	More	detailed	description	of	the	findings	is	given	in	the	original	
publication III.
11.5.2 Smokers’ and quitters’ perceptions of NRT usage patterns 
From the discussions of smokers and quitters a great variety of NRT usage patterns 
emerged,	with	the	emphasis	on	avoiding	NRT	use	or	at	 least	minimizing	the	dose	and	
treatment	period.	Though	the	importance	of	sufficient	dosage	and	treatment	period	were	
also highlighted (Study IV). 
The	negative	perceptions	(Chapter	11.4.1)	 towards	NRT	were	reflected	 in	 the	aim	of	
avoiding NRT use in SC. If this was the case, use of NRT products should be intentionally 
restricted to as short a time and as little a dosage as possible, limiting the use only to the 
worst moments. Strict control of the use was perceived as a way to avoid the feared NRT 
dependence.  
On the other hand, in the discussions, it was highlighted that it is important to use NRT 
as	long	as	recommended	in	the	instructions	for	use	and	with	a	sufficient	dosage.	The	suf-
ficient	treatment	period	and	dosage	were	considered	crucial	in	learning	to	cope	with	the	
psychological tobacco dependence. It was also highlighted that the low dosage may have 
been the reason for failure in previous quitting attempts. 
In contrast to this, some participants perceived based on their own self-reported expe-
rience, that very low a dosage and a short treatment period are enough to overcome phys-
iological dependence. In the discussions, a detailed NRT treatment plan, which included 
an	individualized	and	decreasing	dosage	regimen,	was	recommended	to	gain	SC.	It	was	
also seen to help in avoiding the feared NRT dependence. More detailed description of the 
usage patterns from smokers’ and quitters’ perspective is given in the original publication 
IV, Table 1 and Supplementary Table 1. 
11.6 Key findings of the study 
Key	findings	of	this	study	are	presented	in	Figure	12.	
86                8      6
98   1
11         36                53
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(I) Principles of evidence-informed decision-making were not followed in NRT deregulation: 
• Five central themes emerged from the analysis of the political debate: 1) how deregulation may 
influence on SC, 2) appropriate and safe use of NRT when taking into account the special characteristics 
of these products, 3) the principle of who is allowed to sell medicines, 4) how evidence-informed the 
decision was, and 5) the way the political decision-making process was carried out. 
• Key reasons: poor NRT availability and the positive influence of NRT deregulation in SC in real life 
conditions were based on assumptions, though throughout the policy-making process much evidence 
was brought up.
(III, IV) Different NRT usage 
patterns, underuse was the 
most common:
• Underuse, use intentionally or 
unintentionally, for a lower dosage 
or shorter time compared to 
usage instructions, were the most 
commonly emerged usage pattern 
among Finnish NRT users (III, IV).
• Fears and true existence of 
dependence on NRT products in 
addition to negative perceptions 
associated with nicotine may 
partly explain NRT underuse (IV).
• Smokers and quitters 
perceived NRT as one part of a 
comprehensive SC strategy, which 
was needed for permanent SC. 
However, the role of sole NRT use 
was not highlighted (IV).
Summary of studies I-IV: NRT Deregulation is a contradictory phenomenon
Deregulation was presented as a significant, evidence-informed public health policy. Public health was 
presented as a start-point for deregulation but the key justifications, expected increase in SC and public 
health benefits of NRT deregulation were based on assumptions instead of evidence (I).
Familiarity with the Finnish SC Guideline and its implementation among community pharmacists had 
proceeded to some extent. Familiarity reflected directly on the level of SC actions taken by pharmacist.  NRT 
deregulation was contradictory to this development  as the deregulation diminished, especially pharmacy 
owners’ motivation towards SC counselling (III), Still, a majority of all the community pharmacists perceived 
SC and NRT counselling as important (II,III).
The role of NRT in SC was much highlighted during deregulation (I). Consumers’ best was used as one 
justification for deregulation (I). However, among smokers and quitters neutral or negative perceptions on 
NRT are far more predominant than the perception that NRT is crucial for SC (IV). 
There exist a great variety of NRT usage patterns in Finland, underuse use being most predominant. Aim of 
deregulation was to increase NRT use. The existing negative perceptions of NRT may at least partly explain 
why NRT is little utilized in SC attempts (III,IV).
(IV) Smokers and quitters 
had mostly either negative or 
neutral perceptions of NRT:
• Distrust and negative attitude 
on NRT were explained by fear of 
NRT dependence, the aim to be 
totally free from nicotine and own 
negative experiences of NRT use.
• Neutral acceptance of NRT as 
part of SC treatment: medication 
was needed, but quitter must 
do the work him/herself. 
Psychological dependence is 
worst to over-come, but NRT 
was needed to give peace to 
concentrate on overcoming 
psychological dependence.
• Trust on critical role of NRT 
and other SC medicines was less 
common and mostly associated 
with prescription SC medicines.
(II, III) NRT deregulation 
reflected negatively, especially 
on pharmacy owners’ 
motivation to be involved in SC
• Nearly half (47%) of the 
pharmacists were familiar with the 
Finnish SC Guideline.
• Familiarity was significantly 
associated with the level 
of implementation of more 
sophisticated SC services. The 
actual level of implementation was 
still low. 
• One year after NRT deregulation 
NRT sales at pharmacies had 
diminished but still clients came 
often at pharmacy for an advice. 
• The motivation towards SC 
had diminished especially among 
pharmacy owners.
Figure 12. Summary of the key findings of the study.
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12 Discussion 
This thesis investigated the reasons for the deregulation of NRT products from pharmacy 
only	distribution	to	general	sales	in	Finland	and	the	reflections	of	this	change	on	SC	prac-
tises. This work consisted of two parts: the literature review and the empirical part. 
In the literature review of this thesis, evidence related to NRT deregulation was syn-
thetized	from	various	viewpoints.	The	effectiveness	and	usage	patterns	of	OTC	NRT	and	
the	reflections	of	NRT	deregulation	on	smoking	prevalence	have	been	widely	studied	es-
pecially in the USA (see Chapters 4,5,6). Also some perspectives related to the Finnish 
deregulation have been previously investigated (Alaranta and Aalto-Setälä 2007, Rainio 
et	al.	2010,	Rainio	et	al.	2011).	However,	all	these	reflections	of	NRT	deregulation	were	
combined	for	the	first	time	in	the	literature	review	of	this	thesis.	Furthermore,	at	the	time	
this	 thesis	was	written,	nine	years	after	 the	Finnish	NRT	deregulation,	 there	was	suffi-
cient	data	 to	assess	what	were	 the	reflections	of	 the	NRT	deregulation	on	 the	develop-
ment of NRT sales and Finnish tobacco prevalence (see Chapter 5). Therefore the litera-
ture review of this thesis also provided additional evidence related to a less investigated 
phenomenon from various viewpoints. Thus the literature review complemented the em-
pirical part.  
  The empirical part (later study) of this thesis focused on three levels of the deregula-
tion: 1) political (NRT deregulation as a political process) level, 2) Health service provid-
ers’ (community pharmacists’) level, and 3) customers’ (smokers’ and quitters’) level. 
 At the political level this study provides new information on the principles of how and 
why NRT deregulation as a political process took place, based on the analysis of the politi-
cal debate during the deregulation process. Internationally it is still less known whether 
the principles of evidence-informed policymaking apply to pharmaceutical policy-making 
(Maynard and Bloor 2003, Lyles 2004, Fox 2005, Aaserud et al. 2006). 
This	study	also	provides	new	information	on	the	reflections	of	NRT	deregulation	on	SC	
practises from the health service providers’ level. According to the Finnish SC Guideline 
(The Finnish Medical Society Duodecim 2002, 2006, 2012), community pharmacists are 
the health professional group expected to be most involved in guiding the rational use 
of	NRT.	For	this	reason	their	involvement	in	SC	and	how	deregulation	had	influenced	in	
their practises were assessed one year after the deregulation took place. Although, there 
are some systematic reviews assessing the effectiveness of community pharmacist-based 
SC	interventions	(Cramp	et	al.	2007,	Saba	et	al.	2013),	this	study	was	the	first	to	assess	the	
nationwide implementation of a SC guideline among community pharmacists. In addi-
tion, although some non-prescription medicines were switched to general sales in several 
countries, little is known about community pharmacists’ attitudes to this change. There 
is some evidence of the effects of NRT products OTC availability on health care providers’ 
practises	(Shiffman	et	al.	2007c).	However	it	appears	that	this	is	the	first	study	assessing	
pharmacists’ perceptions of the use of NRT products and of the deregulation of non-pre-
scription medicines to general sales. 
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This study also provides new information at the customers’ level on how NRT is valued 
in SC. This is important because one key question in planning SC services is what kind of 
assistance quitters actually want in SC. The literature on SC is predominantly produced 
by scientists investigating tobacco dependence and SC pharmacotherapy, clinicians and 
public health experts supporting evidence-based SC practices and stakeholders of tobac-
co control. There are some studies assessing quitters’ preferences, but their numbers are 
minimal	compared	with	studies	assessing	the	efficacy	and	effectiveness	of	SC	 interven-
tions. 
Finally, this study provides new information on what kinds of NRT usage patterns exist 
in Finland. The evidence on this matter in Finland was only limited before this study. The 
following	paragraphs	compare	the	key	findings	of	the	study	with	previous	literature	and	
the methodological quality of the study is discussed. 
12.1 Key findings in relation to earlier literature
12.1.1 NRT deregulation from the political level
From the political level, the Finnish NRT deregulation is an example of decision-making 
which	is	influenced	by	various	features	other	than	the	sole	evidence-informed	decision	
advancing public health, though it was presented as such. Public health provides a widely 
accepted	motive	and	goal	for	many	kinds	of	political	initiatives	even	though	the	scientific	
evidence of their effectiveness can be missing or weak. This pattern can also be seen in the 
NRT deregulation case: two of the most important motives for deregulation, namely poor 
NRT availability and NRT’s effectiveness in SC, were mostly based on assumption instead 
of	actual	scientific	evidence.	
12.1.1.1 The evidence base for the political decision of NRT deregulation 
In	the	political	debate	on	NRT	deregulation,	efficacy	of	NRT	in	SC	was	highlighted	but	
less attention was given to NRT products’ effectiveness in real-life. Furthermore, the con-
cepts	of	efficacy	and	effectiveness	were	discussed	synonymously	in	the	Finnish	debate	on	
NRT	deregulation,	though	there	are	several	reasons	why	information	on	efficacy	cannot	
directly	be	generalized	to	real	life	conditions	(see	Chapter	4).	
There is some previous evidence that the concept of effectiveness can be used to jus-
tify decision-making though it can be misunderstood by its users (Simonen et al. 2009). 
Authorities using effectiveness data should better understand the concept itself, method-
ology and limitations of the studies (Simonen et al. 2009, Lyles 2011, Patten et al. 2011). 
Since information on effectiveness is often used to guide decision-making, there also is a 
need for better quality information on effectiveness. Poor information at worst can result 
in misleading and biased decisions (Cochrane 1972, Lyles 2004, Oxman et al. 2009, Mc-
Caughey	et	al.	2010).	Decision-makers	should	be	aware	of	the	influence	of	imperfect	in-
formation on decision-making and its consequences. 
Though the evidence base of NRT deregulation has developed during the years after 
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NRT deregulation, a great body of evidence was available at the time NRT deregulation 
was conducted in Finland. For instance the US and British smoking statistics had 
provided evidence that NRT deregulation in these countries did not lead to a remarkable 
decrease in smoking prevalence as it was expected to do in Finland (see Chapter 5.4, 
Hyland et al. 2004, West et al. 2005). Also some population-based effectiveness studies 
were published already at this time (Thorndike et al. 2002, Pierce and Gilpin 2002). This 
raises	the	question,	why	this	information	was	not	utilized	in	the	decision-making	at	the	
time	of	NRT	deregulation?	Though	scientific	evidence	is	only	one	form	of	knowledge	in	
political decision-making, more discussion is needed why policy-based evidence, personal 
experience, opinions and political ideologies are still a common base in decision-making, 
instead of evidence-informed public health priorities (Dobrow et al. 2004, Lyles 2004, 
Aaserud et al. 2006, Brownson  et al. 2009, Jansen et al. 2010). 
Another widely accepted motive and goal for political initiatives is “consumer’s best”, 
i.e.,	stating	that	the	proposed	political	changes	will	benefit	consumers	(Noerreslet	et	al.	
2005). During the NRT deregulation process, medicine-users’ possibilities to purchase 
and try NRT were introduced as ways to support the empowerment consumers by those 
supporting the deregulation. On the other hand, those against it highlighted the safe and 
effective use of medicines and consumers’ needs for counselling to guide the rational use 
of	pharmaceuticals.	They	also	emphasized	that	consumers	should	be	protected	from	med-
icalization.	However,	these	arguments	were	based	on	limited	evidence,	because	authentic	
consumers’ perceptions were not assessed. 
According to the previous literature and the results of this study on consumers’ level, 
there	are	several	reasons	why	NRT	is	little	utilized	(see	Chapters	6	and	11.4).	Less	actual	
evidence exists of the poor availability for these products compared with the other rea-
sons hindering the use of NRT among smokers and quitters. 
12.1.1.2 Evidence-informed decision-making and the NRT deregulation process
In	decision-making	it	is	highly	recommended	to	compare	the	beneficial	and	harmful	ef-
fects and the health outcomes of different policies to assess the superiority of one policy 
over another (Oxman et al. 2009, Jansen et al. 2010, Nutley et al. 2010, Lyles 2011). Also 
the measured outcomes should be agreed in advance (Lyles 2011). Despite these recom-
mendations, the decision on NRT deregulation was not compared with any other tobac-
co policy options. Furthermore, the key health outcome, an increase in SC, was consid-
ered impossible to estimate beforehand. Likewise, the authorities stated that the decision 
on deregulation was impossible to evaluate. The Parliamentary Social Affairs and Health 
Committee expected the decision to be monitored. The monitoring was prepared by a spe-
cial monitoring group, which gave its report less than a year after the deregulation was 
enacted (Ministry of Social Affairs and Health 2007). The decision and its outcomes have 
not been remonitored since then. In the Memorandum of the monitoring group (2007) 
it	was	stated	that	it	will	be	impossible	to	evaluate	the	influence	of	the	decision	on	pub-
lic	health	because	smoking	is	influenced	by	several	factors	taking	place	at	the	same	time.	
However,	it	would	have	been	important	to	assess	how	the	decision	influences	on	SC	rates	
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and practises related to NRT use in SC over the longer term.
Similar to the NRT deregulation process, it is still common to consider monitoring and 
evaluation unimportant (Simonen et al. 2009, Jansen et al. 2010, McCaughey et al. 2010). 
Collaboration between researches and decision-makers in all stages of decision-making 
(preparation, deciding, implementation and evaluation) is needed to alter the culture of 
policy-making (Brownson et al. 2009, Jansen et al. 2010, Nutley et al. 2010). In the case 
of NRT deregulation, all key stakeholders gave their statements, but these were used only 
selectively to justify decisions already made in the preparation stage. In the future all the 
stages of the decision-making processes should be made more systematic, transparent 
and informed through the best evidence available, to allocate the scarce resources most 
efficiently	(Apollonio	and	Bero	2009,	Brownson	et	al.		2009,	Oxman	et	al.	2009,	Jansen	et	
al.	2010,	Nutley	et	al.	2010).	It	is	important	to	separate	scientific	facts	from	political	goals	
in the decision-making processes. This is extremely important in public health questions.
 
12.1.2 NRT deregulation from health service providers’ level 
From the health service providers’ level, the aim of this study was to gain an understand-
ing	how	the	policy	change	in	NRT	access	is	influencing	on	the	structures	of	service	pro-
vision within health care. This was measured by assessing pharmacists’ commitment to 
keep up their professional skills and motivation to support SC. In addition, to understand 
the context of service-provision related to NRT the level of community pharmacists’ in-
volvement in SC was investigated. 
12.1.2.1 Community pharmacists’ involvement in SC
One year after the NRT deregulation, this countrywide study on community pharmacists 
showed that approximately half (47%) of the Finnish pharmacists were familiar with the 
Finnish SC Guideline i.e., they reported knowing its main principles or having even bet-
ter knowledge of it. 
In an earlier survey conducted among community pharmacists in Iowa in 2002, only 
10% of the respondents were familiar with the US SC guideline (Aquilino et al. 2003). At 
the time of this study, similar nationwide surveys were conducted among Finnish general 
practitioners and public health nurses assessing the familiarity of the Finnish SC Guide-
line by similar self-reported measurement than among community pharmacists (Sand-
ström et al. 2007, Kurko et al. 2010). The result showed that 36% of the public health 
nurses and 25% of the general practitioners were familiar with the Finnish SC Guideline. 
Compared	with	these	findings,	the	level	of	the	SC	Guideline	familiarity	was	relatively	high	
among Finnish community pharmacists a year after deregulation. 
In this study the SC Guideline familiarity was positively associated with the pharma-
cist’s	positive	perception	towards	SC	and	SC	actions	taken	in	their	workplace.	These	find-
ings of the facilitators of SC Guideline familiarity were in line with previous ones (See 
Chapter 3.3, Table 3). No variables related to the characteristics of the working pharmacy, 
such	as	pharmacy’s	size,	ownership	or	geographical	location	influenced	SC	Guideline	fa-
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miliarity. This suggests that at the time this study was conducted (2006-2007) all Finns 
had equal access to SC services provided by community pharmacies regardless of where 
they	lived.	This	is	important	from	a	public	health	viewpoint,	and	opposite	to	the	findings	
from the USA; the study conducted in the pharmacies of New York City area found better 
availability and lower prices of NRT products in the pharmacies in the wealthiest living 
areas (Bernstein et al. 2009). 
 According to this study community pharmacists’ guideline familiarity was associated 
with the use of more sophisticated SC methods, such as recommending non-pharmaco-
logical methods, use of 5A’s Intervention and participation in local multidisciplinary SC 
actions.	However,	the	SC	Guideline	familiarity	did	not	influence	on	the	recommendation	
of NRT products to smoking customers, which clearly was the most common SC action 
taken among the pharmacists. Similarly, a survey among Australian physicians found a 
high rate of NRT recommendation, whereas behavioural quitting advice or quit date set-
ting were far rarer (Young and Ward 2001). 
However, it is important to notice that still a majority (53%) of the Finnish community 
pharmacists were unfamiliar with the Finnish SC Guideline. In addition, only a minor-
ity of the Finnish pharmacists took other SC actions in addition to counselling on the use 
of NRT or offered more sophisticated SC services (see Figure 2, Table 10). These actions 
were offered disappointingly rarely, although the AFP (2008) had, over several years, sys-
tematically promoted pharmacists’ involvement in SC. Although SC guideline implemen-
tation among health professionals (Chapter 3.3) is challenging, the reasons for this dis-
crepancy need further discussion. 
According to the results of this study and the previous literature on pharmacists’ SC 
practises,	the	customers’	degree	of	initiative	significantly	influences	on	community	phar-
macists’ SC counselling activity (Aquilino et al. 2003, Brewster et al. 2005). As health 
care	service	providers,	community	pharmacists	must	find	a	balance	in	their	daily	practise	
between the aims of health promotion and the principles of customer service. They do 
not prefer taking a proactive role to SC, because they fear affecting customers’ intimacy 
(Brewster et al. 2005). In addition, community pharmacists’ traditional role in customer 
service used to have less emphasis on life-style counselling. This may partly explain these 
findings.		
12.1.2.2 Community pharmacists’ perceptions of their professional role in SC 
  after NRT deregulation  
According to the most recent evaluation, only 20% of NRT products are bought from phar-
macies in Finland (Finnish Agency for Medicines and Social Insurance Institution 2014). 
At the time of this study, nearly all pharmacy owners saw that their sales of NRT products 
had decreased. Despite this community pharmacy owners’ and staff pharmacists’ com-
mitment to SC was strong one year after the deregulation. Nearly all the staff pharmacists 
and pharmacy owners saw their participation in supporting SC as their duty and counsel-
ling of NRT products highly important. However, it was also noteworthy that even a third 
(30%) of the pharmacy owners and 17% of staff pharmacists claimed that their motivation 
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towards counselling of NRT use had decreased due to the deregulation. 
Information is only limited on how the deregulation of non-prescription medicines to 
general	sales	influences	on	pharmacists’	perceptions	and	practises.	Evidence	of	a	pseudo	
patron study from Sweden suggests that, after the deregulation of all non-prescription 
medicines to general sales, Swedish community pharmacists are becoming more com-
mercial and putting less effort on systematic counselling of their customers (Bardage et al. 
2013). It would be worthwhile to assess how pharmacists’ NRT counselling practises have 
developed in Finland after the NRT deregulation. 
Because of the limited information on pharmacists’ attitudes towards the deregulation 
of a non-prescription medicine, the only data on which to compare pharmacists’ percep-
tions originates from the studies of physicians’ perceptions of the switch of prescription 
medicines to OTC (Rosenau 1994). Similar to pharmacy owners in this study, the physi-
cians	found	the	switch	to	OTC	influencing	on	them	economically	and	professionally,	al-
though they considered it inappropriate to admit the economic effect (Rosenau 1994). On 
the other hand, the review of Shiffman and Sweeney (2008) suggested that physician’s in-
volvement in supporting SC had not changed because of the US NRT deregulation. 
At the time of this study 80% of Finnish pharmacists had participated in SC related 
continuing education while the corresponding rate, for example, among US pharmacists 
was 8% (Aquilina et al. 2003, Zillich et al. 2004, Hudmon et al. 2006). Furthermore, at 
the time of this survey 23% of the staff pharmacists and 44% of pharmacy owners saw 
that	their	working	place	had	focused	recently	on	education	supporting	SC.	These	findings	
suggest that the systematic efforts by the AFP, including the nationwide educational cam-
paigns and provision of materials to support SC, had succeeded to some extent (Chapter 
3.4). However, based on the more recent results of the Annual Review Questionnaire for 
Pharmacies by the AFP it seems that a few years after NRT deregulation, only a minority 
of	pharmacies	are	organizing	SC	related	in-house	training	(Kurko	et	al.	2011).
In	summary,	the	findings	of	this	study	at	a	service	providers’	level	indicate	that	the	sys-
tematic, nationwide efforts conducted at the beginning of the 2000’s to increase Finnish 
community pharmacists’ involvement in the treatment chain of SC were adopted in com-
munity	pharmacies	to	some	extent.	NRT	deregulation	has	negatively	influenced	on	this	
development in pharmacies. The development of community pharmacists’ involvement 
in SC originates from long-term, international programs, which have been systematical-
ly implemented in Finnish community pharmacies (See Chapter 3.4). In contrast to this, 
the NRT deregulation as a political process was rapid, involving an ad hoc policy with a 
limited evidence-base. Findings of this study and later evidence from AFP indicate that 
the NRT deregulation may have stopped the development of implementing countrywide 
evidence-based SC practises among community pharmacists.  
12.1.3 NRT deregulation from the customers’ level
The NRT deregulation from the customers’ level was assessed by analysing the authentic 
perceptions related to NRT use in SC of Finnish smokers and quitters in the nationwide 
internet-discussion	forum	STUMPPI	over	a	five	year	period	immediately	after	NRT	de-
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regulation (2007-2012). The most commonly emerged perceptions were a negative atti-
tude towards NRT use offset by acceptance of NRT use as a necessary SC aid in a SC at-
tempt. NRT was only seen as one form of support which was needed in maintaining SC. 
This indicates that in customers’ level NRT deregulation may not be that crucial in SC as 
suggested during the political deregulation debate.  
According to smokers’ and quitters’ viewpoint, the most important component of per-
manent SC is the psychological empowerment, which included quitter’s own decision-
making and ability to maintain abstinence, in other words the capability to maintain a 
new smoke-free lifestyle. These perceptions of Finnish smokers’ and quitters’ found in 
this study are in contrast to the idea that after NRT deregulation sole NRT product use 
guarantees	successful	quitting	(Shiffman	and	Sweeney	2008).	In	addition,	the	findings	of	
this study indicate that among a reasonable proportion of smokers and quitters there is a 
comprehensive understanding of the SC process which is less dependent on one pharma-
ceutical. At the same time the NRT sales have almost doubled but this development is not 
reflecting	in	the	smoking	statistics	(See	Chapter	5).	This	discrepancy	merits	further	inves-
tigation on the real life NRT use in Finland. 
12.1.3.1 Explanation given to the negative attitude towards NRT 
Surprisingly many STUMPPI discussion forum participants had a negative attitude to-
wards or experiences of NRT use. The key explanation that emerged from the postings to 
this	was	the	fear	or	experience	of	dependence	to	NRT.	This	is	in	line	with	previous	find-
ings (Etter and Pernager 2001, Bansal et al. 2004, Vogt et al. 2008, Chapter 6). Smokers 
and quitters fear dependence on NRT and perceive NRT use only as a change of nicotine 
delivery from tobacco to NRT and maintenance of their nicotine dependence (see Chap-
ters 6 & 11.4). 
This perception was obvious in this study although NRT deregulation was proposed to 
make NRT more an everyday consumer product and convenient to use (see Chapters 3.5, 
11.1). During the NRT deregulation process also the possible dependence on NRT was dis-
cussed. In this study, nearly all the community pharmacists perceived that it was possible 
that their customers could become dependent on NRT products. Similarly, in a qualita-
tive study among British physicians it was considered that mere NRT without behavioural 
support was quite ineffective and smokers without additional counselling might transmit 
their dependence on cigarettes to NRT (Vogt et al. 2006). 
Although population based studies suggest that NRT dependence is rare (Hughes et al. 
2004b, Hughes et al. 2005) the fear of NRT dependence is true among smokers and quit-
ters and it hinders appropriate NRT use. On the other hand, health professionals should 
be better aware of the group of NRT users who have become dependent on these products 
and need help in a planned withdrawal. 
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12.1.3.2 NRT usage patterns in Finland in the post-deregulation period
Based on data collected by two methods, this study found that there is a great variety of 
NRT usage patterns in Finland. The most common one seems to be the use of NRT for a 
minimal usage period or dosage, which is too low compared with the instructions for use 
(underuse	or	suboptimal	use).	This	finding	was	consistent	in	the	results	of	the	pharma-
cists’	survey	and	the	analysis	of	smokers’	and	quitters’	discussions.	The	overall	key	find-
ings on NRT usage patterns are also in line with the usage patterns widely reported in the 
literature (Chapter 6). 
 As described in Chapter 6 it is common that NRT is used in a suboptimal way in a quit-
ting attempt, making that attempt ineffective (Amodei and Lamb 2008, Zhu et al. 2012). 
This underuse can partly explain why the increased NRT use has not been by followed a 
sizeable	reduction	in	the	smoking	prevalence	in	Finland.	On	the	other	hand,	consistent	
with	previous	findings	(Burns	and	Levinson	2008,	Balmford	et	al.	2011),	the	qualitative	
findings	of	this	study	imply	that	sometimes	the	use	of	minimal	dosage	and	treatment	pe-
riod may be enough to gain SC. This matter highlights the individuality of SC pharmaco-
therapy.
This study (III) also found evidence, that NRT use for harm reduction was common 
in	Finland,	even	before	it	became	an	official	indication	of	NRT	use	in	August	2011	(Lohi	
S, Personal Information from Fimea, June 16th 2014). On the other hand, smokers and 
quitters	 especially	 emphasized	 that	 NRT	 use	 should	 be	 restricted	 to	 only	 supporting	
total abstinence from tobacco use, not for diminishing the number of smoked cigarettes. 
However it seems that NRT use for other purposes than quitting has increased during 
2005-2013 (Helakorpi et al. 2005, Hélldan et al. 2013).
 
12.2 Methodological considerations 
This study focused on the Finnish NRT deregulation from three selected levels. In assess-
ing these levels, method triangulation	was	utilized	(Smith	2002).	Method	triangulation	
means combining different methodological approaches (Smith 2002, Kemper et al. 2003, 
Guion et al. 2014). Triangulation increases the overall validity of this study. This is be-
cause, the qualitative studies on the political (I) and customers’ (IV) level provided deep-
er explaining information of less studied phenomena. On the other hand, the quantative 
studies based on a nationwide, representative sample of community pharmacists (II,III) 
provided	the	more	generalizable	data	of	the	investigated	perspective.	
Method	triangulation	made	it	also	possible	to	compare	the	findings	from	these	studies	
and thus gain a more comprehensive understanding of NRT deregulation. However the 
results of this study related to the role of NRT in SC were contradictory. This inconsist-
ency may be explained by the different studied levels (political versus health care profes-
sionals and customers) rather than as a sign related to the lack of validity of this study. On 
the	other	hand,	the	findings	related	to	NRT	products’	real	 life	usage	patterns,	originat-
ing from the community pharmacists’ survey and from the qualitative study on smokers’ 
and	quitters’	perspectives,	were	in	line	and	the	findings	complemented	each	other.	This	
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in turn supports the reliability of this study. The following paragraphs will discuss some 
methodological considerations crucial for each study. Special attention is paid to the va-
lidity and reliability.
12.2.1 Qualitative studies  
In	both	the	qualitative	studies	(I&IV)	inductive	content	analysis	was	utilized	as	the	most	
suitable analysis method (Graneheim and Lund 2004, Elo and Kyngäs 2008). The objec-
tives of these studies were to gain genuine insights into phenomena, which were not pre-
viously (I) or less studied (IV) (Elo and Kyngäs 2008). Inductive content analysis made it 
possible to gain a rich overview, true to the original data.  
For qualitative studies the concepts of validity and reliability need to be operational-
ized	in	a	different	manner	compared	with	quantitative	research	(Mayes	and	Pope	2000).	
For this reason, for the two qualitative studies, the evaluation criteria for qualitative stud-
ies	of	trustworthiness	by	Lincoln	and	Guba	(1985)	were	utilized.	The	evaluation	criteria	
are	1)	credibility,	which	refers	to	the	confidence	and	truthfulness	of	data	and	how	well	
the data and analysis process address the intended focus of the study. 2) Dependability, 
which refers to stability of data over time and conditions. 3) Conformability, which means 
objectivity and neutrality of the data so that two or more people can reach an agreement 
on	the	data’s	relevance	and	meaning.	4)	Transfermability,	which	refers	to	generalizabil-
ity	of	the	data,	meaning	to	what	extent	the	findings	can	be	applied	to	other	settings	and	
populations in addition to the investigated ones. The further paragraphs describe the key 
components of the evaluation criteria of trustworthiness related to each study (I&IV). 
 
12.2.1.1 Analysis of the political process of NRT deregulation 
This study was based on the analysis of all the publicly available documents on the politi-
cal	process	in	NRT	deregulation.	Utilizing	written	sources	of	information	and	analysing	
all the documents increases the credibility and dependability of the data and further anal-
ysis (Lincoln and Guba 1987, Im and Chee 2006). Additional information was received by 
interviewing MPs, and the information from documents and interviews was triangulated. 
The data triangulation increased the credibility of the analysis as two data sources were 
complementary to each other’s. 
The	analysis	of	the	NRT	deregulation	as	a	political	process	was	conducted	five	years	af-
ter the deregulation took place, which helped to give distance to the actual lively debate 
proceeding NRT deregulation in the autumn of 2005 and thus increase the credibility of 
the analysis. During the data collection and analysis the data saturated, which is highly 
important for the conformability of the study.
On the other hand, the data analysis was conducted by only one investigator, which 
can	influence	on	the	credibility	and	conformability	of	the	analysis.	There	are	several	opin-
ions on using multiple investigators in the data analysis and seeking agreement, as each 
researcher interprets the data according to their subjective perspective (Graneheim and 
Lundman 2004). For instance Sandelowski (1993) states that it is questionable to use 
102
multiple researchers for achieving agreement, as each interpretation is subjective. This 
matter was taken into account by using the following procedures: Most importantly, dur-
ing the entire research process, several methodological and data analysis sessions were 
held within the research group. Secondly the emerged results were critically discussed 
with some key participants involved in the decision-making. Finally, the results were con-
trolled for materials outside the analysis. No data was found outside the themes, which is 
a sign of increased conformability. 
Though	this	study	and	its	findings	focused	on	the	Finnish	deregulation	case,	the	trans-
fermability	of	the	findings	can	be	discussed	from	the	following	viewpoints.	First,	the	prin-
ciple of evidence-informed decision making (Lomas et al. 2000), was the theoretical back-
ground	of	 this	study.	Secondly,	utilizing	this	principle	 in	decision-making	was	one	key	
finding	emerging	from	the	analysis.	This	finding	can	be	transformed	to	other	legislative	
procedures related to pharmaceuticals. Further, the key arguments supporting Finnish 
NRT deregulation are in line with international experiences (Table 5). 
12.2.1.2 Smokers’ and quitters’ perspective 
In this study the evaluation criteria of the rigour of qualitative analysis (Lincoln and Guba 
1985),	modified	suitably	for	internet-based	research	by	Im	and	Chee	(2006),	were	applied.	
The automatic transcripts provided by the Stumppi forum discussions increase credibil-
ity and dependability. 
There are several perspectives related to the credibility of this study. The analysis of 
3152 postings over a 5-year period (2007-2012) was selected for this study, to give longi-
tudinal data and an understanding of smokers’ perceptions on SC. This unique material 
provided genuine insights into smokers’ and quitters’ thoughts and behaviours without 
the interference of a researcher. On the other hand, internet-discussion-based data must 
be interpreted cautiously (Rollman et al. 2000, Im and Chee 2006, Seale et al. 2010). The 
analysis of internet discussions is based on what the posters on the forums ‘said’, rather 
than on their interpretation of what happened. The investigator must rely on postings 
without verifying these interpretations i.e.by further questions, as could be done in an in-
terview setting (Seale et al. 2010). Furthermore, there is evidence that proactive postings 
in the threads may receive the greatest diversity of responses, which can highlight the 
most critical viewpoints (Rollman et al. 2000). Further, due to the anonymity in the dis-
cussion forums, it is possible to express fabricated comments. Perhaps, especially too pos-
itive	comments	on	any	medicine	use	could	be	motivated	by	financial	interests.	However,	it	
was noticed that the most positive or highly critical comments were balanced by other dis-
cussion participants and as such the discussion chains presented mostly balanced opin-
ions. Furthermore, the vast amount of material assessed offered a great variety of aspects 
of NRT use, which was balanced by different viewpoints.
Saturation point is crucial for reaching the conformability of the analysis. Especially in 
an	internet-based	study,	it	can	be	difficult	to	estimate	(Im	and	Chee	2006,	Seale	2010).	
However, in this study a balance between estimating theoretical saturation by research-
ers’ real time participation (Im and Chee 2006, Seale et al. 2010) and appreciation of the 
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natural	occurrence	of	postings	was	achieved.	Only	five	discussion	areas	were	analysed	be-
cause	most	of	the	postings	in	Stumppi	Forum	were	made	in	these	five	areas.	These	discus-
sion areas were systematically analysed and the data collection continued until no new 
viewpoints emerged. By doing this a saturated, rich and full overview of different aspects 
was gained. 
The	emerged	results	were	discussed	with	the	professionals	in	the	STUMPPI	organiza-
tion who daily follow the virtual discussions. This increased dependability. However in 
terms of dependability and transfermability, it must be borne in mind that this study did 
not include those smokers and quitters who do not use the internet. In addition, it may be 
possible that the participants in the STUMPPI Forum may be more aware of SC and NRT 
use compared with all Finnish smokers and quitters. This matter must be taken into ac-
count	when	interpreting	these	findings.	
This	is	the	first	study	in	Finland	assessing	NRT	use	from	the	smokers’	and	quitters’	per-
spective.	As	these	findings	on	NRT	usage	patterns	were	in	line	with	the	ones	previously	re-
ported	in	the	international	literature	(Table	6),	it	can	be	expected	that	these	findings	give	
genuine insights into the smokers’ and quitters’ perceptions. 
12.2.2 Community pharmacists’ survey 
In this countrywide representative study, the overall response rate was 54% which is in 
accordance with (or better than) earlier surveys among pharmacists (Aquilina et al. 2003, 
Hudmon et al. 2006a). As the original survey questionnaire was six-paged with 62 sets of 
questions,	acknowledging	the	findings	on	the	effects	of	the	length	of	a	survey	instrument	
affecting the response rate (Jepson et al. 2005) the response rate was relatively high.
The respondents represented well all Finnish community pharmacists at the time of 
the	survey,	in	terms	of	academic	degree,	geographical	location,	the	size	of	the	pharmacy	
and ownership of the pharmacy (public vs. private, see Table 9). Because more than 90% 
of	 Finnish	 pharmacies	 have	 a	 specialized	 pharmacist	 for	 asthma,	 diabetes	 and	 cardio-
vascular diseases through the professional programs of the AFP (Association of Finnish 
Pharmacies	2007),	these	specialized	pharmacists	answered	more	readily	compared	with	
other pharmacists (Table 9). This is quite understandable because pharmacists with a 
specialization	can	be	expected	to	be	more	interested	in	SC.	This	may	though	magnify	the	
positive attitude towards SC and its importance with all the pharmacists. 
Instead of analysing the characteristics of non-respondents, respondents in different 
phases were compared. A higher proportion of pharmacy owners responded in phase I 
compared with staff pharmacists who responded more commonly in phase II (Chi Square 
test,	 p	 <	 0.001).	No	 other	 statistically	 significant	 differences	were	 found	 between	 the	
respondents in the two phase. This suggests that the bias of non-responses is minimal 
(Brenner 1995).
In assessing the familiarity and implementation of the Finnish SC Guideline, respond-
ents’ familiarity with the Finnish SC Guideline was chosen to be the main outcome meas-
ure. It was considered more reliable for the respondents to assess their own familiarity 
with the Guideline than the actual level of implementation, which can be biased by lim-
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ited ability to recall or by self-perceptions. However, the level of actual implementation 
can be more reliably assessed by population based intervention studies or pseudo patron 
studies. 
The role of NRT was studied from the pharmacists’ view-point which does not illus-
trate the perceptions of other health care professionals or quitters or smokers on NRT 
and its use. This information was, however complemented by the qualitative study among 
Stumppi participants (Study IV) and in the literature review section of this thesis. 
In	assessing	the	reflections	of	NRT	deregulation,	the	operationalized	concepts	(see	Ap-
pendix 3) were designed for assessing pharmacy practitioners’ perceptions on the issue 
based on their daily contacts with customers buying NRT products and needing their ad-
vice in SC. Most of the customer service work is done by staff pharmacists. On the con-
trary, pharmacy owners deal more with management and planning the services. This can 
be seen for example, in the “no opinion” responses to the question related to the develop-
ment of NRT sales, (owners 4% no opinion vs. staff pharmacists no opinion 25%). These 
“no	opinion”	responses	can	be	considered	as	a	reflection	of	these	different	roles	and	truth-
ful answers based on their knowledge, experiences and understanding. 
This study was conducted during a lively public debate on the delivery routes of NRT 
and other OTC medicines and on the importance of pharmacists’ advice in general, which 
may	have	influenced	on	respondents’	opinions.	However,	the	main	findings	are	in	accord-
ance with the earlier studies on NRT. This increases the reliability of the study. 
Although the survey instrument was developed in cooperation with SC experts and pre-
tested	at	pharmacies,	 some	statements	and	concepts	may	have	been	difficult	 to	under-
stand. For example, the statement regarding the use of NRT on smoking reduction may 
have caused confusion due to the recent discussion on harm reduction and its role in SC. 
Finally, to note, this cross-sectional study conducted a year after the launch of the deregu-
lation does not allow to draw causal- relationship conclusions between the outcomes vari-
ables and the deregulation.
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13 Conclusions, implications for further   
 evaluation, research and health care
  services
13.1 Conclusions 
This study found that NRT deregulation from pharmacy-only to general sales was a prin-
cipally	significant	but	contradictory	change	in	the	pharmaceutical	legislation.	According	
to this study, at the time of the NRT deregulation was carried out in the Finnish Parlia-
ment,	it	was	politically	communicated	as	a	straightforward	and	significant	intervention	
to increase SC among the Finnish population and thus promote public health. Based on 
the	literature	review	of	this	thesis	and	the	key	findings	of	this	study	it	can	be	concluded	
that	NRT	deregulation	did	not	directly	benefit	public	health	as	remarkably	as	suggested	
during	the	policy-making	process.	The	deregulation	has	reflected	negatively	on	commu-
nity pharmacists’ involvement in SC, making one health care resource in SC less available. 
More detailed conclusions of this study, on the key reasons of the Finnish NRT deregula-
tion	and	its	reflections	on	SC	practises,	are	as	follows:		
The politically presented key public health goal of the deregulation, an increase in SC, •	
was supported by only limited evidence. Actually, it was mostly based on the assump-
tions of poor availability and OTC NRT effectiveness. Furthermore, during the policy-
making process of NRT deregulation, several aspects related to the principle in the 
way the decision-making process was carried out and the fundamental change the de-
regulation	caused	in	the	Finnish	pharmaceutical	policy	were	debated.	The	findings	of	
this study address the need for policy-makers to critically evaluate the evidence and 
its suitability in the decision-making context.
This study indicates that community pharmacists could constitute a potential public •	
health resource in SC, which is easily accessible throughout the whole country. One 
year after the NRT deregulation the development to involve Finnish community phar-
macists in the treatment chain of SC had advanced to some extent, measured by the 
familiarity with and the implementation of the Finnish SC Guideline. NRT deregula-
tion	influenced	negatively	on	this	development	among	community	pharmacists.	This	
is because the NRT deregulation diminished community pharmacists’ and especially 
pharmacy owners,’ motivation to serve and counsel customers buying NRT. If com-
munity pharmacists’ motivation and expertise in supporting SC and counselling NRT 
use are further diminished due to the deregulation, one health care resource in SC 
may	be	lost	instead	of	the	expected	public	health	benefits	of	the	NRT	deregulation.		
Based on the analysis of internet-based discussions, among smokers and quitters •	
NRT products were seen as a less important component of gaining permanent absti-
nence. More importantly from their viewpoint was their own psychological empower-
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ment	and	the	learning	of	a	new	smoke-free	lifestyle.	These	findings	were	in	opposi-
tion to the importance of the sole NRT in SC, highlighted during the decision-making 
leading up to the deregulation. Furthermore, a negative attitude towards NRT was 
the most commonly emerged theme in the analysed smokers’ and quitters’ postings. 
This was mostly explained by the fear and experiences of dependence towards NRT 
use. 
Based	on	qualitative	and	quantative	findings,	this	study	indicates	that	among	Finn-•	
ish smokers and quitters there are NRT usage patterns which may be suboptimal. Es-
pecially underuse, use with too small a dosage, or too a short a time, emerged often 
from the qualitative analysis among Finnish smokers and quitters. It was also the 
most	often	reported	usage	pattern	in	the	community	pharmacists’	survey.	This	find-
ing may at least partly explain why the increase in NRT use after deregulation, based 
on	the	Finnish	national	sales	data,	may	not	have	been	clearly	reflected	in	the	Finnish	
smoking statistics.  
13.2 Implications for further research and evaluation
Although the Parliamentary Social Affairs and Health Committee expected the monitor-
ing	of	NRT	deregulation,	only	very	short-term	influences	were	evaluated	by	the	Working	
Group Monitoring the Sales of Nicotine Preparations in 2007 (Ministry of Social Affairs 
and	Health	2007).	The	findings	of	this	study	suggest,	that	this	evaluation	should	be	re-
peated	to	assess	the	real	life	benefits	of	NRT	deregulation.	Based	on	this	study	the	follow-
ing points are suggested as implications for further research and evaluation:  
It is important to assess what is the role for NRT products in SC -will they turn out to •	
be less important tools for health care professionals’ work and less important in SC? 
Also the pharmacoeconomical aspect of the NRT deregulation should be assessed. 
We have some evidence of the pricing of NRT after the deregulation (Aalto- Setälä 
and Alaranta 2008), but it is important to assess how the availability and prices of 
the products have developed during the nearly ten year period after NRT deregula-
tion and how they will develop in the future. 
There is a need for more research from the smokers’ and quitters’ perspective to as-•	
sess the real value of NRT compared with other methods in SC. Also smokers’ and 
quitters’ preferences in SC in general should be further assessed. This information 
could be used in planning service structures which would be most suitable for their 
needs in SC.  There is also a need to investigate the possible existence of dependence 
on NRT products from the smokers’ and quitters’ perspective. In recent years, there 
has been a radical increase in the popularity of e-cigarettes. Therefore it should also 
be assessed how smokers and quitters perceive e-cigarettes in comparison with NRT 
as a SC method. 
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The survey among community pharmacists was conducted in 2006 – 2007, i.e., about •	
nine	years	ago.	This	study	should	be	revised	in	order	to	find	out	the	long-term	effects	
of the deregulation on pharmacists’ attitudes, motivation, participation in SC and 
practises to counsell NRT use. This is especially important as the NRT sales and con-
tacts with customers at pharmacies have constantly decreased. Furthermore, there is 
a need to assess the value of counselling provided by pharmacists in the SC drug use. 
For instance, could the suboptimal usage patterns of NRT be avoided through phar-
macists’ or other health care professionals’ support and guidance? 
Since the NRT deregulation, several new tobacco control initiatives have been imple-•	
mented in Finland (Chapter 5.4). Also a new prescription medicine was launched for 
SC in 2006 and it was included under the national health insurance scheme in 2014. 
Despite	these	significant	changes,	the	real	life	effectiveness	of	SC	interventions	has	
not been studied in Finland. This kind of study would be important to evaluate the 
real life importance of different SC interventions and practises in Finland. 
13.3 Implications for health care services 
Based	on	the	findings	of	this	study	and	the	literature	review	of	this	thesis	the	following	
implications for the health care services are suggested:
Many smokers and quitters have several reasons why they use SC medications in a •	
suboptimal	way.	Therefore,	customized	medicine	information,	which	addresses	their	
perceptions related to SC, including SC medication use, could support optimal SC 
medication	use.	In	addition,	some	smokers	and	quitters	could	benefit	from	even	a	
more comprehensive approach; an individually tailored SC plan (Raupach and van 
Schayck 2011). This plan could take advantage of the smoker’s own willingness to 
quit	and	make	lifestyle	changes.	This	kind	of	individualized	SC	plan	could	support	
optimal SC pharmacotherapy and among NRT users it could prevent the feared NRT 
dependence. However, support of optimal SC medication use is only one part of the 
individualized	plan.	Instead	the	SC	plan	should	also	include	non-medical	methods	
supporting SC. This would be in line with STUMPPI Forum participants’ perceptions, 
which highlighted the importance of empowerment and quitter’s own decision-
making to maintain a new smoke-free lifestyle in gaining permanent abstinence. 
This kind of plan has been offered in some Finnish health care practises including 
community pharmacies, but this plan should be made more readily available for 
smokers and quitters. 
It is also important to discuss the ways of how to support community pharmacists’ in-•	
volvement in SC, despite their diminished motivation towards SC after NRT deregu-
lation. All health care professionals’, including community pharmacists’, professional 
role and knowledge-base in SC could be strengthened by educational activities (Table 
3). These activities should focus on supporting communication skills and understand-
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ing	of	the	importance	of	empowerment	in	SC.	Also	participation	in	a	well-organized	
multidisciplinary education can support pharmacists’ understanding of the overall 
importance of the SC treatment chain and their own professional role in a wider con-
text. This kind of education is already available for most of the Finnish pharmacy stu-
dents.	Like	the	Finnish	SC	Guideline	suggests,	all	health	care	professionals	benefit	
from local multidisciplinary SC practices (The Finnish Medical Society Duodecim 
2012). This kind of collaboration and local practise could also support pharmacists’ 
motivation	towards	SC.	Finally,	based	on	the	British	and	Danish	experience	financial	
support for more sophisticated SC services provided by community pharmacists has 
increased	the	utilization	these	SC	services	among	their	users	(Bradley	et	al.	2006,	As-
sociation of Danish Pharmacies 2008). This matter should also be discussed in Fin-
land	in	the	wider	context	of	organizing	local	health	care	services.
Finally,	all	health	professionals	should	find	new	innovative	and	customized	ways	of	•	
being involved in the SC process in partnership with smokers and quitters. This is es-
pecially important as the ultimate goal of the Finnish Tobacco Control Policy is to end 
the use of tobacco products in Finland.   
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Appendix 1: Summary of key findings related to efficacy of NRT product in relation to behavioral support in     
SC drawn from the systematic reviews of Cochrane Tobacco Addiction Group, meta-analysis of the US Clinical Practice 
Guideline and the meta-analysis assessing the long-term effect of NRT use. 
Name (citation) and objective of 
the review 
Number of trials included, medication 
and control groups, intervention, other 
requirements
Evidence supporting sole use of 
NRT (OTC NRT)
Evidence supporting the 
combination of  behavioural 
support  and NRT use
Nicotine replacement therapy for 
smoking cessation (Stead et al. 
2012):
To determine the effect of NRT 
compared to placebo in aiding 
smoking cessation and to 
“Determine whether the effect on 
SC is influenced by the dosage, 
form and timing of use of NRT; the 
intensity of additional advice and 
support offered to the smoker; or the 
clinical setting in which the smoker 
is recruited and treated.”
150 placebo-controlled trials, with > 
50 000 smokers. The participants were 
motivated to quit and smoked > 15 
cigarettes a day. 
Medication group received NRT 
Control group placebo. 
Almost all trials provided similar 
behavioral support, advice, counseling 
and number of follow-up visits, for 
the NRT and control groups. Between 
different trials there were differences in 
the amount of support.  
In some analyses the amount of 
behavioral support was categorized to 
low and high. Low meant a visit in usual 
care and high if the duration exceeded 30 
minutes or included several visits to the 
clinic or trial center.
Risk Ratio (RR) for abstinence 
for any NRT form compared to 
placebo is 1.60 (CL 95% 1.53-
1.69).
The RR’s for different NRT 
formulations varied between 1.49 
(gum) to 2.02 (nasal spray). 
NRT use increases the quitting 
rate by 50 -70 %.    
The results remained similar 
regardless of the setting, 
including OTC NRT vs. 
prescription NRT, duration of the 
therapy or additional support 
provided.  
According to the meta-regression 
conducted there was no evidence 
that the relative effect differed by 
the type of support.
Results of five trials in community 
volunteers in OTC setting were 
pooled. The RR (2.71, 95% CI 2.11 
to 3.49) was significantly higher 
than in other settings.  This was 
explained by the most lowest quit 
rate of control group in OTC studies 
(2.1%) and the highest smoking 
clinics (12.1%). For this reason, the 
authors suggested, that absolute 
increase in quit rates in OTC setting 
may be small. 
The authors discussed that the 
absolute increase in SC rates 
related to NRT use will be larger if 
the baseline chance of success is 
already raised by the provision of 
intensive behavioral support.
Behavioral interventions as
adjuncts to pharmacotherapy for 
smoking cessation (Stead and 
Lancaster 2012a): 
”To evaluate the effect of increasing 
the intensity of behavioral support 
for people using smoking cessation 
medications, and to assess whether 
there are different effects depending 
on the type of pharmacotherapy, 
or the amount of support in each 
condition.”
38 RCTs or quasi-randomized controlled 
trials, of which 35 examined NRT use. The 
studies included 15 000 participants, who 
were expected to have the same level of 
motivation towards quitting, though the 
motivation was not assessed.
In the SC medication group the 
participants received similar medication, 
but different amounts of behavioral 
support varying from minimal (e.g. 
written information) to intensive multi-
session counselling. 
Controls could receive any level of 
support (from intensive personal contact 
to written information) but they always 
received lower intensity support than the 
medication group. 
Point prevalence at 12 months was used, 
instead of sustained abstinence. The 
review focused on the amount, not on the 
components or the quality of the support. 
The review detected a small but 
statistically significant benefit from 
more intensive support (RR 1.16, 
95% CI 1.09 to 1.24) for abstinence 
at longest, 12 months, follow-up.
Increasing the amount of 
behavioral support is likely to 
increase the chance of success by 
about 10 to 25%, based on a pooled 
estimate from 38 trials.
The authors concluded that 
providing more intense behavioral 
support for people making a 
cessation attempt with the aid of 
pharmacotherapy will increase the 
success rates by about 16%.
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Name (citation) and objective of 
the review 
Number of trials included, medication 
and control groups, intervention, other 
requirements
Evidence supporting sole use of 
NRT (OTC NRT)
Evidence supporting the 
combination of  behavioural 
support  and NRT use
Combined pharmacotherapy 
and behavioral interventions for 
smoking cessation (Stead and 
Lancaster 2012b):  
“Assess the effect of combining 
behavioral support and SC 
medication, compared to a minimal 
intervention or usual care. To assess 
are there differences between 
characteristics of the treatment 
setting, intervention, population 
treated, or take-up of treatment.” 
41 trials of which the results of 40 trials 
were included in the pooled results. The 
studies included > 20 000 patients. 
Behavioral support was typically provided 
by SC specialists, who offered between 
four and eight contact sessions.
Medication group: SC medication with 
behavioral support (tailored materials, 
brief advice, in person or telephone 
counselling). Most of the trials in this 
review offered one or more types of NRT 
or bupropion.
Control group members received either 
usual care or a brief cessation component 
(i.e. advice to quit) but no other 
behavioral support or medication.
The pooled estimate for the 
remaining 40 trials (RR 1.82, 
95%CI 1.66 to 2.00) suggests that 
a combined intervention might 
typically increase the SC rate 
between 70- 100%.  
One trial, The Lung Health Study, 
demonstrated a large benefit of a 
multimodal therapy.
At one year follow-up SC rate 
was 35% in the intervention 
group and 9% in the control. 
Sustained benefits after five years 
and reduced mortality in the 
intervention group were reported.
Compared to the estimates from 
the Cochrane reviews of the effects 
for NRT (50-70%) or bupropione 
alone, the additional benefit from 
the behavioral component might 
seem small. No formal statistical 
comparison between medication 
use and behavioral support is 
conducted and thus the effects 
cannot be compared directly. 
Treating Tobacco Use and 
Dependence update 2008 
(Fiore et al. 2008 pages 101-103) 
”whether combining counseling 
and medication improved SC rates 
compared to either of these alone.”
The effect of adding counseling to 
medication was based on a meta-
analysis of 18 studies comparing either 
medication alone or medication with 
counseling. 
The effect of adding medication to 
counseling was based on meta-analysis 
of 9 studies, which provided 24 arms 
to compare medication and counseling 
alone.
Medication and counseling 
both are effective and should 
be provided as stand-alone 
interventions when it is not 
feasible to do the both. 
The combination of medication 
and counseling is more effective for 
SC than either component alone. 
Therefore, combining medication 
and counseling should both be 
provided to patients trying to quit 
smoking (page 101). There is a 
strong relationship between the 
number of counseling sessions 
when combined with medication 
and the likelihood of a successful 
SC (page 103). 
OR for combining counseling to 
medication was 1.4 (1.2-1.6) and 
the OR for combining medication 
to counseling was 1.7 (1.3-2.1). 
Nicotine replacement therapy for 
long-term smoking cessation: a 
meta-analysis (Etter and Stapleton 
2006): 
”To assess if the effect of a single 
treatment episode with NRT 
enhances SC over many years. This 
was the first systematic review of 
the long-term effects of NRT in the 
treatment of tobacco dependence. 
The authors suggest it provides the 
most reliable evidence that NRT aids 
in achieving permanent SC.” 
Meta-analysis of all randomized trials of 
NRT with final follow-up of more than 
one year after the start of the treatment 
(n= 12). The authors also expected that 
treatment and controls only differed by 
the inclusion of an active NRT product in 
the treatment arm. The most stringent 
definition of abstinence was used 
(prolonged abstinence). 
The follow-up periods varied between 2-8 
years. All the studies provided SC rates at 
12 months and later follow-up points. 
The effect of any advice or behavioral 
counselling was also given.  
Medication group: received different 
NRT products and different dosages (n= 
2 408). 
Controls: placebo (n= 2 384)
Most of the trials allowed to use NRT for 
three months but four trials allowed the 
use for four months. In addition, in all the 
trials  supportive advice or counselling 
was given to some extent. 
All the trials were conducted in clinical 
settings instead of “self-help” settings 
where NRT is bought (at pharmacies or 
supermarkets).
Of the 12 trials included, six 
provided statistical evidence 
on the effect of NRT at the 
final follow-up and six gave null 
results.
The combined data from all the 
trials provided good evidence for 
the efficacy of NRT beyond 12 
months.   
The use of NRT in addition to 
brief advice or behavioral support 
offered in the included studies 
gave and odds ratio 2 and suggests 
70-90% increase in the SC rate 
achieved without NRT. 
The long term success rate of 
NRT use is extremely modest, 
representing success in SC of about 
only 9% of those initially treated 
by NRT.
These results suggest, that nicotine 
addiction should be treated as a 
chronic recurring disease in the 
brain. Its treatment should be 
planned on a long term basis. 
The quit rates remained long 
term among those quitters, who 
had received more intensive and 
experienced behavioral support 
as part of the trial. This finding 
suggests that NRT use is more 
effective in SC, when used in 
addition to counselling. 
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  A
ll 
in
cl
ud
ed
 s
tu
di
es
 
us
ed
 b
io
ch
em
ic
al
 v
er
ifi
ca
ti
on
 o
f 
ab
st
in
en
ce
. 
Th
is
 s
ys
te
m
at
ic
 re
vi
ew
 w
as
 a
bl
e 
to
 lo
ca
te
 
to
ta
lly
 9
 e
lig
ib
le
 s
tu
di
es
. 
A
ll 
O
TC
 N
RT
 v
er
su
s O
TC
 p
la
ce
bo
 tr
ia
ls
 w
er
e 
ra
nd
om
is
ed
, p
ar
al
le
l g
ro
up
s 
st
ud
ie
s.
 
A
lt
og
et
he
r 4
 tr
ia
ls
 w
er
e 
in
cl
ud
ed
 in
 th
e 
fin
al
 
an
al
ys
is
. I
n 
75
%
 o
f t
he
 s
tu
di
es
 th
e 
fo
llo
w
-
up
 p
er
io
d 
w
as
 6
 m
on
th
s.
 W
he
n 
th
e 
re
su
lts
 
of
 th
es
e 
st
ud
ie
s 
w
er
e 
co
m
bi
ne
d 
in
 a
 m
et
a-
an
al
ys
is
, t
he
 o
ve
ra
ll 
O
R
 w
as
 2
.5
 (9
5%
 C
L 
1.
8 
to
 3
.6
).
 Th
er
e 
w
er
e 
4 
st
ud
ie
s 
co
m
pa
ri
ng
 O
TC
 N
R
T 
to
 
Rx
 N
RT
. T
he
 O
R’
s 
va
rie
d 
be
tw
ee
n 
th
e 
st
ud
ie
s 
fr
om
 0
.3
- 3
.6
 (O
R 
<1
 in
di
ca
tin
g 
O
TC
 N
RT
 
no
t e
ffi
ci
en
t)
.  
In
 th
e 
m
et
a-
an
al
ys
is
 th
e 
fin
al
, 
co
m
bi
ne
d 
O
R
 w
as
 1
.4
 (9
5%
 C
L 
0.
6 
to
 3
.3
)
Th
e 
ab
so
lu
te
 q
ui
t r
at
e,
 in
cl
ud
in
g 
al
l t
he
 
st
ud
ie
s 
w
it
h 
 6
 m
on
th
s 
fo
llo
w
-u
p 
w
as
 7
%
 (C
l 
95
%
 4
%
 to
 1
1%
)
In
 s
om
e 
O
TC
 tr
ia
ls
 th
e 
pa
rt
ic
ip
an
ts
 
vi
si
te
d 
th
e 
st
ud
y 
ce
nt
re
 a
t v
ar
io
us
 
tim
es
. I
n 
ea
ch
 p
la
ce
bo
 v
er
su
s 
N
RT
 tr
ia
l, 
pa
rt
ic
ip
an
ts
 re
ce
iv
ed
 O
TC
-N
RT
 fr
ee
 o
f 
ch
ar
ge
. 
B
as
ed
 o
n 
th
ei
r fi
nd
in
gs
 th
e 
au
th
or
s 
co
nc
lu
de
d,
 th
at
 O
TC
 N
RT
 a
nd
 
pr
es
cr
ip
tio
n 
N
RT
 y
ie
ld
ed
 s
im
ila
r q
ui
t 
ra
te
s.
 
Th
e 
au
th
or
s 
re
co
m
m
en
de
d 
th
at
 
th
e 
re
qu
ire
m
en
t o
f s
im
ul
ta
ne
ou
s 
co
un
se
lli
ng
 re
la
te
d 
to
 N
RT
, d
em
an
de
d 
in
 m
an
y 
SC
 p
ro
gr
am
s,
 s
ho
ul
d 
be
 
re
la
xe
d.
 
YE
S
H
ug
he
s 
et
 a
l. 
20
11
: 
To
 re
vi
ew
 n
on
-r
an
do
m
iz
ed
 te
st
s 
to
 
as
se
ss
 e
ff
ec
ti
ve
ne
ss
 o
f O
TC
 N
R
T
M
os
t i
nc
lu
de
d 
st
ud
ie
s 
w
er
e 
co
nd
uc
te
d 
in
 th
e 
U
S.
Li
te
ra
tu
re
 re
vi
ew
 in
cl
ud
in
g 
re
tr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
di
es
 c
om
pa
rin
g 
N
RT
 u
se
rs
 a
nd
 
no
n-
us
er
s 
an
d 
st
ud
ie
s 
co
m
pa
rin
g 
qu
it 
ra
te
s 
be
fo
re
 a
nd
 a
ft
er
 O
TC
 s
w
itc
h.
St
ud
ie
s 
w
er
e 
in
cl
ud
ed
 if
 th
ey
 re
po
rt
ed
 
ab
st
in
en
ce
 ra
te
s 
an
d 
w
er
e 
as
se
ss
in
g 
eff
ec
ti
ve
ne
ss
, n
ot
 e
ffi
ca
cy
. 
Th
e 
au
th
or
s 
w
er
e 
ab
le
 to
 d
et
ec
t 
11
 re
tr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
di
es
, 
in
cl
ud
in
g 
14
 c
om
pa
ri
so
ns
 o
f t
he
 q
ui
t 
ra
te
s 
of
 O
TC
 N
RT
 u
se
rs
 v
er
su
s 
no
n-
us
er
s 
an
d 
co
m
pa
ri
ng
 e
ff
ec
ti
ve
ne
ss
 
of
 O
TC
-N
RT
 a
nd
 R
x-
 N
RT
 in
cl
ud
in
g 
co
un
se
lin
g
Th
e 
au
th
or
s 
in
cl
ud
ed
 s
tu
di
es
, w
hi
ch
 
ei
th
er
 w
er
e 
re
tr
os
pe
ct
iv
e,
 p
op
ul
at
io
n-
ba
se
d 
co
ho
rt
 s
tu
di
es
 (n
=4
, a
ll 
co
nd
uc
te
d 
in
 th
e 
U
S)
, r
et
ro
sp
ec
ti
ve
 
co
ho
rt
 c
on
ve
ni
en
ce
 s
am
pl
es
 (n
=3
, 
co
nd
uc
te
d 
in
 th
e 
U
S,
 C
an
ad
a 
an
d 
U
K
) 
or
 re
tr
os
pe
ct
iv
e 
co
ho
rt
 tr
ea
tm
en
t 
st
ud
ie
s 
(n
=3
, a
ll 
co
nd
uc
te
d 
in
 th
e 
U
S)
. 
Th
e 
re
su
lts
 o
f t
he
 s
tu
di
es
 a
re
 s
um
m
ar
iz
ed
 b
y 
fo
ur
 m
et
ho
ds
 fo
r e
ac
h 
st
ud
y 
ty
pe
.  
R
et
ro
sp
ec
ti
ve
 s
tu
di
es
:
- E
xp
er
im
en
ta
l r
ep
lic
at
io
n:
 th
e 
au
th
or
s 
ca
lc
ul
at
ed
 q
ui
t r
at
es
 fo
r N
RT
 a
nd
 n
on
-N
RT
 
us
er
s:
 N
R
T 
us
e 
w
as
 b
en
efi
ci
al
- P
ro
po
rt
io
n 
of
 s
tu
di
es
, fi
nd
in
g 
 s
ta
ti
st
ic
al
ly
 
si
gn
ifi
ca
nt
 e
vi
de
nc
e 
su
pp
or
ti
ng
 N
R
T 
us
e 
co
m
pa
re
d 
to
 n
ot
 u
se
: N
R
T 
us
e 
w
as
 m
or
e 
be
ne
fic
ia
l
- A
ss
es
sm
en
t o
f t
he
 m
os
t i
nt
er
na
lly
 a
nd
 
ex
te
rn
al
ly
 ri
go
ro
us
 s
tu
dy
 a
nd
 it
s 
re
su
lt
s:
 
N
R
T 
w
as
 n
ot
 e
ff
ec
ti
ve
- S
pe
ci
fic
it
y:
 in
st
an
ce
s 
w
hi
ch
 O
TC
 N
R
T 
us
e 
di
d 
no
t i
nc
re
as
e 
qu
it 
ra
te
s 
 b
ut
 o
th
er
 
eff
ec
ti
ve
 m
et
ho
ds
 d
id
: N
R
T 
w
as
 e
ff
ec
ti
ve
 
- C
om
pl
ia
nc
e 
to
 O
TC
 N
RT
 w
as
 w
ea
k.
Th
e 
au
th
or
s 
lo
ca
te
d 
se
ve
n 
pr
e-
 a
nd
 p
os
t O
TC
 
N
R
T-
 s
tu
di
es
: T
hr
ee
 u
se
d 
a 
re
tr
os
pe
ct
iv
e 
po
pu
la
tio
n-
ba
se
d 
sa
m
pl
e 
an
d 
fo
ur
 a
 
co
nv
en
ie
nc
e 
sa
m
pl
e.
- E
xp
er
im
en
ta
l r
ep
lic
at
io
n:
 N
R
T 
us
e 
w
as
 
m
or
e 
be
ne
fic
ia
l t
ha
n 
no
n-
us
e
- F
ra
ct
io
n 
of
 s
tu
di
es
: o
nl
y 
in
 1
 o
ut
 o
f t
he
 4
 
st
ud
ie
s 
fo
un
d 
N
R
T 
us
e 
m
or
e 
be
ne
fic
ia
l
- A
ss
es
sm
en
t o
f t
he
 m
os
t  
ri
go
ro
us
 s
tu
dy
: 
N
R
T 
w
as
 n
ot
 e
ff
ec
ti
ve
- S
pe
ci
fic
it
y:
 c
ou
ld
 n
ot
 b
e 
te
st
ed
Th
e 
in
cl
ud
ed
 s
tu
di
es
 w
er
e 
fa
r t
oo
 
he
te
ro
ge
ne
ou
s 
fo
r m
et
a-
an
al
ys
is
.
O
TC
 N
R
T 
ap
pe
ar
ed
 to
 b
e 
le
ss
 e
ff
ec
ti
ve
 
in
 re
tr
os
pe
ct
iv
e 
st
ud
ie
s.
B
as
ed
 o
n 
th
e 
m
ix
ed
 re
su
lt
s 
it
 is
 
im
po
ss
ib
le
 to
 d
ra
w
 a
ny
 fu
rt
he
r 
co
nc
lu
si
on
s 
on
 th
e 
eff
ec
ti
ve
ne
ss
 o
f O
TC
 
N
RT
. 
Th
e 
au
th
or
s 
hi
gh
lig
ht
 th
e 
ne
ed
 fo
r a
 
fu
rt
he
r, 
hi
gh
-q
ua
lit
y 
re
tr
os
pe
ct
iv
e,
 
po
pu
la
tio
n 
ba
se
d 
st
ud
y.
  
U
N
C
LE
A
R
A
pp
en
di
x 
2:
 E
xa
m
pl
es
 o
f s
tu
di
es
 s
ho
w
in
g 
co
nt
ra
di
ct
or
y 
ev
id
en
ce
 o
n 
th
e 
eff
ec
tiv
en
es
s 
of
 O
TC
 N
R
T 
fo
r s
m
ok
in
g 
ce
ss
at
io
n.
R
ef
er
en
ce
, o
bj
ec
ti
ve
 a
nd
 s
et
ti
ng
St
ud
y 
de
si
gn
/ k
ey
 c
ha
ra
ct
er
is
ti
cs
Pa
rt
ic
ip
an
ts
 /
H
ow
 a
bs
ti
ne
nc
e 
 is
 d
efi
ne
d
K
ey
 F
in
di
ng
s 
re
la
te
d 
to
 t
he
 e
ff
ec
ti
ve
ne
ss
 o
f 
O
TC
 N
R
T 
To
 n
ot
ic
e 
(k
ey
 p
oi
nt
s 
in
 d
is
cu
ss
io
n,
 
lim
it
at
io
ns
 a
nd
 s
tr
en
gt
hs
 o
f t
he
 s
tu
dy
)
Su
pp
or
ts
 th
e 
eff
ec
ti
ve
ne
ss
 o
f 
O
TC
 N
R
T?
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
di
es
 
K
ot
z 
et
 a
l. 
20
14
:
Sm
ok
in
g 
To
ol
K
it
 S
tu
dy
To
 a
ss
es
s 
th
e 
re
al
-w
or
ld
 
eff
ec
ti
ve
ne
ss
 o
f S
C
 m
ed
ic
at
io
ns
 w
it
h 
be
ha
vi
ou
ra
l c
ou
ns
el
lin
g,
 c
om
pa
re
d 
to
 u
se
 o
f O
TC
 N
RT
 a
nd
 u
na
id
ed
 
qu
itt
in
g.
 Th
e 
U
K
N
at
io
na
lly
 re
pr
es
en
ta
tiv
e 
su
rv
ey
 
co
nd
uc
te
d 
am
on
g 
th
os
e 
ov
er
 1
6 
ye
ar
s 
by
 fa
ce
-t
o-
fa
ce
 w
ith
 c
om
pu
te
r-
as
si
st
ed
 
m
et
ho
ds
 e
ve
ry
 m
on
th
. 
Th
is
 s
tu
dy
 in
cl
ud
ed
 a
gg
re
ga
te
d 
da
ta
 
fr
om
 N
ov
em
be
r 2
00
6 
to
 M
ay
 2
01
2.
 
En
gl
an
d 
is
 th
e 
co
un
tr
y 
w
ith
 th
e 
hi
gh
es
t 
ra
te
 o
f S
C 
m
ed
ic
in
es
 u
se
, a
s 
th
es
e 
ar
e 
re
im
bu
rs
ed
 u
nd
er
 th
e 
na
tio
na
l h
ea
lth
 
in
su
ra
nc
e.
 N
RT
 is
 a
va
ila
bl
e 
bo
th
 b
y 
pr
es
cr
ip
tio
n 
(r
ei
m
bu
rs
ed
) o
r O
TC
 in
 
ge
ne
ra
l s
al
es
. T
he
 a
id
s 
ha
ve
 b
ee
n 
av
ai
la
bl
e 
ov
er
 1
0 
ye
ar
s.
St
ud
y 
po
pu
la
ti
on
:
Th
os
e 
re
sp
on
de
nt
s,
 w
ho
 e
ith
er
 w
er
e 
sm
ok
in
g 
at
 th
e 
tim
e 
of
 s
ur
ve
y 
or
 h
ad
 
sm
ok
ed
 fo
r a
t l
ea
st
 1
2 
m
on
th
s 
be
fo
re
 
th
e 
su
rv
ey
 a
nd
 h
ad
 m
ad
e 
at
 le
as
t 
on
e 
qu
it 
at
te
m
pt
 in
 th
e 
 p
ro
ce
ed
in
g 
12
 m
on
th
s 
be
fo
re
 th
e 
su
rv
ey
 b
ut
 h
ad
 
qu
itt
ed
. 
Se
lf-
re
po
rt
ed
 a
bs
tin
en
ce
 w
as
 k
ey
 
ou
tc
om
e.
 T
he
re
 is
 e
vi
de
nc
e 
th
at
 
se
lf-
re
po
rt
ed
 a
bs
tin
en
ce
 is
 a
 re
lia
bl
e 
m
ea
su
re
m
en
t i
n 
su
rv
ey
 s
et
tin
g.
 
D
at
a 
fo
r t
he
 m
os
t r
ec
en
t q
ui
t a
tt
em
pt
 
w
as
 a
ss
es
se
d.
St
ud
y 
po
pu
la
ti
on
 (n
 =
 1
0 
33
5)
 c
on
si
st
ed
 o
f 
8 
93
2 
sm
ok
er
s 
an
d 
14
03
 q
ui
tt
er
s.
 
H
al
f o
f t
he
 s
tu
dy
 p
op
ul
at
io
n 
(5
1.
3%
) h
ad
 n
ot
 
us
ed
 a
ny
 p
ha
rm
ac
ot
he
ra
py
, a
 th
ird
 h
ad
 u
se
d 
O
TC
 -N
R
T,
 1
6.
5%
 h
ad
 re
ce
iv
ed
 p
re
sc
ri
pt
io
n 
an
d 
br
ie
f c
ou
ns
el
in
g,
 a
nd
 2
%
 h
ad
 re
ce
iv
ed
 
m
ed
ic
at
io
n 
by
 p
re
sc
rip
tio
n 
an
d 
sp
ec
ia
lis
t 
co
un
se
lin
g.
 O
f t
he
 p
re
sc
rip
tio
n 
m
ed
ic
at
io
n 
us
er
s,
 th
e 
m
aj
or
ity
 h
ad
 u
se
d 
N
RT
 b
y 
pr
es
cr
ip
tio
n.
 
A
cc
or
di
ng
 to
 th
e 
fin
al
 a
na
ly
si
s 
th
e 
O
R
’s
 fo
r 
qu
it
ti
ng
 w
er
e 
fo
r w
ho
le
 s
tu
dy
 p
op
ul
at
io
n:
 
am
on
g 
th
os
e 
re
sp
on
de
nt
s 
w
ho
 h
ad
 re
ce
iv
ed
 
m
ed
ic
at
io
n 
by
 p
re
sc
rip
tio
n 
an
d 
sp
ec
ia
lis
t 
co
un
se
lin
g 
th
e 
3.
25
 (9
5%
 C
l [
2.
05
-5
.1
5]
);
 
pr
es
cr
ip
ti
on
 a
nd
 b
ri
ef
 c
ou
ns
el
in
g 
O
R
: 1
.6
1 
(9
5%
 C
L[
1.
33
-1
.9
4]
);
 N
R
T-
O
TC
 O
R
: 0
.9
6 
(9
5%
 C
l[0
.8
6-
1.
31
] c
om
pa
re
d 
to
 n
o 
us
e 
of
 
ph
ar
m
ac
ot
he
ra
py
. 
Th
er
e 
ex
is
te
d 
no
 s
ou
rc
es
 o
f r
ec
al
l b
ia
s 
re
la
te
d 
to
 u
se
 o
f O
TC
-N
RT
. 
Th
e 
ke
y 
ou
tc
om
e 
w
as
 a
dj
us
te
d 
to
 m
ai
n 
po
te
nt
ia
l c
on
fo
un
de
rs
, w
hi
ch
 w
er
e 
as
se
ss
ed
 b
ef
or
eh
an
d.
 
O
f t
he
se
 th
e 
m
os
t i
m
po
rt
an
t w
as
 th
e 
le
ve
l o
f t
ob
ac
co
 d
ep
en
de
nc
e,
 w
hi
ch
 
w
as
 a
ss
es
se
d 
by
 u
rg
es
 to
 s
m
ok
e.
 A
ls
o 
de
m
og
ra
ph
ic
s 
an
d 
nu
m
be
r o
f q
ui
t 
at
te
m
pt
s 
pr
oc
ee
di
ng
 th
e 
m
os
t r
ec
en
t 
on
e 
an
d 
tim
e 
w
he
n 
th
e 
m
os
t r
ec
en
t q
ui
t 
at
te
m
pt
 w
as
 in
iti
at
ed
 w
er
e 
ta
ke
n 
in
to
 
ac
co
un
t.
 T
he
se
 p
os
si
bl
e 
co
nf
ou
nd
er
s 
w
er
e 
in
cl
ud
ed
 in
 th
e 
fin
al
 re
gr
es
si
on
 
an
al
ys
is
 a
s 
in
te
ra
ct
io
n 
te
rm
s.
 
A
ls
o 
po
ss
ib
le
 re
ca
ll 
bi
as
 w
as
 ta
ke
n 
in
to
 
ac
co
un
t i
n 
th
e 
fin
al
 a
na
ly
si
s.
 
Th
e 
st
ud
y 
di
d 
no
t a
ss
es
s 
le
ve
l o
f 
m
ed
ic
at
io
n 
ad
he
re
nc
e.
 
N
O
Th
es
e 
fin
di
ng
s 
qu
es
tio
n 
th
e 
eff
ec
ti
ve
ne
ss
 o
f 
O
TC
 N
RT
 a
m
on
g 
En
gl
is
h 
sm
ok
er
s.
R
ef
er
en
ce
, o
bj
ec
ti
ve
 a
nd
 
se
tt
in
g
St
ud
y 
de
si
gn
/ k
ey
 c
ha
ra
ct
er
is
ti
cs
Pa
rt
ic
ip
an
ts
 /
H
ow
 a
bs
ti
ne
nc
e 
 is
 d
efi
ne
d
Ke
y 
Fi
nd
in
gs
 re
la
te
d 
to
 th
e 
eff
ec
ti
ve
ne
ss
 o
f O
T
C
 N
R
T
 
To
 n
ot
ic
e 
(k
ey
 p
oi
nt
s 
in
 d
is
cu
ss
io
n,
 
lim
it
at
io
ns
 a
nd
 s
tr
en
gt
hs
 o
f t
he
 
st
ud
y)
Su
pp
or
ts
 th
e 
eff
ec
ti
ve
ne
ss
 
of
 O
TC
 N
R
T?
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
di
es
 
K
as
za
 e
t a
l. 
20
13
:
In
te
rn
at
io
na
l T
ob
ac
co
 C
on
tr
ol
 F
ou
r 
Co
un
tr
y 
Su
rv
ey
, I
CT
Ev
al
ua
te
 th
e 
po
pu
la
tio
n 
eff
ec
ti
ve
ne
ss
 o
f S
C
 m
ed
ic
at
io
ns
 a
nd
 
ac
co
un
tin
g 
fo
r p
ot
en
tia
l r
ec
al
l b
ia
s 
by
 c
on
tr
ol
lin
g 
th
e 
re
ce
nc
y 
of
 th
e 
qu
it 
at
te
m
pt
.
Fo
ur
 c
ou
nt
ry
 s
ur
ve
y 
st
ud
y:
 th
e 
U
K
, 
C
an
ad
a,
 A
us
tr
al
ia
 a
nd
 th
e 
U
S.
Si
nc
e 
th
e 
20
02
 re
pr
es
en
ta
tiv
e 
sa
m
pl
es
 
of
 s
m
ok
er
s 
fr
om
 a
ll 
th
e 
fo
ur
 c
ou
nt
rie
s 
ar
e 
in
te
rv
ie
w
ed
 b
y 
th
e 
ra
nd
om
- d
ig
it-
 
di
al
ec
t t
ec
hn
iq
ue
. 
Ea
rli
er
 a
na
ly
si
s 
of
 th
is
 s
ur
ve
y 
ha
s 
pr
ov
en
 
th
es
e 
sa
m
pl
es
 re
pr
es
en
ta
tiv
e 
an
d 
th
at
 n
on
-r
es
po
ns
e 
is
 n
ot
 a
 s
ou
rc
e 
of
 
sy
st
em
at
ic
 b
ia
s 
in
 th
is
 s
tu
dy
.
Th
is
 s
tu
dy
 in
cl
ud
es
 d
at
a 
co
lle
ct
ed
 
be
tw
ee
n 
20
02
-2
00
9 
(e
ig
ht
 fi
rs
t s
ur
ve
y 
w
av
es
).
A
na
ly
si
s 
w
as
 re
st
ric
te
d 
to
 th
os
e 
pa
rt
ic
ip
an
ts
, w
ho
 p
ar
tic
ip
at
ed
 in
 a
t 
le
as
t t
w
o 
co
ns
ec
ut
iv
e 
w
av
es
 a
nd
 h
ad
 
m
ad
e 
th
ei
r l
as
t q
ui
t a
tt
em
pt
 b
et
w
ee
n 
tw
o 
su
rv
ey
 w
av
es
. (
n=
 7
43
6)
Su
rv
ey
 p
ar
tic
ip
an
ts
 w
er
e 
re
-c
on
ta
ct
ed
 
ap
pr
ox
im
at
el
y 
an
nu
al
ly
 to
 c
om
pl
et
e 
th
e 
fo
llo
w
-u
p.
 T
ho
se
 lo
st
- t
o 
fo
llo
w
-u
p 
ar
e 
re
pl
ac
ed
 b
y 
ne
w
 p
ar
tic
ip
an
ts
. 
A
bs
ti
ne
nc
e:
 s
el
f-
re
po
rt
ed
 c
on
ti
nu
es
 
ab
st
in
en
ce
, 1
 m
on
th
s 
/ 6
 m
on
th
s 
w
as
 
as
se
ss
ed
 in
 th
e 
fo
llo
w
-u
p 
in
te
rv
ie
w
 b
y 
di
ff
er
en
t q
ue
st
io
ns
. 
B
as
ed
 o
n 
lo
gi
st
ic
 re
gr
es
si
on
 a
na
ly
si
s,
 u
se
 o
f 
N
RT
 p
at
ch
, (
lik
e 
va
re
ni
cl
in
e 
an
d 
bu
pr
op
io
n 
as
 w
el
l) 
w
as
 s
ig
ni
fic
an
tl
y 
as
so
ci
at
ed
 w
it
h 
ob
ta
in
in
g 
on
e 
m
on
th
 (O
R
’s
 1
.1
9-
 2
.3
5)
 a
nd
 s
ix
 
m
on
th
 (O
R
 1
.1
5-
 4
.0
9)
 a
bs
ti
ne
nc
e 
co
m
pa
re
d 
w
ith
 n
o 
m
ed
ic
at
io
n 
us
e.
 
A
m
on
g 
th
os
e,
 w
ho
 h
ad
 b
ee
n 
ab
st
in
en
t f
or
 
on
e 
m
on
th
 o
r s
ix
 m
on
th
s 
at
 th
e 
tim
e 
of
 th
e 
su
rv
ey
 th
is
 a
ss
oc
ia
tio
n 
w
as
 m
os
t r
ob
us
t,
 
in
di
ca
tin
g 
th
at
 re
ca
ll 
bi
as
 m
ay
 e
xp
la
in
 to
 
so
m
e 
ex
te
nt
 th
e 
po
or
 re
al
 li
fe
 e
ff
ec
ti
ve
ne
ss
 
re
po
rt
ed
 in
 th
e 
lit
er
at
ur
e.
 
Th
e 
ev
id
en
ce
 o
f r
ea
l l
ife
 e
ff
ec
ti
ve
ne
ss
 w
as
 
no
t f
ou
nd
 fo
r o
ra
l N
RT
 p
ro
du
ct
s.
 
A
s 
th
e 
in
ve
st
ig
at
or
s 
tig
ht
en
ed
 th
e 
co
nt
ro
l o
ve
r r
ec
al
l b
ia
s,
 th
e 
be
ne
fic
ia
l 
eff
ec
ts
 o
f m
ed
ic
at
io
n 
us
e 
in
cr
ea
se
d.
 
St
re
ng
th
s 
of
 th
is
 s
tu
dy
 w
er
e 
br
oa
d 
re
pr
es
en
ta
tiv
e 
sa
m
pl
e,
 la
rg
e 
sa
m
pl
e 
si
ze
, b
al
an
ce
 o
f r
ec
al
l b
ia
s,
 c
oh
or
t 
de
si
gn
, r
ep
ea
te
d 
lo
ng
itu
di
na
l 
an
al
ys
is
 a
nd
 a
dj
us
tm
en
t o
f p
ot
en
tia
l 
co
nf
ou
nd
er
s.
 
YE
S
A
lp
er
t e
t a
l. 
20
12
:
O
bj
ec
t:
 T
o 
ex
am
in
e 
th
e 
po
pu
la
ti
on
 
eff
ec
ti
ve
ne
ss
 o
f N
R
T,
  w
it
h 
or
 
w
ith
ou
t p
ro
fe
ss
io
na
l c
ou
ns
el
lin
g
Th
e 
U
S,
 M
as
sa
ch
us
et
ts
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
 w
ith
 a
 
pr
ob
ab
ili
ty
 s
am
pl
e 
w
as
 c
on
du
ct
ed
 b
y 
re
-in
te
rv
ie
w
in
g 
th
e 
re
sp
on
de
nt
s 
in
 th
re
e 
w
av
es
.  
 B
et
w
ee
n 
Ja
nu
ar
y 
20
01
 a
nd
 Ju
ne
 2
00
2 
pr
of
es
si
on
al
 te
le
ph
on
e 
in
te
rv
ie
w
er
s 
at
 th
e 
Ce
nt
er
 fo
r S
ur
ve
y 
Re
se
ar
ch
, 
U
ni
ve
rs
it
y 
of
 M
as
sa
ch
us
et
ts
 B
os
to
n 
ob
ta
in
ed
 a
 p
ro
ba
bi
lit
y 
sa
m
pl
e 
of
 
67
39
 M
as
sa
ch
us
et
ts
 a
du
lts
 w
ith
 o
ve
r-
sa
m
pl
in
g 
of
 a
du
lt 
sm
ok
er
s 
an
d 
re
ce
nt
 
qu
it
te
rs
 (d
ur
in
g 
pa
st
 2
 y
ea
rs
).
 A
t fi
rs
t 
w
av
e 
fin
al
ly
 e
lig
ib
le
 re
sp
on
se
s 
w
er
e 
re
ce
iv
ed
 fr
om
 4
6%
 (n
= 
49
91
) o
f t
he
 
or
ig
in
al
 s
am
pl
e.
 
B
et
w
ee
n 
Ja
n 
20
03
 a
nd
 Ju
ly
 2
00
4 
al
to
ge
th
er
 2
80
5 
pa
rt
ic
ip
an
ts
 w
er
e 
re
-
in
te
rv
ie
w
ed
 a
nd
 b
et
w
ee
n 
Ja
n 
20
05
 a
nd
 
Ju
ly
 2
00
6 
al
to
ge
th
er
 1
91
6 
pa
rt
ic
ip
an
ts
 
w
er
e 
re
-in
te
rv
ie
w
ed
. 
Th
e 
an
al
yt
ic
 s
am
pl
e 
fin
al
ly
 c
on
si
st
ed
 
of
 7
87
 a
du
lt 
sm
ok
er
s,
 w
ho
 h
ad
 q
ui
tt
ed
 
du
ri
ng
 la
st
 2
 y
ea
rs
 p
ri
or
 th
e 
fir
st
 w
av
e.
 
O
f t
he
se
 4
80
 c
om
pl
et
ed
 th
e 
se
co
nd
 
w
av
e 
an
d 
of
 th
es
e 
tw
o 
th
ir
ds
 (n
=2
48
) 
co
m
pl
et
ed
 th
e 
th
ird
 w
av
e.
 
A
m
on
g 
th
e 
pa
rt
ic
ip
an
t A
 to
ta
l o
f 3
64
 
co
m
pl
et
in
g 
th
e 
se
co
nd
 w
av
e 
ha
d 
co
m
pl
et
el
y 
qu
itt
ed
, b
ut
 a
lm
os
t o
ne
 
th
ird
 h
ad
 re
la
ps
ed
 b
y 
th
e 
tim
e 
of
 th
e 
se
co
nd
 w
av
e 
an
d 
a 
th
ird
 o
f t
ho
se
 
co
m
pl
et
in
g 
th
e 
th
ird
 w
av
e 
in
te
rv
ie
w
 
ha
d 
re
la
ps
ed
.  
 
Se
lf-
re
po
rt
ed
 a
nd
 re
ca
lle
d 
ab
st
in
en
ce
A
bo
ut
 o
ne
 in
 fi
ve
 o
f t
he
 p
ar
ti
ci
pa
nt
s 
at
 w
av
es
 
1&
2 
ha
d 
us
ed
 N
RT
. 
Th
ou
gh
 o
nl
y 
7.
5%
 h
ad
 u
se
d 
it
 fo
r m
or
e 
th
an
 
6w
ee
ks
 a
t w
av
e 
1 
an
d 
13
.3
%
 a
t w
av
e 
2.
Th
e 
od
ds
 fo
r s
m
ok
in
g 
re
la
ps
e 
w
as
 h
ig
he
st
 
(O
R 
2.
68
) f
or
 h
ig
h-
de
pe
nd
en
t s
m
ok
er
s,
 w
ho
 
re
po
rt
ed
 u
se
 o
f N
RT
 fo
r a
ny
 le
ng
th
 w
ith
ou
t 
pr
of
es
si
on
al
 a
dv
ic
e.
Th
e 
od
ds
 fo
r r
el
ap
se
 w
er
e 
lo
w
es
t a
m
on
g 
pe
rs
on
s 
w
ho
 re
po
rt
ed
 a
bs
ti
ne
nc
e 
> 
6 
m
on
th
s
 
Th
e 
au
th
or
s 
di
sc
us
se
d 
 s
el
ec
tio
n 
cr
ite
ria
 
in
 tr
ia
ls
 a
nd
 th
e 
ge
ne
ra
liz
ab
ili
ty
 o
f t
he
 
fin
di
ng
s 
fr
om
 tr
ia
ls
 to
 re
al
-l
ife
. 
Th
e 
au
th
or
s 
al
so
 c
on
cl
ud
ed
 th
at
 th
os
e 
he
av
ily
 d
ep
en
de
nt
 s
m
ok
er
s 
us
in
g 
N
RT
 
w
ith
ou
t s
up
po
rt
 m
ay
 h
av
e 
un
re
al
is
tic
 
ex
pe
ct
at
io
ns
 fo
r t
he
 th
er
ap
y 
an
d 
th
us
 
th
ey
 re
la
ps
e.
 
Th
e 
au
th
or
s 
di
sc
us
se
d 
th
e 
lo
ss
 to
 
fo
llo
w
-u
p 
du
rin
g 
th
e 
fo
ur
 y
ea
rs
 fo
llo
w
-
up
 p
er
io
d 
to
 b
e 
th
e 
m
os
t i
m
po
rt
an
t 
po
ss
ib
ili
ty
 o
f b
ia
s 
To
 n
ot
e!
 T
hi
s 
st
ud
y 
an
d 
es
pe
ci
al
ly
 
co
nc
lu
si
on
 m
ad
e 
ha
s 
be
en
 d
eb
at
ed
 
am
on
g 
th
e 
sc
ie
nt
ifi
c 
co
m
m
un
it
y.
 
N
O
R
ef
er
en
ce
, o
bj
ec
ti
ve
 a
nd
 
se
tt
in
g
St
ud
y 
de
si
gn
/ k
ey
 c
ha
ra
ct
er
is
ti
cs
Pa
rt
ic
ip
an
ts
 /
H
ow
 a
bs
ti
ne
nc
e 
 is
 d
efi
ne
d
Ke
y 
Fi
nd
in
gs
 re
la
te
d 
to
 th
e 
eff
ec
ti
ve
ne
ss
 o
f O
T
C
 N
R
T
 
To
 n
ot
ic
e 
(k
ey
 p
oi
nt
s 
in
 d
is
cu
ss
io
n,
 
lim
it
at
io
ns
 a
nd
 s
tr
en
gt
hs
 o
f t
he
 
st
ud
y)
Su
pp
or
ts
 th
e 
eff
ec
ti
ve
ne
ss
 
of
 O
TC
 N
R
T?
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
di
es
 
B
al
m
fo
rd
 e
t a
l. 
20
11
:
Th
e 
an
nu
al
 In
te
rn
at
io
na
l T
ob
ac
co
 
Co
nt
ro
l F
ou
r C
ou
nt
ry
 c
oh
or
t s
ur
ve
y
Fo
ur
 C
ou
nt
rie
s
Th
e 
U
K
, U
S,
 C
an
ad
a 
an
d 
A
us
tr
al
ia
Th
e 
fo
ur
 c
ou
nt
ry
 c
oh
or
t s
ur
ve
y 
w
as
 
co
nd
uc
te
d 
in
 O
ct
ob
er
 2
00
6-
 F
eb
ru
ar
y 
20
07
 a
nd
 S
ep
te
m
be
r 2
00
7 
–F
eb
ru
ar
y 
20
08
. i
nc
lu
di
ng
 a
lto
ge
th
er
 in
fo
rm
at
io
n 
on
 1
 2
19
 s
m
ok
er
s
Th
e 
su
rv
ey
 in
cl
ud
ed
 o
nl
y 
cu
rr
en
t,
 
ad
ul
t s
m
ok
er
s.
 
Th
e 
da
ta
 o
f s
m
ok
er
s 
w
as
 c
ol
le
ct
ed
 
on
ly
 fr
om
 o
ne
 w
av
e,
 e
it
he
r 5
 o
r 6
 
in
 re
la
tio
n 
to
 th
ei
r m
ed
ic
at
io
n 
us
e 
du
rin
g 
la
st
 y
ea
r. 
O
nl
y 
in
fo
rm
at
io
n 
on
 th
e 
us
e 
of
 
on
e 
m
ed
ic
at
io
n,
 e
ith
er
 N
RT
 o
r R
x 
m
ed
ic
at
io
n 
w
as
 in
cl
ud
ed
 in
to
 th
e 
fin
al
 
sa
m
pl
e.
 
A
bs
ti
ne
nc
e:
6 
m
on
th
s 
ab
st
in
en
ce
, s
el
f r
ep
or
te
d
A
 m
aj
or
ity
 (n
=9
81
) h
ad
 u
se
d 
N
RT
, e
ith
er
 
O
TC
 (n
=6
70
) o
r b
y 
R
x 
(n
=3
11
).
 In
 th
e 
U
K
 th
e 
m
aj
or
ity
 o
bt
ai
ne
d 
N
RT
 b
y 
Rx
. 
A
 th
ir
d 
(3
0.
9%
, n
=3
45
) u
se
d 
m
ed
ic
at
io
n 
at
 
le
as
t f
or
 8
 w
ee
ks
 a
nd
 6
3.
4%
 (n
=7
73
) s
to
pp
ed
 
th
e 
us
e 
pr
em
at
ur
el
y.
 1
01
 p
er
so
ns
 (5
.7
%
) 
co
nt
in
ue
d 
th
e 
us
e 
be
yo
nd
 8
 w
ee
ks
. 
23
%
 o
f t
ho
se
 w
ho
 p
ur
ch
as
ed
 O
TC
 N
R
T 
ha
d 
di
sc
on
ti
nu
ed
 u
se
 in
 th
e 
fir
st
 w
ee
k.
 A
 m
in
or
it
y,
 
5.
5%
 u
se
d 
th
e 
m
ed
ic
at
io
n 
be
yo
nd
 6
 m
on
th
s.
A
m
on
g 
O
TC
 N
RT
 p
ur
ch
as
er
s 
th
er
e 
w
er
e 
si
gn
ifi
ca
nt
ly
 m
or
e 
pr
em
at
ur
e 
di
sc
on
tin
ua
tio
ns
 a
nd
 e
ar
ly
 re
la
ps
es
 th
an
 
am
on
g 
th
os
e 
w
ho
 p
ur
ch
as
ed
 N
RT
 b
y 
pr
es
cr
ip
tio
n.
Th
er
e 
w
er
e 
no
 d
iff
er
en
ce
s 
ac
hi
ev
in
g 
6 
m
on
th
s 
ab
st
in
en
ce
 b
et
w
ee
n 
O
TC
 a
nd
 
pr
es
cr
ip
tio
n 
N
RT
 u
se
rs
. 
O
f t
he
 1
02
0 
in
cl
ud
ed
 s
m
ok
er
s,
 5
48
 p
er
so
ns
 
SC
 o
ut
co
m
es
 w
er
e 
ab
le
 to
 b
e 
de
te
ct
ed
 a
ft
er
 6
 
m
on
th
s.
 O
f t
he
se
 2
2.
6%
 a
ch
ie
ve
d 
si
x 
m
on
th
s 
ab
st
in
en
ce
. T
hi
s 
w
as
 m
or
e 
co
m
m
on
 a
m
on
g 
pr
es
cr
ip
tio
n 
m
ed
ic
at
io
n 
th
an
 N
RT
 u
se
rs
.
Th
e 
au
th
or
s 
di
sc
us
s 
th
at
 o
nl
y 
a 
qu
ar
te
r 
of
 S
C 
m
ed
ic
at
io
n 
us
er
s 
ar
e 
lik
el
y 
to
 
co
m
pl
et
e 
th
e 
re
co
m
m
en
de
d 
8 
w
ee
ks
 
tr
ea
tm
en
t c
ou
rs
e.
M
ai
n 
re
as
on
 w
as
 re
la
ps
e 
ba
ck
 s
m
ok
in
g.
 
Th
is
 w
as
 e
sp
ec
ia
lly
 in
 th
e 
ca
se
 o
f 
N
RT
 u
se
rs
 a
nd
 th
os
e 
w
ith
 h
ig
he
r 
de
pe
nd
en
ce
.
Li
ke
lih
oo
d 
of
 s
uc
ce
ss
 w
as
 in
cr
ea
se
d 
by
 
du
ra
tio
n 
of
 th
e 
m
ed
ic
at
io
n 
us
e.
 T
ho
ug
h,
 
th
os
e 
w
ho
 d
is
co
nt
in
ue
d 
th
e 
tr
ea
tm
en
t 
be
ca
us
e 
th
ey
 d
id
 n
ot
 n
ee
d 
it 
an
y 
lo
ng
er
 
a 
si
gn
ifi
ca
nt
 p
ro
po
rt
io
n 
w
as
 a
bs
ti
ne
nt
 in
 
si
x 
m
on
th
s 
fo
llo
w
-u
p.
 O
ve
r t
w
o 
th
ird
s 
of
 th
os
e 
w
ho
 b
el
ie
ve
d 
th
e 
m
ed
ic
at
io
n 
ha
d 
w
or
ke
d 
an
d 
th
us
 
di
sc
on
tin
ue
d 
w
er
e 
ab
st
in
en
t i
n 
si
x 
m
on
th
s 
fo
llo
w
-u
p.
YE
S
W
es
t a
nd
 Z
ho
u 
20
07
:
To
 a
dd
re
ss
 is
 N
R
T 
eff
ec
ti
ve
 in
 re
al
 
lif
e?
M
ul
tin
at
io
na
l s
tu
dy
, g
at
he
rin
g 
da
ta
 fr
om
 th
e 
U
S,
 U
K
, C
an
ad
a 
an
d 
Fr
an
ce
. I
n 
al
l t
he
 c
ou
nt
rie
s 
 N
RT
 w
as
 
so
ld
 O
TC
 b
y 
th
e 
tim
e 
of
 th
e 
st
ud
y.
 
Pr
os
pe
ct
iv
e,
 lo
ng
itu
di
na
l c
oh
or
t s
tu
dy
Ph
as
e 
I s
ur
ve
y 
w
as
 c
on
du
ct
ed
 in
 s
pr
in
g 
20
03
 in
 th
e 
fo
ur
 c
ou
nt
rie
s 
w
ith
 a
 s
am
pl
e 
of
 2
00
9 
sm
ok
er
s.
 T
he
y 
w
er
e 
fo
llo
w
ed
 
ev
er
y 
th
re
e 
m
on
th
s.
 
P
ha
se
 2
 in
vo
lv
ed
 3
64
5 
sm
ok
er
s 
fr
om
 th
e 
fo
ur
 c
ou
nt
rie
s 
an
d 
Sp
ai
n.
 
In
te
rn
et
 u
se
rs
 b
et
w
ee
n 
35
-6
5 
ye
ar
s,
 
sm
ok
in
g 
>5
 c
ig
ar
et
te
s 
a 
da
y.
O
nl
y 
pa
rt
ic
ip
an
ts
 w
ith
 a
 q
ui
t a
tt
em
pt
, 
w
er
e 
us
ed
 in
 th
e 
an
al
ys
is
 (p
ha
se
 1
, n
= 
15
78
; p
ha
se
 2
, n
= 
98
3)
.
 Se
lf-
re
po
rt
ed
 a
bs
tin
en
ce
, a
ss
es
se
d 
at
 
3 
m
on
th
s 
an
d 
6 
m
on
th
s 
pe
rio
ds
. O
nl
y 
co
nt
in
ue
s 
ab
st
in
en
ce
 th
ro
ug
ho
ut
 th
e 
w
ho
le
 3
 m
on
th
s 
in
 b
ot
h 
fo
llo
w
-u
p 
pe
rio
ds
 w
as
 a
cc
ep
te
d.
Pa
rt
ic
ip
an
ts
 w
er
e 
as
ke
d 
to
 li
st
 
m
et
ho
ds
 th
ey
 u
se
d 
in
 th
ei
r q
ui
tt
in
g 
at
te
m
pt
  T
ho
se
, w
ho
 h
ad
 re
ce
iv
ed
 
be
ha
vi
or
al
 s
up
po
rt
 o
r u
se
d 
bu
pr
op
io
n,
 
w
er
e 
ex
cl
ud
ed
 fr
om
 th
e 
an
al
ys
is
.  
  
A
 to
ta
l o
f 3
57
 p
ar
ti
ci
pa
nt
s 
fr
om
 p
ha
se
 1
 
an
d 
73
2 
fr
om
 p
ha
se
 2
 w
er
e 
fo
llo
w
ed
 th
e 
si
x 
m
on
th
s 
pe
rio
d.
O
f t
he
se
 p
ar
tic
ip
an
ts
 1
27
 fr
om
 p
ha
se
 1
 u
se
d 
N
RT
 a
nd
 2
30
 d
id
 n
ot
. 2
17
 fr
om
 p
ha
se
 2
 u
se
d 
N
R
T 
an
d 
51
5 
di
d 
no
t.
 
A
cc
or
di
ng
 to
 lo
gi
st
ic
 re
gr
es
si
on
 a
na
ly
si
s 
co
nd
uc
te
d 
N
RT
 u
se
 w
as
 a
ss
oc
ia
te
d 
w
ith
 
si
gn
ifi
ca
nt
 li
ke
lih
oo
d 
of
 a
ch
ie
vi
ng
 s
ix
 m
on
th
s 
ab
st
in
en
ce
 c
om
pa
re
d 
to
 n
on
-u
se
. 
A
m
on
g 
Ph
as
e 
1 
pa
rt
ic
ip
an
ts
 O
R 
w
as
 3
.0
 (C
l 
95
%
 1
.2
-7
.5
),
 a
m
on
g 
ph
as
e 
2 
pa
rt
ic
ip
an
ts
 O
R
 
w
ad
  2
.1
 (C
l 9
5%
 1
.0
-4
.1
) a
nd
 c
om
bi
ne
d 
O
R
 
w
as
 2
.2
 ( 
C
l 9
5%
 1
.3
-3
.9
).
 T
he
 re
su
lt
s 
w
er
e 
co
nt
ro
lle
d 
fo
r n
ic
ot
in
e 
de
pe
nd
en
ce
.
Th
e 
fin
di
ng
 s
up
po
rt
in
g 
O
TC
-N
R
T 
eff
ec
ti
ve
ne
ss
 w
as
 re
pl
ic
at
ed
 in
 th
e 
bo
th
 
se
pa
ra
te
 c
oh
or
t s
am
pl
es
 a
nd
 s
tu
dy
 
pa
rt
ic
ip
an
ts
 w
er
e 
fr
eq
ue
nt
ly
 fo
llo
w
ed
. 
Lo
ss
 to
 fo
llo
w
-u
p 
w
as
 c
on
si
de
re
d 
pr
ob
le
m
at
ic
 a
nd
 th
e 
sa
m
pl
es
 w
er
e 
re
cr
ui
te
d 
fr
om
 th
e 
in
te
rn
et
 a
nd
 th
e 
sa
m
pl
e 
co
ns
is
te
d 
of
 p
er
so
ns
 in
te
nd
in
g 
to
 q
ui
t d
ur
in
g 
th
e 
fo
llo
w
in
g 
th
re
e 
m
on
th
s 
of
 th
ei
r e
nr
ol
m
en
t.
 
Y
E
S
R
ef
er
en
ce
, o
bj
ec
ti
ve
 a
nd
 
se
tt
in
g
St
ud
y 
de
si
gn
/ k
ey
 c
ha
ra
ct
er
is
ti
cs
Pa
rt
ic
ip
an
ts
 /
H
ow
 a
bs
ti
ne
nc
e 
 is
 d
efi
ne
d
Ke
y 
Fi
nd
in
gs
 re
la
te
d 
to
 th
e 
eff
ec
ti
ve
ne
ss
 o
f O
T
C
 N
R
T
 
To
 n
ot
ic
e 
(k
ey
 p
oi
nt
s 
in
 d
is
cu
ss
io
n,
 
lim
it
at
io
ns
 a
nd
 s
tr
en
gt
hs
 o
f t
he
 
st
ud
y)
Su
pp
or
ts
 th
e 
eff
ec
ti
ve
ne
ss
 
of
 O
TC
 N
R
T?
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
di
es
 
H
yl
an
d 
et
 a
l. 
20
05
a:
 
N
at
io
na
l C
an
ce
r I
ns
tit
ut
e’
s 
ev
al
ua
tio
n 
of
 th
e 
Co
m
m
un
ity
 
In
te
rv
en
tio
n 
Tr
ia
l f
or
 S
C 
(C
O
M
M
IT
).
Th
e 
U
S
Ra
nd
om
iz
ed
 c
om
m
un
ity
-b
as
ed
 
ce
ss
at
io
n 
st
ud
y.
 T
he
 o
rig
in
al
 c
oh
or
t 
w
as
 id
en
ti
fie
d 
by
 a
 ra
nd
om
-d
ig
it-
di
al
ed
 
te
le
ph
on
e 
su
rv
ey
 in
 1
98
8 
an
d 
th
is
 
or
ig
in
al
 s
am
pl
e 
of
 s
m
ok
er
s 
ha
s 
be
en
 
fo
llo
w
ed
 a
nn
ua
lly
.
 (lo
ss
 o
f f
ol
lo
w
-u
p 
ea
ch
 y
ea
r 8
%
).
 
.
In
 1
99
3 
al
to
ge
th
er
 1
2 
43
5 
sm
ok
er
s 
w
er
e 
in
te
rv
ie
w
ed
 a
nd
 5
77
8 
(3
5%
) w
er
e 
co
m
pl
et
el
y 
re
-in
te
rv
ie
w
ed
 in
 2
00
1.
 O
f 
th
es
e 
16
39
 w
er
e 
N
RT
 u
se
rs
.
Th
er
e 
w
er
e 
51
9 
pr
e-
O
TC
 N
R
T 
us
er
s 
an
d 
87
8 
po
st
-O
TC
 u
se
rs
 in
 
th
e 
an
al
ys
is
. T
he
re
 w
er
e 
no
 g
re
at
 
di
ff
er
en
ce
s 
be
tw
ee
n 
th
e 
so
ci
o-
ec
on
om
ic
 o
r s
m
ok
in
g 
ch
ar
ac
te
ris
tic
s 
of
 th
es
e 
gr
ou
ps
 w
ith
 th
e 
ex
ce
pt
io
n 
of
 
de
si
re
 to
 q
ui
t.
Se
lf-
re
po
rt
ed
 a
bs
tin
en
ce
 fo
llo
w
in
g 
ea
ch
 N
RT
 a
ss
is
te
d 
qu
it 
at
te
m
pt
 o
r 
lo
ng
-t
er
m
 c
es
sa
tio
n 
am
on
g 
N
RT
 
us
er
s.
 S
ix
 m
on
th
s 
ab
st
in
en
ce
. 
U
se
 o
f N
R
T 
pa
tc
h 
de
cr
ea
se
d 
fr
om
 2
2.
5%
 in
 
th
e 
pr
e-
O
TC
 p
er
io
d 
to
 1
8.
5%
 in
 th
e 
po
st
-O
TC
 
pe
rio
d.
 A
ft
er
 O
TC
 s
w
itc
h 
th
e 
du
ra
tio
n 
of
 
pa
tc
h 
us
e 
de
cr
ea
se
d.
 
Q
ui
t r
at
es
 o
f g
um
 u
se
rs
 in
cr
ea
se
d 
fr
om
 9
.7
%
 
to
 1
4.
6%
 in
 th
e 
po
st
- O
TC
 p
er
io
d.
 T
he
re
 w
er
e 
no
 d
iff
er
en
ce
s 
be
tw
ee
n 
pa
tc
h 
us
er
s 
in
 th
es
e 
pe
rio
ds
. 
N
RT
 g
um
 a
ss
is
te
d 
or
 a
ny
 N
RT
 a
ss
is
te
d 
qu
it 
at
te
m
pt
s 
w
er
e 
no
t s
ta
ti
st
ic
al
ly
 d
iff
er
en
t 
be
tw
ee
n 
pr
e-
 a
nd
 p
os
t-
 O
TC
 p
er
io
d.
Pe
rs
on
s 
w
ith
 le
ss
 d
es
ire
 to
 q
ui
t w
er
e 
m
or
e 
lik
el
y 
to
 u
se
 N
RT
 in
 th
e 
O
TC
 p
er
io
d,
 
su
gg
es
tin
g 
O
TC
 N
RT
 to
 in
cr
ea
se
 q
ui
t 
at
te
m
pt
s.
O
nl
y 
fe
w
 s
m
ok
er
s 
us
ed
 N
RT
 in
 a
ny
 q
ui
t 
at
te
m
pt
.
A
dv
an
ta
ge
s 
of
 th
is
 s
tu
dy
 w
er
e 
la
rg
e 
sa
m
pl
e 
si
ze
, d
ur
at
io
n 
of
 N
RT
 u
se
 
as
se
ss
ed
 a
nd
 g
eo
gr
ap
hi
c 
di
ve
rs
ity
. 
K
ey
 li
m
it
at
io
n:
 th
e 
su
bj
ec
ts
’ r
ec
al
l o
f 
de
ta
ils
 d
ur
in
g 
8 
ye
ar
s 
pe
rio
d 
ca
n 
be
 a
 
so
ur
ce
 o
f b
ia
s.
 
It 
w
as
 d
is
cu
ss
ed
 th
at
 in
 a
dd
iti
on
 to
 
be
tt
er
 N
RT
 u
til
iz
at
io
n 
al
so
 b
et
te
r 
aw
ar
en
es
s 
of
 h
ar
m
s 
re
la
te
d 
to
 s
m
ok
in
g,
 
ne
w
 c
le
an
 in
do
or
 p
ol
ic
ie
s,
 in
cr
ea
se
d 
N
RT
 m
ar
ke
tin
g,
 , 
hi
gh
er
 c
ig
ar
et
te
 p
ric
es
 
m
ay
 a
ls
o 
ha
ve
 in
flu
en
ce
d 
on
 N
R
T 
us
e 
an
d 
SC
.
YE
S
Th
e 
re
su
lts
 
sh
ow
 in
cr
ea
se
 
in
 u
til
iz
at
io
n 
w
ith
ou
t a
 
si
gn
ifi
ca
nt
 d
ro
p 
in
 e
ffi
ca
cy
 in
 
th
e 
po
st
-O
TC
 
pe
rio
d.
 
Po
pu
la
ti
on
-b
as
ed
 c
ro
ss
-s
ec
ti
on
al
 s
ur
ve
ys
G
ilp
in
 e
t a
l. 
20
06
:
Ca
lif
or
ni
a 
To
ba
cc
o 
Su
rv
ey
s 
To
 a
ss
es
s 
ab
st
in
en
ce
 fo
llo
w
in
g 
th
e 
m
os
t r
ec
en
t q
ui
t a
tt
em
pt
 in
 th
e 
pa
st
 y
ea
r.
Th
e 
U
S,
 C
al
ifo
rn
ia
Po
pu
la
tio
n-
ba
se
d 
cr
os
s-
se
ct
io
na
l, 
su
rv
ey
s 
in
 1
99
9 
(n
=1
4 
72
9 
/ 2
1 
65
7,
 
68
.4
%
 c
om
pl
et
ed
) a
nd
 in
 2
00
2 
(2
0 
52
5/
 
32
 6
54
 6
2.
8%
 c
om
pl
et
ed
).
 T
he
 s
ur
ve
ys
 
w
er
e 
co
m
bi
ne
d 
to
 p
ro
vi
de
 a
de
qu
at
e 
st
at
is
tic
al
 p
ow
er
 to
 in
ve
st
ig
at
e 
fa
ct
or
s 
su
pp
or
tin
g 
in
cr
ea
se
 in
 a
bs
tin
en
ce
 
du
ra
tio
n.
 
P
ar
ti
ci
pa
nt
s:
 m
od
er
at
e 
to
 h
ea
vy
 
de
pe
nd
en
t,
 a
du
lt 
sm
ok
er
s,
 
co
ns
um
in
g 
at
 le
as
t 1
5 
ci
ga
re
tt
es
 a
 d
ay
 
pr
io
r t
o 
th
e 
su
rv
ey
. 
In
 1
99
9 
th
er
e 
w
er
e 
33
67
 a
nd
 in
 2
00
2 
al
to
ge
th
er
 3
09
6 
re
ce
nt
 q
ui
tt
er
s.
Pa
rt
ic
ip
an
ts
 w
er
e 
ra
nd
om
ly
 s
el
ec
te
d 
fo
r a
n 
ex
te
rn
al
 in
te
rv
ie
w
. 
A
bs
ti
ne
nc
e:
 S
el
f-
re
po
rt
ed
U
se
 o
f N
R
T 
or
 b
up
ro
pi
on
 w
as
 m
or
e 
co
m
m
on
 
am
on
g 
m
od
er
at
e 
to
 h
ea
vy
 s
m
ok
er
s 
th
an
 
am
on
g 
lig
ht
 n
on
-d
ai
ly
 s
m
ok
er
s.
 Th
er
e 
ap
pe
ar
ed
 to
 b
e 
a 
sl
ig
ht
 s
ho
rt
-t
er
m
 
be
ne
fit
 fr
om
 p
ha
rm
ac
eu
ti
ca
l a
id
 u
se
, w
hi
ch
 
di
sa
pp
ea
re
d 
ra
pi
dl
y 
ov
er
 ti
m
e 
fr
om
 th
e 
ce
ss
at
io
n,
 w
he
n 
fo
llo
w
ed
 fo
r u
p 
to
 1
80
 d
ay
s.
Th
e 
au
th
or
s 
co
nc
lu
de
d 
th
at
 a
ft
er
 
th
e 
N
RT
 d
er
eg
ul
at
io
n 
th
e 
m
es
sa
ge
s 
re
ga
rd
in
g 
ce
ss
at
io
n 
ha
d 
ch
an
ge
d 
an
d 
le
d 
to
 le
ss
 m
ot
iv
at
ed
 a
nd
 le
ss
 p
re
pa
re
d 
sm
ok
er
s 
to
 m
ak
e 
a 
qu
it 
at
te
m
pt
.
N
O
P
ie
rc
e 
an
d 
G
ilp
in
 2
00
2:
To
 re
po
rt
 p
op
ul
at
io
n 
tr
en
ds
 a
nd
 
eff
ec
ti
ve
ne
ss
 o
f N
R
T 
us
e 
by
 re
ce
nt
 
sm
ok
er
s 
un
de
rg
oi
ng
  S
C 
in
 
fr
om
 1
99
2 
to
 1
99
9.
Th
e 
U
S,
 C
al
ifo
rn
ia
Th
e 
la
rg
e 
po
pu
la
tio
n-
ba
se
d 
Ca
lif
or
ni
a 
To
ba
cc
o 
Su
rv
ey
s,
 C
TS
 c
on
du
ct
ed
 in
 
19
92
, 1
99
6,
 a
nd
 1
99
9.
A
 ra
nd
om
- d
ig
it-
di
al
ed
 te
le
ph
on
e 
in
te
rv
ie
w
 m
et
ho
d 
w
as
 u
se
d.
 C
om
pl
et
ed
in
te
rv
ie
w
s 
w
er
e 
re
ce
iv
ed
 fr
om
 7
1.
3%
 o
f 
ad
ul
ts
 (n
=5
24
7)
 in
 1
99
2;
 7
2.
9%
  (
n=
97
25
) 
in
  1
99
6 
an
d 
68
.4
%
 (n
=6
41
2)
 in
 1
99
9 
. 
CT
S 
ar
e 
w
ei
gh
te
d 
to
 m
ak
e 
th
e 
da
ta
 
re
pr
es
en
ta
tiv
e 
of
 th
e 
Ca
lif
or
ni
a 
po
pu
la
tio
n 
an
d 
to
 a
cc
ou
nt
 fo
r t
he
ov
er
sa
m
pl
in
g 
of
 s
m
ok
er
s.
Po
pu
la
ti
on
: R
ec
en
t f
or
m
er
 s
m
ok
er
s 
(1
2 
m
on
th
s 
ag
o 
bu
t n
ot
 c
ur
re
nt
ly
) 
un
de
rg
oi
ng
 S
C 
A
bs
ti
ne
nc
e 
m
ea
su
re
:
Se
lf-
re
po
rt
ed
 re
ca
ll 
of
 c
es
sa
tio
n.
 
Th
e 
du
ra
tio
n 
of
 o
nl
y 
sm
ok
er
s’
 m
os
t 
re
ce
nt
 in
te
nt
io
na
l c
es
sa
tio
n 
at
te
m
pt
 
in
 th
e 
pa
st
 y
ea
r l
as
tin
g 
a 
da
y 
or
 lo
ng
er
 
(t
he
 a
cc
ep
te
d 
de
fin
it
io
n 
of
 a
 s
er
io
us
 
ce
ss
at
io
n 
at
te
m
pt
). 
U
se
 o
f p
ha
rm
ac
eu
ti
ca
l a
id
s 
(m
os
tl
y 
O
TC
 s
in
ce
 1
99
6)
, a
nd
 c
es
sa
tio
n 
su
cc
es
s 
w
er
e 
al
so
 a
ss
es
se
d.
B
et
w
ee
n 
19
92
 a
nd
 1
99
9,
 S
C
 a
tt
em
pt
s 
am
on
g 
C
al
ifo
rn
ia
 s
m
ok
er
s 
in
cr
ea
se
d 
61
.4
%
 (f
ro
m
 
38
.1
%
 to
 6
1.
5%
).
  
N
RT
 u
se
 in
 th
e 
m
os
t r
ec
en
t S
C 
at
te
m
pt
 
in
cr
ea
se
d 
si
gn
ifi
ca
nt
ly
 (5
0.
5%
) f
ro
m
 9
.3
%
 in
 
19
92
 to
 1
2.
7%
 in
 1
99
6,
 a
nd
 to
 1
4.
0%
 in
 1
99
9.
A
n 
es
tim
at
ed
 3
.6
 -f
ol
d 
gr
ow
th
 in
 N
RT
 u
se
 
to
ok
 p
la
ce
 b
et
w
ee
n 
19
92
 -1
99
9.
  
Th
er
e 
w
as
 a
n 
85
%
 in
cr
ea
se
 in
 th
e 
pr
op
or
ti
on
 
of
 q
ui
tt
er
s 
us
in
g 
ph
ar
m
ac
eu
tic
al
 a
id
 fr
om
 
19
92
 to
 1
99
9 
am
on
g 
th
e 
Ca
lif
or
ni
a 
qu
itt
er
s 
fo
r t
he
ir 
m
os
t r
ec
en
t S
C 
at
te
m
pt
. 
In
 1
99
6 
an
d 
19
99
, t
he
 m
ed
ia
n 
du
ra
tio
n 
of
 a
id
 
us
e 
w
as
 o
nl
y 
14
 d
ay
s.
To
 a
ss
es
s 
qu
itt
in
g 
su
cc
es
s 
an
d 
us
e 
of
 N
RT
 th
e 
st
ud
y 
ut
ili
ze
d 
re
gr
es
si
on
 m
od
el
. A
cc
or
di
ng
 to
 
its
 re
su
lts
 in
 c
on
tr
as
t w
ith
 1
99
2 
an
d 
19
96
, t
he
 
be
ne
fic
ia
l e
ff
ec
t o
f N
R
T 
us
e 
fo
r S
C
 in
 1
99
9 
w
as
 o
nl
y 
sh
or
t-
te
rm
; a
ft
er
 a
bo
ut
 3
 m
on
th
s 
th
e 
su
cc
es
s 
fo
r N
RT
 u
se
rs
 a
nd
 n
on
-N
RT
 u
se
rs
 
th
e 
ra
te
s 
w
er
e 
si
m
ila
r. 
Th
e 
su
rv
ey
 a
ss
es
se
d 
lo
ca
l S
C 
pr
ac
tis
es
, 
w
hi
ch
 c
an
 a
ls
o 
be
 in
flu
en
ce
d 
by
 o
th
er
 
so
ci
al
, e
nv
iro
nm
en
ta
l o
r p
ol
iti
ca
l 
te
nd
en
ci
es
. 
D
iff
er
en
ce
s 
in
 p
ar
ti
ci
pa
nt
 s
el
ec
ti
on
 
cr
it
er
ia
 c
an
 e
xp
la
in
 w
hy
 d
iff
er
en
t s
ur
ve
y 
st
ud
ie
s 
ha
ve
 d
iff
er
en
t fi
nd
in
gs
.
Th
e 
ce
ss
at
io
n 
an
d 
ab
st
in
en
ce
 
ob
se
rv
at
io
ns
 a
re
 b
as
ed
 o
n 
se
lf-
re
po
rt
ed
 
re
ca
ll 
of
 c
es
sa
tio
n 
ev
en
ts
 fr
om
 a
 c
ro
ss
-
se
ct
io
na
l s
ur
ve
y 
no
t f
ro
m
 a
 lo
ng
itu
di
na
l 
fo
llo
w
-u
p 
of
 in
di
vi
du
al
s 
w
ho
 q
ui
tt
ed
.
N
O
R
ef
er
en
ce
, o
bj
ec
ti
ve
 a
nd
 
se
tt
in
g
St
ud
y 
de
si
gn
/ k
ey
 c
ha
ra
ct
er
is
ti
cs
Pa
rt
ic
ip
an
ts
 /
H
ow
 a
bs
ti
ne
nc
e 
 is
 d
efi
ne
d
Ke
y 
Fi
nd
in
gs
 re
la
te
d 
to
 th
e 
eff
ec
ti
ve
ne
ss
 o
f O
T
C
 N
R
T
 
To
 n
ot
ic
e 
(k
ey
 p
oi
nt
s 
in
 d
is
cu
ss
io
n,
 
lim
it
at
io
ns
 a
nd
 s
tr
en
gt
hs
 o
f t
he
 
st
ud
y)
Su
pp
or
ts
 th
e 
eff
ec
ti
ve
ne
ss
 
of
 O
TC
 N
R
T?
Pr
e-
 a
nd
 P
os
t O
TC
 N
R
T 
st
ud
ie
s 
R
ee
d 
et
 a
l. 
20
05
:
To
 a
ss
es
s 
th
e 
im
m
ed
ia
te
 s
ho
rt
-t
er
m
 
eff
ec
ts
 o
f t
he
 a
va
ila
bi
lit
y 
of
 O
TC
 N
R
T 
on
 re
po
rt
ed
 q
ui
t a
tt
em
pt
s 
an
d 
on
 
ab
st
in
en
ce
 in
 C
al
ifo
rn
ia
 d
ur
in
g 
th
e 
m
on
th
s 
pr
io
r t
o 
an
d 
im
m
ed
ia
te
ly
 
fo
llo
w
in
g 
O
TC
 a
va
ila
bi
lit
y 
of
 N
RT
.
Th
e 
U
S,
 C
al
ifo
rn
ia
Se
e 
de
sc
rip
tio
n 
ab
ov
e 
of
 C
al
ifo
rn
ia
n 
To
ba
cc
o 
Su
rv
ey
.
 Th
e 
qu
it 
at
te
m
pt
s 
w
er
e 
ca
lc
ul
at
ed
 fo
r 
ea
ch
 m
on
th
. T
he
 a
tt
em
pt
s 
w
er
e 
di
vi
de
d 
ac
co
rd
in
g 
to
 th
e 
us
e 
of
 N
RT
. T
he
 re
su
lts
 
ar
e 
ba
se
d 
on
 th
e 
re
gr
es
si
on
 m
od
el
s 
of
 
th
e 
su
rv
ey
 d
at
a.
 
Q
ui
t a
tt
em
pt
s 
an
d 
ab
st
in
en
ce
 re
po
rt
ed
 
fr
om
 N
ov
em
be
r 1
99
5 
th
ro
ug
h 
Ju
ly
 1
99
6 
w
er
e 
co
de
d 
as
 p
re
- O
TC
 p
at
ch
 q
ui
ts
 a
nd
 
fr
om
 A
ug
us
t 1
99
6 
to
 N
ov
em
be
r 1
99
6 
as
po
st
-O
TC
 p
at
ch
 q
ui
ts
.  
St
ud
y 
po
pu
la
tio
n 
w
as
 d
ra
w
n 
fr
om
 
th
e 
19
96
 C
al
ifo
rn
ia
n 
To
ba
cc
o 
Su
rv
ey
. 
Th
e 
an
al
ys
is
 c
on
ce
nt
ra
te
d 
on
 c
ur
re
nt
 
an
d 
fo
rm
er
 s
m
ok
er
s,
 a
ge
d 
>2
5,
 w
ho
 
re
po
rt
ed
 b
ei
ng
 a
 d
ai
ly
 s
m
ok
er
 1
2 
m
on
th
s 
pr
io
r t
o 
th
e 
su
rv
ey
 
(n
=5
 8
88
).
  
A
bs
ti
ne
nc
e:
 S
el
f-
re
po
rt
ed
 a
bs
ti
ne
nc
e 
(r
es
po
ns
e 
no
t a
t a
ll 
sm
ok
in
g 
at
 
th
e 
tim
e 
of
 s
ur
ve
y)
. M
os
t r
ec
en
t 
ab
st
in
en
ce
, l
as
tin
g 
at
 le
as
t o
ne
 
m
on
th
. 
8.
77
 ±
 0
.9
6%
 w
er
e 
ab
st
in
en
t a
t
th
e 
tim
e 
of
 th
e 
su
rv
ey
. T
hi
s 
tr
an
sl
at
es
 in
to
 
24
.8
%
 o
f t
ho
se
 w
ho
 re
po
rt
ed
 a
n 
at
te
m
pt
 to
 
qu
it 
be
in
g 
ab
st
in
en
t f
or
  m
on
th
s.
 
Re
su
lts
 fr
om
 th
e 
re
gr
es
si
on
 a
na
ly
si
s 
co
nd
uc
te
d 
sh
ow
ed
 a
 s
ig
ni
fic
an
t i
nc
re
as
e 
in
 
th
e 
pr
op
or
tio
n 
of
 s
m
ok
er
s 
us
in
g 
th
e 
pa
tc
h 
(p
 <
 0
.0
1)
 a
nd
 g
um
 (p
 <
 0
.0
5)
 im
m
ed
ia
te
ly
 
fo
llo
w
in
g 
th
ei
r O
TC
 a
va
ila
bi
lit
y
Th
er
e 
w
as
 a
ls
o 
a 
si
gn
ifi
ca
nt
ly
 h
ig
he
r 
pr
op
or
tio
n 
of
 s
m
ok
er
s 
re
po
rt
in
g 
ab
st
in
en
ce
 
w
it
h 
gu
m
 u
se
 (p
 <
 0
.0
1)
 a
nd
 a
 s
ig
ni
fic
an
t 
in
cr
ea
se
 in
 re
po
rt
ed
 a
bs
tin
en
ce
 w
ith
 p
at
ch
 
us
e 
(p
 <
 0
.0
1)
 fo
llo
w
in
g 
O
TC
 a
va
ila
bi
lit
y.
 
Th
e 
st
ud
y 
us
ed
 c
oh
or
t d
at
a,
 b
ut
 
it
s 
fin
di
ng
s 
w
er
e 
ba
se
d 
on
 fu
tu
re
 
es
tim
at
io
ns
 o
f N
RT
 u
se
. 
YE
S
Th
or
nd
ik
e 
et
 a
l. 
20
02
:
Co
m
pa
re
d 
ra
te
s 
of
 q
ui
t a
tt
em
pt
s,
 
SC
 a
nd
 N
RT
 u
se
 b
ef
or
e 
an
d 
af
te
r 
N
RT
 d
er
eg
ul
at
io
n.
Th
e 
U
S,
 M
as
sa
ch
us
et
ts
Th
e 
an
al
ys
is
 c
om
pa
re
d 
da
ta
 c
ol
le
ct
ed
 b
y  
tw
o 
co
m
pa
ra
bl
e 
su
rv
ey
s:
In
 th
e 
pr
e-
de
re
gu
la
tio
n 
Pr
e-
 N
RT
 
de
re
gu
la
tio
n 
 p
er
io
d 
 d
at
a 
w
as
 c
ol
le
ct
ed
 
fr
om
 th
e 
M
as
sa
ch
us
et
ts
 T
ob
ac
co
 S
ur
ve
y 
(f
ro
m
 O
ct
ob
er
 1
99
3 
th
ro
ug
h 
Fe
br
ua
ry
 
19
94
 [n
=1
78
4]
 b
y 
a 
ra
nd
om
-d
ig
it-
di
al
ed
 
te
le
ph
on
e 
su
rv
ey
. 
  In
 th
e 
po
st
- N
RT
 d
er
eg
ul
at
io
n 
N
RT
 
pe
rio
d 
da
ta
 w
as
 c
ol
le
ct
ed
 fr
om
 th
e 
M
as
sa
ch
us
et
ts
 A
du
lt 
To
ba
cc
o 
ra
nd
om
-
di
gi
t-
di
al
ed
 S
ur
ve
y 
(f
ro
m
 A
ug
us
t 1
99
7 
to
 Ju
ne
 1
99
9 
[n
=1
24
0]
).
 T
he
 s
am
pl
e 
w
as
 
lim
ite
d 
to
 th
os
e 
pa
rt
ic
ip
an
ts
, w
ho
 m
ad
e 
a 
qu
it 
at
te
m
pt
 a
ft
er
 th
e 
de
re
gu
la
tio
n 
(i.
e.
, a
ft
er
 Ju
ly
 1
99
6)
.
P
ar
ti
ci
pa
nt
s:
 
Su
rv
ey
 re
sp
on
de
nt
s 
w
ho
 m
ad
e 
at
 le
as
t 1
 q
ui
t a
tt
em
pt
 in
 th
e 
pa
st
 
ye
ar
 in
cl
ud
in
g 
th
os
e 
th
at
 w
er
e 
 
un
su
cc
es
sf
ul
 (i
.e
., 
w
ho
 w
er
e 
sm
ok
er
s 
at
 th
e 
tim
e 
of
 th
e 
su
rv
ey
) a
nd
 q
ui
tt
er
s 
(a
 p
er
so
n,
 w
ho
 re
po
rt
s 
ha
vi
ng
 s
m
ok
ed
 
at
 le
as
t 1
00
 c
ig
ar
et
te
s 
in
 h
is
 /h
er
 
lif
et
im
e 
an
d 
cu
rr
en
tl
y 
sm
ok
es
 “
no
t 
at
 a
ll.
”)
   
  T
he
 a
na
ly
si
s 
w
as
 li
m
ite
d 
to
 
re
sp
on
de
nt
s 
ei
th
er
 w
ho
 s
m
ok
ed
 a
t 
th
e 
tim
e 
of
 th
e 
in
te
rv
ie
w
 o
r w
ho
 h
ad
 
qu
it 
w
ith
in
 th
e 
pa
st
 y
ea
r (
pa
st
-y
ea
r 
qu
itt
er
s)
.
A
bs
ti
ne
nc
e:
Se
lf-
re
po
rt
ed
, a
t l
ea
st
 o
ne
 
da
y 
ab
st
in
en
ce
. P
as
t-
ye
ar
 q
ui
tt
er
 w
as
 
de
fin
ed
 s
el
f-
re
po
rt
ed
 q
ui
tt
in
g 
du
ri
ng
 
th
e 
pa
st
 y
ea
r .
O
ve
ra
ll,
 th
e 
ra
te
 o
f s
uc
ce
ss
fu
l q
ui
tt
in
g 
in
cr
ea
se
d 
fr
om
 1
7.
1%
 p
re
- O
TC
 to
 2
4.
7%
 
po
st
-O
TC
, t
ho
ug
h 
no
t s
ta
ti
st
ic
al
ly
 s
ig
ni
fic
an
t 
(P
=.
10
). 
Su
cc
es
sf
ul
 q
ui
tt
in
g 
in
cr
ea
se
d 
am
on
g 
N
R
T 
us
er
s 
fr
om
 1
8.
7%
 to
 3
1.
1%
 
(P
=.
28
) a
nd
  a
m
on
g 
no
n-
N
RT
 u
se
rs
 fr
om
 
16
.7
%
 to
 2
3.
0%
 (P
=.
22
). 
Th
e 
in
cr
ea
se
 in
 q
ui
t r
at
es
 b
et
w
ee
n 
th
e 
pr
e 
an
d 
th
e 
po
st
-O
TC
-N
RT
 p
er
io
ds
 w
as
 h
ig
he
r 
fo
r N
R
T 
us
er
s 
th
an
 n
on
-u
se
rs
 (1
2.
4%
 v
s 
6.
3%
),
 th
ou
gh
 n
ot
 s
ta
ti
st
ic
al
ly
 s
ig
ni
fic
an
t.
A
lm
os
t h
al
f o
f s
m
ok
er
s 
m
ad
e 
qu
it 
at
te
m
pt
 
be
fo
re
 a
nd
 a
ft
er
 N
RT
 d
er
eg
ul
at
io
n 
an
d 
th
is
 
pa
tt
er
n 
ha
d 
no
t c
ha
ng
ed
. 
A
ft
er
 N
RT
 d
er
eg
ul
at
io
n 
th
e 
us
e 
in
cr
ea
se
d 
am
on
g 
hi
gh
er
 in
co
m
e 
ho
us
eh
ol
ds
 a
nd
 
de
cr
ea
se
d 
am
on
g 
lo
w
er
 in
co
m
e 
ho
us
eh
ol
ds
. 
A
 s
ub
gr
ou
p 
of
 c
ur
re
nt
 s
m
ok
er
s 
w
er
e 
in
te
rv
ie
w
ed
 d
ur
in
g 
th
e 
po
st
-O
TC
 p
er
io
d 
(n
=5
12
).
 In
 th
is
 s
am
pl
e,
 2
8.
1%
 o
f t
he
 
cu
rr
en
t s
m
ok
er
s 
ha
d 
ne
ve
r u
se
d 
N
RT
. 
O
f t
he
 a
ll 
th
e 
in
te
rv
ie
w
ed
 s
m
ok
er
s,
 
48
.7
%
 u
se
d 
N
R
T 
to
 “
de
la
y 
sm
ok
in
g 
or
 
cu
t d
ow
n”
 o
n 
sm
ok
in
g 
bu
t d
id
 n
ot
 m
ak
e 
a 
qu
it 
at
te
m
pt
.
N
O
 
Q
ui
t a
tt
em
pt
s 
an
d 
qu
it 
 ra
te
s 
di
d 
no
t c
ha
ng
e 
af
te
r O
TC
 s
w
itc
h 
Sh
iff
m
an
 e
t a
l. 
19
97
:
Es
tim
at
e 
th
e 
im
pa
ct
 o
f a
llo
w
in
g 
O
TC
 
N
R
T 
sa
le
s 
in
 th
e 
U
S 
on
 in
cr
ea
si
ng
 
th
e 
nu
m
be
st
 o
f s
m
ok
er
s 
qu
itt
in
g
Th
e 
U
S
Sa
le
s 
an
d 
m
ar
ke
tin
g 
da
ta
 w
er
e 
us
ed
 to
 
co
m
pa
re
 u
se
 o
f N
RT
 b
ef
or
e 
an
d 
af
te
r 
th
e 
de
re
gu
la
tio
n 
an
d 
to
 e
st
im
at
e 
th
e 
eff
ec
ts
 o
f O
TC
 s
al
es
 o
n 
qu
it
 ra
te
s.
 T
hi
s 
el
ec
tr
on
ic
 d
at
ab
as
e 
ga
th
er
s 
da
ily
 d
at
a 
of
 
pr
es
cr
ip
ti
on
s 
fil
le
d 
in
 p
ha
rm
ac
ie
s 
an
d 
it
 
re
pr
es
en
ts
 w
el
l t
he
 a
ct
ua
l s
itu
at
io
n.
 
Pr
e-
de
re
gu
la
tio
n 
da
ta
 w
as
 re
ce
iv
ed
 
fr
om
 th
e 
W
al
sh
 A
m
er
ic
a 
da
ta
ba
se
 
pr
ov
id
ed
 in
 th
e 
Sc
ot
t-
Le
vi
n 
So
ur
ce
 
Pr
es
cr
ip
tio
n 
A
ud
it 
da
ta
ba
se
, t
o 
ga
in
 
re
pr
es
en
ta
tiv
e 
da
ta
 o
n 
pr
es
cr
ip
tio
n 
m
ed
ic
in
es
 u
se
. D
at
a 
of
 th
e 
ca
le
nd
ar
 
ye
ar
 1
99
5 
w
as
 u
se
d.
    
   P
os
t-
O
TC
 d
at
a 
w
as
 re
ce
iv
ed
 fr
om
 
A
C 
N
ie
ls
en
, c
ol
le
ct
in
g 
el
ec
tr
on
ic
 d
at
a 
fr
om
 p
ur
ch
as
es
 in
 m
er
ch
an
di
se
rs
 
an
d 
ba
la
nc
es
 th
e 
ex
is
te
nc
e 
of
 o
ut
le
ts
 
no
t c
ol
le
ct
in
g 
th
e 
el
ec
tr
on
ic
 d
at
a.
 
A
C 
N
ie
ls
en
 a
ls
o 
ga
th
er
s d
at
a 
fr
om
 
a 
re
pr
es
en
ta
ti
ve
 p
an
el
 o
f 4
0 
00
0 
ho
us
eh
ol
ds
, w
hi
ch
 sc
an
 th
ei
r 
pu
rc
ha
se
s.
 D
at
a 
w
as
 u
se
d 
du
rin
g 
th
e 
pe
rio
d 
M
ar
ch
 –
 M
ay
 1
99
7
In
 1
99
5 
th
e 
au
th
or
s 
es
ti
m
at
ed
 th
er
e 
to
 b
e 
2.
5 
m
ill
io
n 
qu
it 
at
te
m
pt
s 
w
ith
 th
e 
us
e 
of
 R
x 
N
RT
. 
In
 th
e 
O
TC
 p
er
io
d,
 b
as
ed
 o
n 
th
e 
es
tim
at
io
n,
 
th
er
e 
w
er
e 
5.
8 
m
ill
io
n 
qu
it
 a
tt
em
pt
s 
w
it
h 
O
TC
 
N
R
T 
in
 1
99
7.
 In
 a
dd
it
io
n 
to
 th
is
 5
00
 0
00
 n
ew
 
N
RT
 p
re
sc
rip
tio
ns
 w
er
e 
pr
es
cr
ib
ed
 in
 1
99
7.
 
Th
e 
au
th
or
s 
co
ns
er
va
tiv
el
y 
es
tim
at
ed
 th
at
 
th
er
e 
w
er
e 
be
tw
ee
n 
11
4 
00
0 
- 3
04
 0
00
 
in
cr
em
en
ta
l q
ui
t a
tt
em
pt
s 
at
tr
ib
ut
ed
 to
 O
TC
 
N
RT
. T
hi
s 
m
ea
ns
 th
os
e 
qu
it 
at
te
m
pt
s,
 w
hi
ch
 
w
ou
ld
 n
ot
 h
av
e 
oc
cu
rr
ed
 w
ith
ou
t O
TC
 N
RT
. 
Th
e 
au
th
or
s 
es
tim
at
ed
 th
at
 O
TC
 N
RT
 m
ay
 
ha
ve
 in
cr
ea
se
d 
SC
 in
 A
m
er
ic
an
 p
op
ul
at
io
n 
by
 1
0-
 2
5%
. 
Th
e 
au
th
or
s 
co
nc
lu
de
d 
th
at
 O
TC
 N
RT
 
ha
s 
sh
ow
n 
a 
gr
ea
t p
ub
lic
 h
ea
lt
h 
be
ne
fit
.
Th
e 
re
su
lts
 a
re
 b
as
ed
 o
n 
es
tim
at
es
 o
f 
sa
le
s 
da
ta
 a
nd
 e
xt
ra
po
la
tio
ns
 o
f t
hi
s 
da
ta
 o
n 
qu
it 
ra
te
s.
YE
S
R
ef
er
en
ce
, o
bj
ec
ti
ve
 a
nd
 
se
tt
in
g
St
ud
y 
de
si
gn
/ k
ey
 c
ha
ra
ct
er
is
ti
cs
Pa
rt
ic
ip
an
ts
 /
H
ow
 a
bs
ti
ne
nc
e 
 is
 d
efi
ne
d
Ke
y 
Fi
nd
in
gs
 re
la
te
d 
to
 th
e 
eff
ec
ti
ve
ne
ss
 o
f O
T
C
 N
R
T
 
To
 n
ot
ic
e 
(k
ey
 p
oi
nt
s 
in
 d
is
cu
ss
io
n,
 
lim
it
at
io
ns
 a
nd
 s
tr
en
gt
hs
 o
f t
he
 
st
ud
y)
Su
pp
or
ts
 th
e 
eff
ec
ti
ve
ne
ss
 
of
 O
TC
 N
R
T?
O
pe
n-
 la
be
l R
CT
 w
it
h 
Si
m
ul
at
ed
 O
TC
 e
nv
ir
on
m
en
t
Sh
iff
fm
an
 e
t a
l. 
20
02
a:
 
To
 a
ss
es
s S
C 
ra
te
s 
ac
hi
ev
ed
 b
y 
N
RT
 
gu
m
 a
nd
 p
at
ch
 in
 s
im
ul
at
ed
 O
TC
 a
nd
 
ac
tu
al
 p
re
sc
rip
tio
n 
en
vi
ro
nm
en
t (
Rx
)
Se
pa
ra
te
 o
pe
n-
la
be
l s
tu
di
es
 in
 O
TC
 a
nd
 
Rx
 e
nv
iro
nm
en
t.
O
TC
 e
nv
iro
nm
en
t w
as
 s
im
ul
at
ed
 s
o,
 
th
at
 th
e 
pa
rt
ic
ip
an
ts
 c
ho
os
e 
th
em
se
lv
es
 
th
e 
N
RT
 p
ro
du
ct
 th
ey
 u
se
d.
 
Th
e 
N
RT
 s
 w
er
e 
pr
ov
id
ed
 w
ith
 p
ro
du
ct
 
la
be
ls
 w
ith
 p
ro
du
ct
 in
fo
rm
at
io
n,
 d
os
ag
e,
 
us
ag
e 
in
st
ru
ct
io
ns
 a
nd
 c
on
tr
ai
nd
ic
at
io
ns
 
in
 a
 p
ha
rm
ac
y 
of
 in
 a
 fo
od
 s
to
re
. 
Pa
rt
ic
ip
an
ts
 p
ai
d 
th
em
se
lv
es
 fo
r t
he
 
pr
od
uc
ts
. T
he
y 
w
er
e 
gi
ve
n 
w
rit
te
n 
pr
od
uc
t l
ab
el
 a
nd
 d
ire
ct
io
ns
 a
nd
 
au
di
ot
ap
e 
w
ith
 q
ui
tt
in
g 
tip
s 
bu
t n
o 
ot
he
r 
gu
id
an
ce
. 
Th
ey
 v
is
ite
d 
th
e 
st
ud
y 
ce
nt
re
 fo
r 
ou
tc
om
es
 a
ss
es
sm
en
t,
 in
 w
hi
ch
 th
ei
r 
sm
ok
in
g 
st
at
us
 w
as
 a
ss
es
se
d,
 th
ey
 
re
po
rt
ed
 th
ei
r p
ro
du
ct
 u
se
 a
nd
 a
dv
er
se
 
eff
ec
ts
. I
f p
ar
ti
ci
pa
nt
s 
di
d 
no
t a
pp
ea
r 
to
 fo
llo
w
-u
p 
vi
si
t,
 th
ey
 w
er
e 
co
nt
ac
te
d 
an
d 
in
vi
te
d.
  
A
ll 
pa
rt
ic
ip
an
ts
 w
er
e 
sm
ok
er
s.
 T
he
y 
re
ce
iv
ed
 a
ct
iv
e 
ni
co
tin
e 
re
pl
ac
em
en
t.
 
O
TC
 g
um
 n
=2
98
1,
 O
TC
 p
at
ch
 2
36
7,
 R
x 
gu
m
 n
=3
24
, R
x 
pa
tc
h 
n=
66
9.
N
o 
in
te
rv
en
tio
n 
w
as
 p
ro
vi
de
d 
in
 O
TC
 
se
tt
in
g 
bu
t p
hy
si
ci
an
s 
pr
es
cr
ib
ed
 th
e 
Rx
 m
ed
ic
at
io
ns
. 
O
TC
 p
ar
tic
ip
an
ts
 w
er
e 
re
cr
ui
te
d 
by
 
ad
ve
rt
is
em
en
t a
nd
 R
x 
pa
rt
ic
ip
an
ts
 
by
 th
ei
r p
re
sc
rip
tio
n 
re
co
rd
s 
of
 
ph
ar
m
ac
y 
ch
ai
n.
 O
nl
y 
pa
rt
ic
ip
an
ts
 
w
ho
 w
er
e 
pr
es
cr
ib
ed
 n
ew
 N
RT
 
Rx
 w
er
e 
in
cl
ud
ed
. T
he
y 
w
er
e 
se
nt
 
an
 in
vi
ta
tio
n 
le
tt
er
 a
nd
 th
os
e 
w
ho
 d
ec
id
ed
 to
 p
ar
tic
ip
at
e 
w
er
e 
in
te
rv
ie
w
ed
 a
t t
he
 p
ha
rm
ac
y.
 
A
bs
ti
ne
nc
e:
 B
io
ch
em
ic
al
ly
 v
al
id
at
ed
 
ab
st
in
en
ce
 a
t 6
 w
ee
ks
 a
nd
 6
 m
on
th
s.
 
O
nl
y 
th
os
e 
pa
rt
ic
ip
an
ts
 w
ho
 w
er
e 
ab
st
in
en
t a
t t
he
 6
 w
ee
ks
 (e
nd
 o
f 
tr
ea
tm
en
t)
 w
er
e 
as
ke
d 
to
 c
on
se
nt
 to
 a
 
fo
llo
w
-u
p 
of
 6
 m
on
th
s.
  
Se
pa
ra
te
 a
na
ly
si
s 
fo
r t
he
 O
TC
 a
nd
 R
x 
pa
rt
ic
ip
an
ts
 w
er
e 
co
nd
uc
te
d 
an
d 
re
su
lts
 w
er
e 
co
m
pa
re
d.
Th
e 
O
TC
 p
at
ch
 u
se
rs
 re
ce
iv
ed
 a
bs
tin
en
ce
 ra
te
 
19
.0
%
 a
t 6
 w
ee
ks
 a
nd
 9
.2
%
 a
t 6
 m
on
th
s.
 T
he
 
R
x 
pa
tc
h 
us
er
s’
 a
bs
ti
ne
nc
e 
ra
te
 w
as
 1
6.
0%
 a
t 
6 
w
ee
ks
 a
nd
 3
%
 a
t 6
 m
on
th
s.
 
Th
e 
O
TC
 g
um
 u
se
rs
 re
ce
iv
ed
 a
bs
tin
en
ce
 ra
te
 
16
.1
%
 a
t 6
 w
ee
ks
 a
nd
 8
.4
%
 a
t 6
 m
on
th
s.
 
Th
e 
R
x 
gu
m
 u
se
rs
’ a
bs
ti
ne
nc
e 
ra
te
 w
as
 7
.7
%
 
at
 6
 w
ee
ks
 a
nd
 7
.7
%
 a
t 6
 m
on
th
s.
 
Th
e 
ou
tc
om
es
 w
er
e 
ad
ju
st
ed
 fo
r i
nd
iv
id
ua
l 
di
ff
er
en
ce
s 
am
on
g 
st
ud
y 
pa
rt
ic
ip
an
ts
 a
nd
 
af
te
r t
hi
s 
ad
ju
st
m
en
t,
 O
TC
 N
RT
 w
as
 fo
un
d 
to
 
be
 m
or
e 
be
ne
fic
ia
l.
B
as
ed
 o
n 
st
ud
y 
pa
rt
ic
ip
an
ts
’ i
nt
er
vi
ew
s 
th
e 
au
th
or
s 
di
sc
us
se
d 
th
at
 th
e 
m
or
e 
be
ne
fic
ia
l 
eff
ec
ts
 o
f O
TC
 N
R
T 
w
er
e 
ex
pl
ai
ne
d 
by
 th
e 
la
ck
 o
f p
hy
si
ci
an
 in
st
ru
ct
io
n 
an
d 
gu
id
an
ce
 
of
 p
re
sc
rip
tio
n 
N
RT
 u
se
rs
. C
on
ve
rs
el
y,
 th
e 
au
di
ot
ap
e 
an
d 
us
e 
in
st
ru
ct
io
ns
 g
iv
en
 to
 
O
TC
 p
ar
tic
ip
an
ts
 m
ay
 h
av
e 
gi
ve
n 
st
ro
ng
er
 
in
st
ru
ct
io
ns
 th
an
 th
e 
ph
ys
ic
ia
ns
’ a
ct
io
ns
.
Pa
rt
ic
ip
an
ts
 w
ho
 d
id
 n
ot
 c
om
pl
et
e 
CO
 
m
on
ito
rin
g 
w
er
e 
co
ns
id
er
ed
 s
m
ok
er
s.
 
A
ll 
pa
rt
ic
ip
an
ts
 w
er
e 
in
cl
ud
ed
 in
 th
e 
an
al
ys
is
 a
s 
in
te
nt
-t
o-
tr
ea
t a
pp
ro
ac
h 
w
as
 u
se
d 
an
d 
no
n-
re
sp
on
de
nt
s 
w
er
e 
co
ns
id
er
ed
 s
m
ok
er
s.
D
ue
 to
 th
e 
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Appendix 3: 
Theoretical framework of the study, its operationalization and key outcome indicators (variables/ indicators) utilized in 
the sub-studies (I-IV).
Study Theoretical framework Key operationalized concepts Measured indicators 
I Evidence-informed policy-making 
(Dobrow et al. 2004, Oxman et 
al. 2009) was the theoretical and 
conceptual background. 
This qualitative study was 
inductive in its nature, 
therefore there are no 
concepts to directly 
operationalize.  However 
concepts such as the use 
of evidence, structures and 
rules of political decision 
making, adopted from the 
theoretical framework were 
used to guide the inductive 
analysis. 
The arguments related to NRT 
deregulation were analyzed. The unit of 
analysis was set as a policy argument, 
which was defined as an oral or written 
statement that advocates the adoption 
of a policy or justifies a decision to adopt 
a policy (Ball 1995). Using this unit of 
analysis made it possible to gain a 
perspective of the key attributes of 
the decision- making context in a wider 
scope. 
II Literature on Guideline 
implementation among healthcare 
professionals and systematic 
meta-review of Francke et al. 
(2008). 
 
  
Literature on  community 
pharmacists’ involvement in SC 
(Chapter 3.4) 
Community pharmacists SC 
activities recommended by the 
Finnish SC Guideline (The Finnish 
Medical Society Duodecim 
2012) and the strategic plans 
of community pharmacists to 
increase their activeness in SC by 
the AFP (Association of Finnish 
Pharmacies 2008). 
According to Francke 
(2008) the familiarity with a 
guideline is the first step in 
guideline implementation
The key operationalized 
concepts were related 
to the characteristics of 
pharmacists’ guideline 
dissemination and the 
characteristics of the 
working place.
SC activities provided by 
pharmacists were based on 
the Finnish SC Guidelines 
and recommendations 
given by AFP, which were 
measured by pharmacists’ 
self-reporting.
This was operationalized in the key 
outcome variable, which assessed the 
familiarity with the Finnish SC Guideline 
(Appendix 4 Survey instrument, question 
number 39).
The key variables were classified into 
those which related to the pharmacist 
and those relating to the working 
pharmacy. 
The variables measuring community 
pharmacists’ involvement in SC were the 
variables, which assessed community 
pharmacists’ self-perception of the 
following key Finnish SC Guideline based 
activities and the more sophisticated 
ones according to the strategy of the 
AFP (see Appendix 4, Survey instrument 
questions number 16-18,23-30).
III Literature on NRT usage patterns 
(see Chapter 6, Table 6). Ideology 
of harm reduction (see  Chapter 
3.7)
Political debate related to NRT 
deregulation, which was analysed 
in detail in study I. 
These were conceptualized 
as 
NRT use patterns most 
commonly reported in the 
literature. 
Professional role, 
competition with food 
stores, experience of 
customer service with 
smoking customers. 
Set of Likert-scale statements 
concerning pharmacists’ perceptions 
on most common NRT use patterns 
(Appendix 4, Survey instrument, 
Statements 34). 
Set of Likert-scale statements 
concerning the influence of deregulation 
on pharmacy owners’ and staff 
pharmacists’ motivation to serve 
and counsel customers purchasing  
NRT products (Appendix 4, Survey 
instrument, Statements 34). 
IV The literature on: NRT usage 
patterns (Table 6), internet 
communities and facilities 
supporting participants’ 
empowerment and self-
management (Van Uden-Kraan et 
al. 2008, Armstrong et al. 2009) 
were used as background.
The theories of empowerment 
and self-management (Routasalo 
et al. 2009) were guiding the 
analysis to help to understand the 
participants’ needs for permanent 
lifestyle change.  
This qualitative study was 
inductive in its nature, 
therefore there are no 
concepts to directly 
operationalize.  However 
concepts such as perception 
of medication, experience, 
peer support and 
empowerment were guiding 
the analysis. 
Unit of analysis was one or more 
sentences dealing with opinions, 
perceptions, experiences or 
expectations related to NRT use or 
comparing NRT to other SC methods 
(prescription medicines or non-
pharmaceutical methods, including cold 
turkey).
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Appendix 4: 
The questions utilized in sub-studies II & III from the original PHARMACIST AND TOBACCO 2006- 2007 
- survey instrument (in English).
BACKGROUND INFORMATION
1. Current working place
1   Community pharmacy  
2   Hospital   
3   Pharmaceutical company   
4   Elsewhere, where?    
2.  Are you 
1   B.Sc. Pharmacist 
2   M.Sc. Pharmacist 
3   Pharmacy owner 
3.  Geographical location by province of your 
working pharmacy?
1   Southern Finland 
2   Eastern Finland 
3   Western Finland 
4   Oulu
5   Lapland 
6   Ahvenanmaa
4.  Where you have worked most of time as 
pharmacist?
1   Commuity pharmacy  
2   Hospital pharmacy  
3   Pharmaceutical company  
4   Elsewhere, where    
5.  Are you?
1   Female
2   Male
6.   Your age?                         years 
7.  What is your most previous degree in 
pharmaceutical science?
1   B.Sc. Pharmacist
2   M.Sc. Pharmacist 
3   Licenciate or Ph.D. 
8.  Place of this degree?
1   University of Helsinki 
2   University of Kuopio 
3   Åbo Akademi
9.   Graduation date?
1   In the 2000’s
2   In the 1990’s
3   In the 1980’s
4   In the 1970’s or before
10. Have you participated in education 
supporting smoking cessation counselling?
TO NOTE: It is possible to choose several 
options.
1   Yes, in-house training
2   Yes, continuing education
3   Yes, in-house training by a   
pharmaceutical company
4   Yes, continuing education by a 
pharmaceutical company
5    Not participated
11. Have you specialized in the treatment of 
public health conditions at your working 
place?  
TO NOTE: It is possible to choose several 
options.
1   Yes, asthma
2   Yes, diabetes
3   Yes, cardiovascular diseases
4   Yes, other, what   
5   No
12. Dispensing counter design of your 
workplace
1   Traditional counter 
2   Sit-down counseling station 
3   Both in use
13. Is your workplace 
1   Privately owned, not belonging to a 
pharmacy chain
2   Privately owned, belongs to a pharmacy 
chain
3   University owned 
14. What was the annual prescription volume 
of your workplace in 2005?
1   Less than 20 000
2   20 001–40 000
3   40 001–60 000
4   60 001–80 000
5   80 001–100 000
6   More than 100 000
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SITUATIONS AT CUSTOMER SERVICE 
15. How often you discuss about smoking with the following customers? 
Always Sometimes     Never 
Customer who buy smoking cessation medicines 1 2 3
Customer who suffers from smoking-related disease 1 2 3
Customer who self-refers to his/her smoking 1 2 3
Customer who smokes and is pregnant 1 2 3
16. Which tools do you recommend to your customers to use in smoking cessation?
TO NOTE: It is possible to choose several options. 
1   Nicotine patch (Nicorette®, Nicotinell®)
2   Nicotine gum (Nicorette®, Nicotinell®)
3   Nicotine inhaler (Nicorette®)
4   Nicotine losange (Nicorette®)
5   Bupropion (Zyban®)
6    Other pharmacotherapy, what?   
7   Advice to see public health nurse 
8   Pharmacy’s own individually tailored smoking cessation service 
9   Group therapy 
10 Internet-based smoking cessation support 
11 Telephone-based smoking cessation support 
12 Participation in ”Quit and Win” competition 
13 Support of family or friends 
14 Written SC support material 
15 Support of own quitting decision 
17. Are there local smoking cessation groups organized by the health care of your area?
TO NOTE: It is possible to choose several options.
 1   Yes, we have organized a cessation group in my working place
2   Yes, I have guided customers to a cessation group 
3   Yes, but I have not guided customers to a cessation group
4   No, there is no group 
5   I do not know 
18. Has your working place participated in local multidisciplinary SC actions?
TO NOTE: It is possible to choose several options.
 1   Yes, we have participated in joint training 
2   Yes, we have considered joint practices 
3   Yes, we have joint practices 
4   No, we do not have any collaboration 
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23. Following statements describe customer service situations. 
Please, choose the most suitable number in each
Always Often With 
every 
second 
customer 
Some-
times 
 Never
How often have you asked about smoking during the 
past week  (7 days) from smoking customers?
1 2 3 4 5
How often you have advised customers you recognized 
to smoke, to quit during the past month prior survey?
1 2 3 4 5
How often you have assessed quitting date with your 
smoking customers during the past month prior survey?
1 2 3 4 5
How often you have told to smoking customers about 
how smoking effects on medication during the past 
month prior survey?
1 2 3 4 5
24. Have you organized an individually tailored smoking cessation service at your work place? 
1  Yes
2  No (if no, continue from question 29)
25. Have you advertised your individually tailored smoking cessation service?
1   Yes, to customers, how?
2   Yes, to other health care, how?
3   No
26. Have you yourself guided an individually tailored smoking cessation service during the past 
year?
1  Yes
2  No
27. Have you had any customers in your individually tailored smoking cessation service? 
1   Yes
2   No
28. Do you use smoking pass supporting smoking cessation at your pharmacy?
1   Yes, we use it always 
2    Yes, we use it sometimes 
3    No
29. Do you use pocket card supporting smoking cessation counseling at your pharmacy?
1   Yes, we use it always
2    Yes, we use it sometimes 
3    No
139
30. How the following statements related to smoking cessation apply to your customers:
Always Almost 
always 
Seldom Never
Smoker willing to quit needs nicotine replacement 
therapy  (Nicorette®, Nicotinell®) in quitting
1 2 3 4
Smoker willing to quit needs prescription medicine 
for example bupropion (Zyban®) or varenicline 
(Champix®) for supporting quitting
1 2 3 4
Group counseling suits well with smoking cessation 
treatment 
1 2 3 4
Health care professionals support is needed in 
smoking cessation 
1 2 3 4
PHARMACOTHERAPY SUPPORTING SMOKING CESSATION 
26.  How you based your recommendation on the use of certain nicotine replacement therapy 
product (NRT)?
1 By Fageström test of nicotine dependence 
2 According to customers wishes
3 Recommending a product, which I personally consider effective
4 Other way, how ______________________________
27.  Do you have an in-house guideline on NRT dispensing
1  Yes, written guideline available 
2  Yes, oral guideline available 
3 No
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34. Next, we ask you to answer the following statements related to nicotine replacement 
therapy products (NRT) based on your perceptions:
TO NOTE: Circle the option most suitable for your perceptions 
Strongly 
agree 
    Agree No 
opinion 
Disagree  Strongly 
disagree 
Education, skills and tasks 
My current personal skills and knowledge are 
adequate to support smoking cessation
1 2 3 4 5
It is a pharmacists’ duty to support smoking 
cessation 
1 2 3 4 5
I would like additional education in supporting 
smoking cessation 
1 2 3 4 5
NRT-products’ characteristics and use 
It is possible to get addicted to NRT products 1 2 3 4 5
I have noticed that minors have abused NRT 
products
1 2 3 4 5
Mere NRT products are not enough for quitting 1 2 3 4 5
I have noticed that NRT products have been 
misused (use for too short a time or too low a 
dosage)
1 2 3 4 5
I have noticed that NRT products have been used 
with the wrong technique (for instance chewing 
gum is chewed  incorrectly)
1 2 3 4 5
I have noticed that customers use cigarettes and 
NRT products concurrently 
1 2 3 4 5
NRT products can be used to replace cigarettes 
when smoking is not allowed
1 2 3 4 5
NRT products can be used to diminish the adverse 
effects smoking causes on ones’ health 
1 2 3 4 5
Deregulation of NRT products to food stores, kiosks 
and gas stations
The sales of NRT products have diminished in my 
working place 
1 2 3 4 5
Clients obtain medical counselling of NRT products 
from pharmacy but buy the products elsewhere 
1 2 3 4 5
Because of the deregulation of NRT products my 
motivation towards the medical counselling of NRT 
has diminished
1 2 3 4 5
Clients value the counselling related to NRT 
products 
1 2 3 4 5
Because of the deregulation of NRT products, their 
role in smoking cessation has diminished  
1 2 3 4 5
In my working place there has been devotion to 
education supporting SC counselling
1 2 3 4 5
The medical counselling of NRT is more important in 
the competition of their markets than the possible 
cheaper prices in other sales channels
1 2 3 4 5
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CURRENT CARE GUIDELINE 
Following questions are related ”Tobacco Dependence and  Cessation” Current Care Guideline.
Please: Circle the option most well describing yourself
39.  How familiar you are with the Current Care Guideline?
1 I have read the Guideline through carefully 
2 I am familiar with its main principles 
3 I have skimmed through it
4 I have heard about it 
5 I am not familiar with it
40.  Use of the Current Care Guideline?
1 I have participated in education related to the Guideline 
2 At my working place it has been encouraged to use the guideline 
3 I have used the Guideline 
4 I have used the Guideline during the last six months 
5 The Guideline has changed my daily practice with customers 
6 I have given the patients’ version of the Guideline to my customers
7 I do not use the Guideline
41.  Your opinion of the Current Care Guideline?
TO NOTE: It is possible to choose several options.
1 I have noticed the Guideline to be practical 
2 The Guideline has made my work faster 
3 The Guideline is difficult to use__________________
4 The Guideline is not suitable for daily practice in the pharmacy 
5 Other opinion _______________________
42.  Your opinion, how the Current Care Guideline is followed at your working place?
1 The Guideline is followed at my working place 
2 The Guideline is followed at my working place to some extent
3 The Guideline is not followed at my working place 
4 No opinion
OWN SMOKING 
43.  Have you ever smoked at least 100 cigarettes (cigars or pipe) up to date?
1 Yes 
2 No (continue to question number 52) 
53. What is your perception of how harmful tobacco is to health?
Not at all Extremely 
How detrimental is smoking to health? 1 2 3 4 5 6 7 8 9 10
How detrimental is cigarette smoke to 
health? 
1 2 3 4 5 6 7 8 9 10
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